

第1日

2月22日(木)

D A Y 1

Thursday, February 22, 2024

ESMO/JSMO Joint Symposium

EJS Economic Issues in Cancer Care	112
---	-----

Joint Symposium

JS1 Consider who will provide support for patients' distress after cancer treatment がん治療後の患者さんの苦痛のサポートをどうするか？	108
JS2 The forefront of translational researches in Japan 我が国におけるトランスレーショナルリサーチの最前線	109
JS3 Onco-cardiology Guideline as a Bridgehead toward the Next Stage Onco-cardiology ガイドライン～新しいステージへ向けての橋頭堡	111
JS4 For well-being of the cancer patients suffering from bone metastases: To develop a new horizon (onco-orthopaedics) 20万骨転移患者のウェル・ビーイングを目指して：新しい地平（オンコールソペディクス）を開拓する	134

Presidential Symposium

PSY1 Infrastructure development for utilization of Real World Data Real World Data (RWD) 活用に向けた基盤整備	103
PSY2 Perioperative treatment that changes with immune checkpoint inhibitor ICIで変わる、周術期治療	103
PSY3 Advances in surgical treatment that medical oncologists want to know 腫瘍内科医に知って欲しい外科治療の進歩	107

Symposium

SY1 Telemedicine in the field of cancer がん領域の遠隔医療	106
SY2 Current landscape of adjuvant therapy for HER2-negative EBC HER2 陰性乳癌の最適な周術期治療を考える	106
SY3 Tumor agnostic drug discovery and development 臓器横断的な抗悪性腫瘍薬の開発	108
SY4 What is the "new normal" of multi-center cancer clinical trial group? 多施設臨床試験グループの new normal とは？	115
SY5 Multidisciplinary approach for hepatocellular carcinoma 肝細胞癌に対する集学的治療	116
SY6 Training Program for Improving Cancer Survivorship: Present and Future がんサバイバーシップの充実に向けた教育研修：現状と将来像	125
SY7 Isn't that treatment overkill? その治療、やり過ぎじゃないですか？	126

SY8	Psychooncology Update ~ Evidence & Practice ~ サイコオンコロジー Update ~エビデンスとプラクティス~	127
SY9	Future aspects of cell therapy 細胞療法のさらなる展開	133
SY10	Clinical pharmacological approaches to appropriate drug therapy for unmet needs アンメットニーズに対する適正な薬物療法に向けた臨床薬理学的アプローチ	135
SY11	To overcome resistance to immune checkpoint inhibitors 免疫チェックポイント阻害薬の耐性克服を目指して	146
Committee Program		
CP1	Practical guideline for febrile neutropenia (3rd Edition) 発熱性好中球減少症 (FN) 診療ガイドライン (改訂第3版)	118
CP1	Outline of the Clinical Practice Guidelines for Tumor-Agnostic Treatment in Adult and Pediatric Patients with Advanced Solid Tumors toward Precision Medicine (3.1 Edition) 成人・小児進行固形がんにおける臓器横断的ゲノム診療のガイドライン (改訂第3.1版) について	118
CP2	Social Medical Working Group Symposium SNS-WG シンポジウム	121
Meet the Experts		
ME1	Advanced Care Planning: What's wrong? What should we do? 懐疑派から見たアドバンスケアプランニング：なにが変なのか？ どうすればいいのか？	149
ME2	Current Insights of Chemotherapy in Colorectal Cancer	149
ME3	How I treat elderly patients with multiple myeloma	149
ME4	Patient Involvement Globally: How patients are becoming integral to healthcare decisions, policies and practices	149
ME5	Rare Cancer Update 希少がんアップデート	150
ME6	Resistance mechanism of targeted therapy for NSCLC with driver mutation. Next step	150
ME7	Immune Surveillance: Perspectives in antigen recognition and response	150
ME8	Cancer survivorship care: How can we contribute to survivors who live beyond treatment? がんサバイバーシップケア — 医療者はがん治療を超えて生きる人にどう貢献できるか？	151
PAGA forum		
		112
Part A-1	Science (MBC)	112
Part A-2	Science (MGC)	112
Part B	Implementability of the PAGA recommendations: Approval, Reimbursement, Infrastructure and Access	113

Room 1 (1号館 2F センチュリーホール)

9:00-10:20 Presidential Symposium 1 / 会長企画シンポジウム 1

PSY1 Infrastructure development for utilization of Real World Data
Real World Data (RWD) 活用に向けた基盤整備



Chairs : Toshio Shimizu (Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University Hospital, Wakayama Medical University Graduate School of Medicine)
Manabu Muto (Kyoto University Graduate School of Medicine, Department of Therapeutic Oncology)
Panelist : Shinsuke Amano (Japan Federation of Cancer Patient Groups)
司会 : 清水 俊雄 (和歌山県立医科大学内科学第三講座 (呼吸器内科・腫瘍内科))
武藤 学 (京都大学大学院医学研究科 腫瘍薬物治療学講座)
パネリスト : 天野 慎介 (全国がん患者団体連合会)

PSY1-1 **RWD creation and utilization in Japan based on the experiences in the US**

Eri Tajima (Flatiron Health, K.K.)

米国における取組みを踏まえた本邦でのRWD構築・活用

田島 絵里 (フラットアイアンヘルス株式会社)

PSY1-2 **The current status and challenges of infrastructure development for the utilization of real-world data (RWD) in Japan**

Shigemi Matsumoto (Department of Real World Data R & D, Graduate School of Medicine, Kyoto University)

本邦におけるリアルワールドデータ (RWD) 活用の基盤整備の現状と課題

松本 繁巳 (京都大学大学院医学研究科 リアルワールドデータ研究開発講座)

PSY1-3 **Measures of the MHLW in medical DX**

Shiho Yoshii (Office of Counsellor for Assistance for Development of Specified Drugs and Medical Information Management, Health Policy Bureau, Ministry of Health, Labour and Welfare)

医療DXの取り組みについて

吉井 史歩 (厚生労働省医政局特定医薬品開発支援・医療情報担当参事官室)

10:30-11:30 Presidential Symposium 2 / 会長企画シンポジウム 2

PSY2 Perioperative treatment that changes with immune checkpoint inhibitor
ICIで変わる、周術期治療



Chairs : Tetsuya Mitsudomi (Kindai University Hospital)
Yoichi Naito (National Cancer Center Hospital East)
司会 : 光富 徹哉 (近畿大学病院)
内藤 陽一 (国立がん研究センター東病院)

PSY2-1 **Perioperative Therapy in Non-Small Cell Lung Cancer**

Hidehito Horinouchi (Department of Thoracic Oncology, National Cancer Center Hospital)

肺癌の周術期治療

堀之内 秀仁 (国立がん研究センター中央病院 呼吸器内科)

PSY2-2 **Adjuvant and neoadjuvant therapy for melanoma**

Kenjiro Namikawa (Department of Dermatologic Oncology, National Cancer Center Hospital)

悪性黒色腫 (メラノーマ) に対する周術期治療

並川 健二郎 (国立がん研究センター中央病院 皮膚腫瘍科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

PSY2-3 Update of neoadjuvant/adjuvant immune checkpoint inhibitor for early breast cancer
 Yukinori Ozaki (Department of Breast Medical Oncology, Department of Advanced Medical Development at The Cancer Institute Hospital of Japanese Foundation for Cancer Research)
乳癌周術期ICI治療の最新情報
 尾崎 由記範 (がん研究会有明病院 乳腺内科/先端医療開発科)

PSY2-4 Current status and future perspectives of perioperative immune checkpoint inhibitors for patients with advanced rectal cancer
 Hideaki Bando (Department of Gastroenterology and Gastrointestinal Oncology)
免疫チェックポイント阻害薬を用いた直腸癌周術期治療開発の現状と展望
 坂東 英明 (国立がん研究センター東病院 消化管内科)

13:40-15:40 Presidential Session 1

PS1 Lung cancer/Thoracic Cancer 

Chairs : Hidetoshi Hayashi (Department of Medical Oncology, Kindai University)
 Pasi Janne (Dana-Farber Cancer Institute)
Discussants : Koichi Azuma (Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine)
 Satoru Miura (Department of Internal Medicine, Niigata Cancer Center Hospital)
 Pasi Janne (Dana-Farber Cancer Institute)
司会 : 林 秀敏 (近畿大学医学部内科学腫瘍内科部門)
 Pasi Janne (Dana-Farber Cancer Institute)
ディスカッション : 東 公一 (久留米大学医学部内科学講座呼吸器神経膠原病部門)
 三浦 理 (新潟県立がんセンター新潟病院 内科)
 Pasi Janne (Dana-Farber Cancer Institute)

PS1-1 Amivantamab Plus Chemotherapy vs Chemotherapy Alone in EGFR Exon20ins NSCLC: Phase 3 PAPILLON study Japanese subgroup
 Akira Ono (Division of Thoracic Oncology, Shizuoka Cancer Center)
 小野 哲 (静岡県立静岡がんセンター 呼吸器内科)

PS1-2 Sotorasib (soto) vs Docetaxel (doce) for Previously Treated KRAS G12C+ Advanced NSCLC: CodeBreak 200 Asian Subgroup
 Isamu Okamoto (Department of Respiratory Medicine, Kyushu University Hospital)
 岡本 勇 (九州大学大学院医学研究院 呼吸器内科学分野)

PS1-3 RELAY: Final Overall Survival with Erlotinib+Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC (mNSCLC)
 Kazuhiko Nakagawa (Department of Medical Oncology, Kindai University Hospital Cancer Center, Osaka, Japan.)

HoD1



Chairs : Hiroji Iwata (Aichi Cancer Center)
Tetsuji Takayama (Department of Gastroenterology and Oncology, Tokushima University
Graduate School of Biomedical Sciences)
司会 : 岩田 広治 (愛知県がんセンター 乳腺科)
高山 哲治 (徳島大学大学院 医歯薬学研究部消化器内科学分野)

HoD1-1 Lung Cancer Thoracic Oncology

Takehito Shukuya (Juntendo University)

呼吸器

宿谷 威仁 (順天堂大学 呼吸器内科)

HoD1-2 Head and Neck Cancer

Susumu Okano (National Cancer Center Hospital East)

頭頸部

岡野 晋 (国立がん研究センター東病院 頭頸部内科)

HoD1-3 Clinical Trial Facilitation Program

Shogo Nomura (Graduate School of Medicine, The University of Tokyo)

臨床試験推進プログラム

野村 尚吾 (東京大学大学院医学系研究科)

HoD1-4 Translational Research/ Clinical Pharmacology

Yosuke Togashi (Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University)

TR・臨床薬理

富樫 庸介 (岡山大学 学術研究院医歯薬学域)

HoD1-5 Multidisciplinary Team Program

Koji Matsumoto (Division of Medical Oncology, Hyogo Cancer Center)

多職種連携プログラム

松本 光史 (兵庫県立がんセンター 腫瘍内科)

Room 2 (1号館 4F レセプションホール)

9:00-10:30 Symposium 1 / シンポジウム 1

SY1 Telemedicine in the field of cancer
がん領域の遠隔医療



Chairs : Hiroya Taniguchi (Aichi Cancer Center Hospital, Department of Clinical Oncology)
Ryuji Hayashi (Toyama University Hospital, Clinical Oncology)
司会 : 谷口 浩也 (愛知県がんセンター 薬物療法部)
林 龍二 (富山大学附属病院 臨床腫瘍部)

SY1-1 Current Status of Remote Pathology Diagnosis

Junya Fukuoka (Nagasaki University Graduate School of Biomedical Sciences)

遠隔病理診断の現状について

福岡 順也 (長崎大学大学院医歯薬学総合研究科)

SY1-2 Telesurgery: Present and Future

Eiji Oki (Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University)

遠隔手術の現在と未来

沖 英次 (九州大学大学院 消化器・総合外科)

SY1-3 Possibility of using smartphones to collect information on food preference in clinical trials

Takuro Mizukami (Department of Medical Oncology, NTT Medical Center Tokyo)

臨床試験におけるスマートフォンを用いた食に関する情報収集の可能性

水上 拓郎 (NTT東日本関東病院 腫瘍内科)

SY1-4 Introduction of online genetic counseling for hereditary cancers using an online medical system and its future prospects

Takeshi Nakajima (Department of Medical Ethics/Medical Genetics, School of Public Health, Graduate School of Medicine, Kyoto University)

オンライン診療システムを用いた遺伝性腫瘍のオンライン遺伝カウンセリング

中島 健 (京都大学大学院医学研究科 社会健康医学系専攻 医療倫理学・遺伝医療学)

13:40-15:10 Symposium 2 / シンポジウム 2

SY2 Current landscape of adjuvant therapy for HER2-negative EBC
HER2 陰性乳癌の最適な周術期治療を考える



Chairs : Sandra M. Swain (Georgetown University Medical Center, MedStar Health)
Junji Tsurutani (Advanced Cancer Translational Research Institute, Showa University)
司会 : Sandra M. Swain (Georgetown University Medical Center, MedStar Health)
鶴谷 純司 (昭和大学 先端がん治療研究所)

SY2-1 Perioperative immunotherapy in HER2 - negative EBC

Sibylle Loibl (GBG, Goethe University Frankfurt)

SY2-2 Targeting HER2-low expression in breast oncology: opportunities and challenges for a new biomarker

Paolo Tarantino (Dana-Farber Cancer Institute)

SY2-3 Development of treatments for TNBC other than immunotherapy

Giuseppe Curigliano (Department of Oncology and Hemato-Oncology, University of Milano, European Institute of Oncology, IRCCS, Milano)

SY2-4 **Biomarkers in HER2-negative early-stage breast cancer**
Alex Prat (Hospital Clinic Barcelona, Spain FRCB IDIBAPS)

15:30-17:00 Presidential Symposium 3 / 会長企画シンポジウム 3

PSY3 Advances in surgical treatment that medical oncologists want to know
腫瘍内科医に知って欲しい外科治療の進歩

Chairs : Yasuhiro Kodera (Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine)
Shigehira Saji (Department of Medical Oncology, Fukushima Medical University)
司会 : 小寺 泰弘 (名古屋大学大学院 消化器外科学)
佐治 重衡 (福島県立医科大学 腫瘍内科学講座)

PSY3-1 **Head and neck cancer**
Nobuhiro Hanai (Department of Head and Neck Surgery, Aichi Cancer Center Hospital)
頭頸部がん領域
花井 信広 (愛知県がんセンター 頭頸部外科部)

PSY3-2 **Recent progress of surgical treatment in digestive surgery**
Seiji Ito (Department of Gastroenterological Surgery, Aichi Cancer Center Hospital)
消化器外科領域における最近の外科治療の進歩
伊藤 誠二 (愛知県がんセンター 消化器外科部)

PSY3-3 **A significant historical step in lung cancer surgical treatment that oncologists should be aware of**
Hisashi Saji (Department of Thoracic Surgery, St. Marianna University School of Medicine)
腫瘍内科医に知って欲しい肺癌外科治療の歴史的な大きな一歩
佐治 久 (聖マリアンナ医科大学 呼吸器外科)

PSY3-4 **Personalized De-escalation Surgery for Breast Cancer in the New Era of Multidisciplinary Treatment**
Takehiko Sakai (Department of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital of JFCR)
腫瘍内科医に知ってほしい外科治療の進歩
～集学的治療新時代における乳癌の個別化De-escalation surgery～
坂井 威彦 (がん研究会有明病院乳腺センター 乳腺外科)

PSY3-5 **Role of surgery for multidisciplinary treatment in advanced urological cancer**
Takahiro Kojima (Department of Urology, Aichi Cancer Center Hospital)
進行性泌尿器がんの集学的治療における外科治療の役割
小島 崇宏 (愛知県がんセンター 泌尿器科)

PSY3-6 **Gynecologic surgical treatment to share with medical oncologists**
Shiro Suzuki (Department of Gynecologic Oncology, Aichi Cancer Center Hospital)
腫瘍内科医と共有しておきたい婦人科手術治療
鈴木 史朗 (愛知県がんセンター 婦人科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Room 3 (1号館 4F 会議室 141+142)

9:15-11:15 Joint Symposium 1 (JSPM/JSMO) / 合同シンポジウム 1 (日本緩和医療学会 / 日本臨床腫瘍学会)

JS1 Consider who will provide support for patients' distress after cancer treatment
がん治療後の患者さんの苦痛のサポートをどうするか？



Chairs : Akira Inoue (Department of Palliative Medicine, Tohoku University School of Medicine)
Satofumi Shimoyama (Aichi Cancer Center Hospital Dept. of Palliative Care)

司会 : 井上 彰 (東北大学大学院)
下山 理史 (愛知県がんセンター 緩和ケア部)

JS1-1 Surgical oncologist's perspective on support for patients' distress after cancer treatment
Yasuo Hirono (Cancer Care Promotion Center, University of Fukui Hospital / Department of Gastroenterology, University of Fukui Hospital)

腫瘍外科の立場からみたがん治療後の患者さんの苦痛のサポート

廣野 靖夫 (福井大学医学部附属病院 がん診療推進センター / 福井大学医学部附属病院 消化器外科)

JS1-2 From cancer survivorship perspective in medical oncology
Jiichiro Sasaki (Division of Clinical Oncology, Department of Comprehensive Medicine, Research and Development Center for New Next Frontiers, Kitasato University School of Medicine)

腫瘍内科の立場から～サバイバーシップの観点で～

佐々木 治一郎 (北里大学医学部附属新世紀医療開発センター 横断的医療領域開発部門臨床腫瘍学)

JS1-3 From a Palliative Care Standpoint
Takeshi Yamada (Iida Municipal Hospital)

緩和ケアの立場から

山田 武志 (飯田市立病院 緩和ケア内科)

**JS1-4 How to support the distress of patients after cancer treatment?
-From a position of psycho-oncology**
Megumi Uchida (Division of Palliative Care and Psycho-oncology, Nagoya City University Hospital, Nagoya, Japan)

がん治療後の患者さんの苦痛のサポートをどうするか？—精神腫瘍の立場から

内田 恵 (名古屋市立大学病院 緩和ケアセンター)

JS1-5 What can we do during cancer treatment to support patients after cancer treatment?
Ikuko Sugiyama (Department of Nursing, Tohoku University Hospital)

がん治療後の患者を支えるためにがん治療中から何ができるか？

杉山 育子 (東北大学病院 看護部 緩和ケアセンター)

13:40-15:10 Symposium 3 / シンポジウム 3

SY3 Tumor agnostic drug discovery and development
臓器横断的な抗悪性腫瘍薬の開発



Chairs : Kenji Tamura (Department of Medical Oncology, Shimane University Hospital)
Toshio Shimizu (Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University Graduate School of Medicine)

司会 : 田村 研治 (島根大学医学部附属病院 先端がん治療センター / 腫瘍内科)
清水 俊雄 (和歌山県立医科大学医学部 内科学第三講座 (呼吸器内科・腫瘍内科))

SY3-1 Tumor-agonistic and organ-specific aspects of BRAF mutant cancers

Hirohichi Ebi (Division of Molecular Therapeutics, Aichi Cancer Center)

BRAF変異腫瘍が有する臓器横断的側面と臓器特異的側面が治療開発に与える影響について

衣斐 寛倫 (愛知県がんセンター がん標的治療TR分野・ゲノム医療センター)

SY3-2	PARP inhibitors for BRCA mutation and HRD-breast, ovarian, pancreatic, and prostate cancer Kenichi Harano (Department of Experimental Therapeutics/Medical Oncology, National Cancer Center Hospital East) BRCA変異およびHRDに対するPARP阻害剤-乳癌、卵巣癌、膵臓癌、前立腺癌 原野 謙一 (国立がん研究センター東病院 先端医療科/腫瘍内科)	Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2
SY3-3	Tumor agnostic HER2-targeted drug development Kenji Tamura (Department of Medical Oncology, Shimane University Hospital) HER2を標的とする臓器横断的な抗悪性腫瘍薬開発 田村 研治 (島根大学医学部附属病院 先端がん治療センター /腫瘍内科)	Room 3
SY3-4	Pembrolizumab for the Treatment of MSI-H/dMMR and TMB-H cancers: Critical Factors that Facilitated these Tumor Agnostic Approvals Scott K Pruitt (Merck, Sharp, and Dohme, United States)	Room 4 Room 5 Room 6
15:20-17:20 Joint Symposium 2 (JCA/JASCO/JSMO) / 合同シンポジウム 2 (日本癌学会 / 日本癌治療学会 / 日本臨床腫瘍学会)		
JS2	The forefront of translational researches in Japan 我が国におけるトランスレーショナルリサーチの最前線	Room 7 Room 8
Chairs :	Masanobu Oshima (Cancer Research Institute, Kanazawa University) Takayuki Yoshino (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East) Seiji Yano (Kanazawa University)	Room 9 Room 10
司会 :	大島 正伸 (金沢大学がん進展制御研究所) 吉野 孝之 (国立がん研究センター東病院 消化管内科) 矢野 聖二 (金沢大学医薬保健研究域医学系 呼吸器内科学)	Room 11 Room 12 Room 13
JS2-1	Translational research for developing strategies targeting oxidative stress-resistant cancer cells Hideyuki Saya (Cancer Center, Fujita Health University) 酸化ストレス耐性がん細胞を標的とした戦略開発のためのトランスレーショナル研究 佐谷 秀行 (藤田医科大学がん医療研究センター)	Room 13 Meet the Experts Poster
JS2-2	Development of novel therapeutic strategy targeted for drug tolerance Tadaaki Yamada (Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine) がん分子標的薬抵抗性を標的とした治療法開発 山田 忠明 (京都府立医科大学大学院 呼吸器内科学)	
JS2-3	The Present & Prospective of Precision Oncology in Solid Tumors - Unraveling from SCRUM & CIRCULATE-Japan Takayuki Yoshino (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East) 固形癌におけるがんゲノム医療の現状と展望 - SCRUM & CIRCULATE-Japanの成果から紐解く 吉野 孝之 (国立がん研究センター東病院 消化管内科)	
JS2-4	Translational research targeting RAS/RAF mutant cancers Hiromichi Ebi (Division of Molecular Therapeutics, Aichi Cancer Center) RAS/RAF変異腫瘍に対するトランスレーショナルリサーチ 衣斐 寛倫 (愛知県がんセンター がん標的治療TR分野・ゲノム医療センター)	

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

JS2-5 Translational research for ADC (Antibody-Drug Conjugate)
Hidetoshi Hayashi (Department of Medical Oncology, Kindai University, Faculty of Medicine)
ADC (抗体薬物複合体) に対するトランスレーショナルリサーチ
林 秀敏 (近畿大学医学部 内科学腫瘍内科)

JS2-6 An Investigator-Initiated Clinical Trial Aimed at Improving Outcomes of Lung Cancer Immunotherapy
Kentaro Tanaka (Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University)
**肺癌免疫療法の治療成績改善を目指した医師主導治験の試み
～ニボルマブとベザフィブラートによる第1相試験～**
田中 謙太郎 (九州大学大学院医学研究院 呼吸器内科学)

Room 4 (3号館 3F 国際会議室)

9:15-11:15 Joint Symposium 3 (JCS/JSMO) / 合同シンポジウム 3 (日本循環器学会 / 日本臨床腫瘍学会)

JS3 Onco-cardiology Guideline as a Bridgehead toward the Next Stage

Onco-cardiology ガイドライン～新しいステージへ向けての橋頭堡



Chairs : Hiroshi Akazawa (Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo)
 Toshimi Takano (Breast Medical Oncology Department, The Cancer Institute Hospital of JFCR)

司会 : 赤澤 宏 (東京大学大学院医学系研究科 循環器内科学)
 高野 利実 (がん研有明病院 乳腺内科)

JS3-1 Essence of Onco-cardiology guidelines

Shingo Yano (Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine)

Onco-cardiology ガイドラインのエッセンス

矢野 真吾 (東京慈恵会医科大学附属病院 血液・腫瘍内科)

JS3-2 Evidence Gaps in Cardio-Oncology Clinical Practice Guidelines - A Sea of Opportunity

Kazuhiro Sase (Clinical Pharmacology and Regulatory Science, Graduate School of Medicine, Juntendo University / Institute for Medical Regulatory Science, Organization for University Research Initiatives, Waseda University)

国内外の腫瘍循環器診療ガイドラインに示されたエビデンス・ギャップと今後の課題

佐瀬 一洋 (順天堂大学大学院医学研究科 臨床薬理学 / 早稲田大学医療レギュラトリーサイエンス研究所)

JS3-3 CQ and FRQ for Cancer Treatment-Related Cardiac Dysfunction

Yuko Tanabe (Department of Medical Oncology, Toranomon Hospital)

がん治療関連心機能障害のCQとFRQ

田辺 裕子 (虎の門病院 臨床腫瘍科)

JS3-4 Clinical Question (CQ) and Future Research Question (FRQ) for Cancer-associated Thrombosis

Kazunori Otsui (Department of General Internal Medicine, Kobe University Graduate School of Medicine)

がん関連血栓症のCQとFRQ

乙井 一典 (神戸大学大学院医学研究科 総合内科学部門)

JS3-5 Clinical questions and future research questions of prevention for cardiovascular adverse events

Akihiko Shimomura (Department of Breast and Medical Oncology, National Center for Global Health and Medicine)

心血管有害事象予防のCQとFRQ

下村 昭彦 (国立国際医療研究センター病院 乳腺・腫瘍内科)

JS3-6 Education and training in the field of Onco-Cardiology

Toru Oka (Department of Internal Medicine, Saitama Cancer Center)

腫瘍循環器領域における医療体制の整備と人材育成

岡 亨 (埼玉県立がんセンター 総合内科)

 Day 1 (Thu)
 Day 2 (Fri)
 Day 3 (Sat)
 On-demand
 Room 1
 Room 2
 Room 3
 Room 4
 Room 5
 Room 6
 Room 7
 Room 8
 Room 9
 Room 10
 Room 11
 Room 12
 Room 13
 Meet the Experts
 Poster

13:40-15:10 ESMO/JSMO Joint Symposium / ESMO/JSMO 合同シンポジウム

EJS Economic Issues in Cancer Care



Chairs : Andrés Cervantes (INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain)

Takayuki Yoshino (National Cancer Center Hospital East)

司会 : Andrés Cervantes (INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain)

吉野 孝之 (国立がん研究センター東病院)

EJS-1 Economic issues for health care: patients, doctors and payers perspectives

Jean-Yves Blay (Centre Leon Berard)

EJS-2 Assessing the value of new cancer drugs for regulatory and HTA decisions- the role of ESMO-MCBS

Bishal Gyawali (Department of Oncology, Queen's University)

EJS-3 Financial Toxicity of Cancer

Kazunori Honda (Department of Clinical Oncology, Aichi Cancer Center)

本多 和典 (愛知県がんセンター 薬物療法部)

EJS-4 Dose-optimization studies of modern oncology drugs for reduction of toxicity and cost

Hideo Kunitoh (Department of Medical Oncology, Japanese Red Cross Medical Center)

毒性とコスト軽減のための用量適正化試験

國頭 英夫 (日本赤十字社医療センター 化学療法科)

16:00-18:00 PAGA forum

Chairs : Chikashi Ishioka (Department of Clinical Oncology, Tohoku University Graduate School of Medicine)

Andrés Cervantes (INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain)

司会 : 石岡 千加史 (東北大学大学院医学系研究科臨床腫瘍学分野)

Andrés Cervantes (INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain)

Part A-1 Science (MBC)



Presentation of clinical case, Asian Young Oncologist

Hee Kyung Ahn (The Sainsbury Laboratory)

Analysis of the Case and Presentation of the PAGA recommendations and Asian practice

Kyung Hun Lee (Seoul National University Hospital)

Perspectives of European practice in MBC

Giuseppe Curigliano (European Institute of Oncology and University of Milano)

Part A-2 Science (MGC)



Presentation of clinical case, Asian Young Oncologist

Yukiya Narita (Department of Clinical Oncology, Aichi Cancer Center Hospital)

成田 有季哉 (愛知県がんセンター 薬物療法部)

Analysis of the Case and Presentation of the PAGA recommendations and Asian practice

Kohei Shitara (National Cancer Center Hospital East)

設楽 絃平 (国立がん研究センター東病院 消化管内科)

Perspectives of European practice

Elizabeth Smyth (Oxford Cancer)

Part B Implementability of the PAGA recommendations: Approval, Reimbursement, Infrastructure and Access



Discussant : All Faculty

Keynote lecture on ESMO MCBS/ESCAT initiative

Andrés Cervantes (INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain)

Keynote lecture on JPN perspective on implementability

Yasuhiro Fujiwara (Pharmaceuticals and Medical Devices Agency/National Cancer Center Hospital)

藤原 康弘 (独立行政法人 医薬品医療機器総合機構/国立がん研究センター中央病院 腫瘍内科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Room 5 (4号館 3F 会議室 431+432)

9:00-10:30 Oral Session 1

01 Lung Cancer/ Thoracic Cancer 1
呼吸器 1

E

Chairs : Satoshi Oizumi (Department of Respiratory Medicine, NHO Hokkaido Cancer Center)
Seiji Yano (Department of respiratory Medicine, Kanazawa University)

Discussants: Takehito Shukuya (Juntendo University)
Yuko Oya (Fujita Health University, Department of Respiratory Medicine)

司会 : 大泉 聡史 (国立病院機構北海道がんセンター 呼吸器内科)
矢野 聖二 (金沢大学医薬保健研究域医学系呼吸器内科学)

マイカサホ: 宿谷 威仁 (順天堂大学 呼吸器内科)
大矢 由子 (藤田医科大学医学部呼吸器内科)

01-1 Codebreak 101: Safety/Efficacy of Sotorasib with Carboplatin/Pemetrexed in 1L and 2L
Encore KRAS G12C-Mutated Advanced NSCLC

Jeffrey M Clarke (Department of Medicine, Duke University School of Medicine)
Jeffrey M Clarke (デューク大学)

01-2 Intracranial efficacy of sotorasib vs docetaxel in pretreated KRAS G12C-mutated
Encore advanced non-small cell lung cancer

Kadoaki Ohashi (Okayama University Hospital, Okayama, Japan)
大橋 圭明 (Okayama University Hospital, Okayama, Japan)

01-3 Amivantamab Plus Lazertinib vs Osimertinib as FL Treatment in Pts With EGFR-mut,
Encore aNSCLC: Primary Results From MARIPOSA

Byoung C Cho (Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine)

01-4 Efficacy of platinum-based chemotherapy with immune checkpoint inhibitor for HER2-
mutant non-small cell lung cancer

Yuki Kato (Department of Thoracic Oncology, National Cancer Center Hospital East)
加藤 祐樹 (国立がん研究センター東病院 呼吸器内科)

01-5 Prediction of prognosis in stage 4 lung cancer using machine learning: A multicenter
cohort study (WJOG15121L:REAL-WIND)

Daichi Fujimoto (Internal Medicine III, Wakayama Medical University)
藤本 大智 (和歌山県立医科大学附属病院 内科学第三講座)

10:30-11:30 Mini Oral Session 1

MO1 Lung Cancer/ Thoracic Cancer 1 (Non-Small Cell Lung Cancer-Immunotherapy 1)
呼吸器 1 (非小細胞肺癌 - 免疫療法 1)

E

Chairs : Hajime Asahina (Department of Respiratory Medicine, NHO Hokkaido Cancer Center)
Eiji Iwama (Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University)

司会 : 朝比奈 肇 (NHO北海道がんセンター 呼吸器内科)
岩間 映二 (九州大学大学院医学研究院呼吸器内科学分野)

MO1-1 6y update of 1L nivolumab + ipilimumab (N+) in metastatic (m) NSCLC, including in
Japanese pts, from CheckMate 227

Makoto Nishio (Department of Thoracic Medical Oncology Cancer Institute Hospital Japanese Foundation for Cancer Research)
西尾 誠人 (がん研究会有明病院 呼吸器内科)

MO1-2	Safety profile of LIGHT-NING 3rd interim analysis: 1L nivolumab + ipilimumab +/- chemotherapy for metastatic NSCLC Koichi Azuma (Division of Respiriology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine) 東 公一 (久留米大学医学部 呼吸器内科)	Day 1 (Thu) Day 2 (Fri)
MO1-3 Encore	Health-related quality of life in the pivotal LUNAR study of TTFIELDS therapy in metastatic non-small cell lung cancer Li Zhang (Sun Yat-sen University Cancer Center (SYSUCC))	Day 3 (Sat) On-demand
MO1-4	Spatial single cell immune profiling dissects tumor microenvironment feature associated with ICI efficacy in NSCLC Kohsuke Isomoto (Department of Medical Oncology, Kindai University Faculty of Medicine) 磯本 晃佑 (近畿大学医学部 腫瘍内科学教室)	Room 1
MO1-5	Early change of peripheral blood immune cells predicts clinical response of immunotherapy in non-small cell lung cancer Xiao-Rong Yang (School of Medicine, South China University of Technology / Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University)	Room 2 Room 3
MO1-6	The COVID-19 Pandemic and Time to Treatment for Patients with Metastatic Lung Adenocarcinoma in the United States Bryan Iorgulescu (Division of Pathology and Laboratory Medicine, MD Anderson Cancer Center)	Room 4 Room 5

13:40-15:10 Symposium 4 / シンポジウム 4

SY4	What is the "new normal" of multi-center cancer clinical trial group? 多施設臨床試験グループの new normal とは？	
Chairs :	Shogo Nomura (Graduate School of Medicine, The University of Tokyo) Yoichi Nakanishi (Kitakyushu City Hospital Organization)	Room 6 Room 7
司会 :	野村 尚吾 (東京大学大学院医学系研究科) 中西 洋一 (北九州市立病院機構)	Room 8 Room 9
SY4-1	Innovative clinical studies in National Cancer Center East Atsushi Ohtsu (National Cancer Center Hospital East) イノベーション指向型臨床開発試験の取り組み 大津 敦 (国立がん研究センター東病院)	Room 10 Room 11
SY4-2	The future strategy of multi-institutional clinical trials supported by the National Cancer Center Hospital Kenichi Nakamura (National Cancer Center Hospital) 国立がん研究センター中央病院における多施設共同試験の方向性 中村 健一 (国立がん研究センター中央病院)	Room 12 Room 13
SY4-3	New attempt to clinical trials of JGOG Muneaki Shimada (Department of Gynecology, Tohoku University Hospital) 婦人科悪性腫瘍研究機構 (JGOG) の臨床試験に対する新たな試み 島田 宗昭 (東北大学病院 婦人科)	Meet the Experts Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

SY4-4 What the AMED Innovative Cancer Therapy Practical Application Research Project is expected to achieve

Tomoki Naoe (NHO Nagoya Medical Center)

AMED 革新的がん医療実用化研究事業が期待すること

直江 知樹 (国立病院機構名古屋医療センター)

15:30-17:00 Symposium 5 / シンポジウム 5

SY5 Multidisciplinary approach for hepatocellular carcinoma
肝細胞癌に対する集学的治療



Chairs : Takuji Okusaka (National Cancer Center Hospital)
Masafumi Ikeda (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East)

司会 : 奥坂 拓志 (国立がん研究センター中央病院)
池田 公史 (国立がん研究センター東病院 肝胆膵内科)

SY5-1 Update evidence of systemic therapy for HCC: From Early to advanced stage

Richard S. Finn (Geffen School of Medicine at UCLA)

SY5-2 Multidisciplinary treatment in advanced hepatocellular carcinoma: Impact of surgery on outcome after systemic therapy

Shinji Itoh (Department of Surgery and Science, Kyushu University)

進行肝細胞癌に対する集学的治療における外科治療介入の意義

伊藤 心二 (九州大学大学院 消化器・総合外科)

SY5-3 Systemic therapies for advanced hepatocellular carcinoma in Japanese real-world practice

Sadahisa Ogasawara (Department of Gastroenterology, Graduate School of Medicine, Chiba University)

小笠原 定久 (千葉大学大学院医学研究院 消化器内科学)

SY5-4 New treatment strategy for intermediate-stage hepatocellular carcinoma: Combination of local and systemic therapy

Kaoru Tsuchiya (Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital)

Intermediate stage 肝細胞癌に対する全身薬物療法と局所療法の併用

土谷 薫 (武蔵野赤十字病院)

SY5-5 Real-world clinical practice data of systemic chemotherapies for unresectable hepatocellular carcinoma from Japanese multicenter study group

Atushi Hiraoka (Gastroenterology Center, Ehime Prefectural Central Hospital / RELPEC/HCC48)

日本における切除可能肝細胞癌に対する全身薬物療法の現状：多施設共同研究リアルワールドデータ

平岡 淳 (愛媛県立中央病院 消化器内科 / RELPEC/HCC48)

Room 6 (1号館 3F 会議室 131+132)

9:00-10:00 Mini Oral Session 2

MO2 Genitourinary Cancer 1 (Novel Strategies for the treatment of Genitourinary Cancer)

泌尿器 1 (泌尿器がん治療における新たな治療戦略)

E

Chairs : Keita Uchino (NTT Medical Center Tokyo, Department of Medical Oncology)
 Ryosuke Oki (Cancer Institute Hospital of Japanese foundation for cancer research, the department of Medical Oncology)

司会 : 内野 慶太 (NTT東日本関東病院 腫瘍内科)
 大木 遼佑 (がん研有明病院)

MO2-1 Dosimetric Comparison: Volumetric Modulated Arc Therapy and Stereotactic Body Radiotherapy for Prostate Cancer Patients

Eva Y W Cheung (School of Medical and Health Sciences, Tung Wah College)

MO2-2 Investigation of the efficacy of Link Seed in Low Dose Rate Brachytherapy

Renato Naito (Department of Integrative Cancer Therapy and Urology Kanazawa University Graduate School of Medical Science)

内藤 伶奈人 (金沢大学大学院医薬保健学総合研究科 泌尿器集学的治療学)

MO2-3 OIP5-AS1/miR-340-5p axis-mediated versican in upper tract urothelial carcinoma modulates cell migration and invasion

Wei - Chi Hsu (Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan)

MO2-4 Investigation of treatment strategies for patients with low risk metastatic castration-sensitive prostate cancer

Hiroaki Iwamoto (Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science)

Low risk mCSPC患者に対する治療戦略の検討

岩本 大旭 (金沢大学大学院医薬保健学総合研究科 泌尿器集学的治療学)

MO2-5 Efficacy and Safety of bi-weekly Docetaxel in Japanese patients with metastatic castration resistant prostate cancer

Mai Shimura (Department of Medical Oncology, National Cancer Center Hospital East)

志村 麻衣 (国立がん研究センター東病院 腫瘍内科)

MO2-6 Does the starting dose of cabozantinib for metastatic renal cell carcinoma affect treatment efficacy/adverse events?


Noriyoshi Miura (Department of Urology, Ehime University)

三浦 徳宣 (愛媛大学大学院医学系研究科 泌尿器科)

 Day 1 (Thu)
 Day 2 (Fri)
 Day 3 (Sat)
 On-demand
 Room 1
 Room 2
 Room 3
 Room 4
 Room 5
 Room 6
 Room 7
 Room 8
 Room 9
 Room 10
 Room 11
 Room 12
 Room 13
 Meet the Experts
 Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

10:00-10:45 Committee Program 1 / 委員会企画 1 (ガイドライン委員会)

CP1 Practical guideline for febrile neutropenia (3rd Edition)
発熱性好中球減少症 (FN) 診療ガイドライン (改訂第3版) 

Chair : Minoru Yoshida (Fourth Department of Internal Medicine, Teikyo University School of Medicine, Mizonokuchi Hospital)
司会 : 吉田 稔 (帝京大学医学部附属溝口病院 第4内科)

CP1-1 The purpose of preparing the revised third edition of the guidelines for the treatment of febrile neutropenia (FN) and explanation of the algorithm

Minoru Yoshida (Fourth Department of Internal Medicine, Teikyo University School of Medicine, Mizonokuchi Hospital)

発熱性好中球減少症 (FN) 診療ガイドライン改訂第3版作成の趣旨とアルゴリズムの解説
吉田 稔 (帝京大学医学部附属溝口病院 第4内科)

CP1-2 Questionnaire on compliance with Febrile Neutropenia (FN) Guidelines 2nd ed. and risk-based patient selection for outpatient treatment in the 3rd ed.

Nobu Akiyama (Sagamihimawari Clinic)

発熱性好中球減少症 (FN) 診療ガイドライン第2版の遵守状況に関するアンケート調査の結果の概要と第3版のFNのリスク評価と外来治療可能な患者の選択
秋山 暢 (さがみひまわりクリニック)

CP1-3 Should we decide to screen the CMV reactivation when febrile neutropenia persisted? (JSMO FN guideline 3rd edition, CQ11)

Masaya Abe (Department of Internal Medicine, Fukuyama City Hospital, Fukuyama, Japan / Department of Hematology, Oncology and Respiratory Medicine, Okayama University, Okayama, Japan)

FNが持続する場合にCMV再活性化のスクリーニングを行うべきか? (JSMO FN診療ガイドライン改訂第3版, CQ11)

阿部 将也 (福山市民病院 内科 / 岡山大学 血液・腫瘍・呼吸器内科学)


CP1-4 The necessity and issues of Recombinant zoster vaccine in cancer patients receiving chemotherapy

Keiji Nakamura (Department of General Internal Medicine, Kyushu University Hospital)

がん薬物療法を行う患者における帯状疱疹ワクチンの必要性と問題点

中村 啓二 (九州大学病院 総合診療科)

10:45-11:30 Committee Program 1 / 委員会企画 1 (ガイドライン委員会)

CP1 Outline of the Clinical Practice Guidelines for Tumor-Agnostic Treatment in Adult and Pediatric Patients with Advanced Solid Tumors toward Precision Medicine (3.1 Edition)
成人・小児進行固形がんにおける臓器横断的ゲノム診療のガイドライン (改訂第3.1版) について 

Chairs : Takayuki Yoshino (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)

Eishi Baba (Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University)

司会 : 吉野 孝之 (国立がん研究センター東病院)

馬場 英司 (九州大学大学院医学研究院 社会環境医学講義連携社会医学分野)

CP1-5 Advanced solid tumor patients with *BRAF* mutation

Takafumi Koyama (Department of Experimental Therapeutics, National Cancer Center Hospital)

BRAF 遺伝子変異固形がん

小山 隆文 (国立がん研究センター中央病院 先端医療科)

CP1-6 **Clinical Practice Guideline for tumor-agnostic precision oncology in patients with *RET*-altered solid tumors**

Saori Mishima (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.)

成人・小児進行固形がんにおける臓器横断的ゲノム診療のガイドライン: *RET*

三島 沙織 (国立がん研究センター東病院 消化管内科)

13:40-14:40 Mini Oral Session 3

MO3	Hepatobiliary/ Pancreatic Cancer 1 (Pancreatic Cancer 1) 肝胆膵 1 (膵臓 1)	E
Chairs :	Kenji Ikezawa (Osaka International Cancer Institute) Akihiro Ohba (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital)	
司会 :	池澤 賢治 (大阪国際がんセンター 肝胆膵内科) 大場 彬博 (国立がん研究センター中央病院 肝胆膵内科)	
MO3-1	HGCSG 1803: Phase 2 study evaluating efficacy of OX-IRIS in metastatic pancreatic cancer as first line therapy Shintaro Nakano (Department of Gastroenterology, Iwamizawa Municipal General Hospital / Department of Gastroenterology and Hepatology, Hokkaido University Hospital) 中野 真太郎 (岩見沢市立総合病院 消化器内科 / 北海道大学病院 消化器内科)	
MO3-2	Comparison of FOLFIRINOX and gemcitabine with nab-paclitaxel as neoadjuvant therapy in BR pancreatic cancer Takafumi Mie (Cancer Institute Hospital of Japanese Foundation for Cancer Research) 三重 克文 (がん研究会有明病院 肝胆膵内科)	
MO3-3	Efficacy of FOLFIRINOX versus G-nP for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Meta-Analysis Yewan Lim (Faculty of Medicine, Pelita Harapan University)	
MO3-4	Efficacy and Safety of FOLFIRINOX in Comparison to Gemcitabine as Adjuvant Therapy for PC Patients: A Systematic Review Edward Taniaily (Faculty of Medicine, Pelita Harapan University)	
MO3-5	Gemcitabine plus nab-paclitaxel for pancreatic cancer and interstitial lung disease: A nationwide longitudinal study Kei Saito (Nihon University School of Medicine Division of Gastroenterology and Hepatology, Department of Internal Medicine / Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo) 齋藤 圭 (日本大学医学部附属板橋病院 消化器・肝臓内科 / 東京大学医学部附属病院 消化器内科)	
MO3-6	Risk factors for gemcitabine induced pneumonitis in patients with advanced pancreatic cancer Tomoyasu Yoshihiro (Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital) 吉弘 知恭 (九州大学病院 血液腫瘍心血管内科)	

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

14:40-15:40 Mini Oral Session 4

MO4 Rare Cancer 1 (Neuroendocrine neoplasm, Thyroid cancer) **E**
希少がん 1 (神経内分泌腫瘍・がん、甲状腺がん)

Chairs : Shogen Boku (Cancer Treatment Center, Kansai Medical University Hospital)
Daisuke Sakai (Department of Medical Oncology, Osaka International Cancer Institute)
司会 : 朴 将源 (関西医科大学附属病院 がんセンター)
坂井 大介 (大阪国際がんセンター 腫瘍内科)

MO4-1 **Clinical Outcome of Peptide Receptor Radionuclide Therapy for Patients with Advanced Neuroendocrine Tumor**

Taro Shibuki (Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan / Department for the Promotion of Drug and Diagnostic Development, Division of Drug and Diagnostic Development Promotion, Translational Research Support Office, National Cancer Center Hospital East)
澁木 太郎 (国立がん研究センター東病院 肝胆膵内科 / 国立がん研究センター東病院医薬品開発推進部門医薬品開発推進部トランスレーショナルリサーチ支援室)

MO4-2 **PRRT Pioneers Novel Therapeutic Network Paradigms for Neuroendocrine Tumors (NETs)**

Izumi Ohno (Department of Clinical Oncology, Chiba University Hospital)
大野 泉 (千葉大学医学部附属病院 腫瘍内科)

MO4-3 **Experience with the whole-genome sequencing of Thyroid cancer**

Yuko Takahashi (Department of Breast and Endocrine Surgery, Okayama University Hospital)
高橋 侑子 (岡山大学病院 乳腺・内分泌外科)

MO4-4 **Short-term outcomes of nivolumab plus chemotherapy for advanced gastric neuroendocrine cell carcinoma**

Misa Onishi (Department of Gastroenterology, Kanagawa Cancer Center)
大西 美沙 (神奈川県立がんセンター 消化器内科)

MO4-5 **Efficacy Of Selpercatinib As Tyrosine Kinase Inhibitor In RET-Mutant Medullary Thyroid Cancer : A Systematic Review**

Reylinge Relia Margouw (Faculty of Medicine, Pelita Harapan University)

MO4-6 **演題取下**

CP2 Social Medical Working Group Symposium
SNS-WG シンポジウム 

Chair : Tomoyuki Goto (Shiga General Hospital)
 Discussants: Takuya Kishi (Department of Graduate School of Medicine (Cardiology), International University of Health and Welfare)
 Yuji Uehara (Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital)
 Daisuke Ogiya (Department of Hematology and Oncology, Tokai University School of Medicine)
 Yukinori Ozaki (Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research)
 Shigemasa Takamizawa (NTT Medical Center Tokyo, Department of Medical Oncology)
 Yuhei Yamaguchi (Nagoya Medical Center)
 司会 : 後藤 知之 (滋賀県立総合病院 腫瘍内科)
 ディスカッサント: 岸 拓弥 (国際医療福祉大学大学院医学研究科 循環器内科)
 上原 悠治 (都立駒込病院 呼吸器内科)
 扇屋 大輔 (東海大学医学部 内科学系 血液・腫瘍内科学)
 尾崎 由記範 (がん研究会有明病院 乳腺内科)
 高見澤 重賢 (NTT東日本関東病院 腫瘍内科)
 山口 祐平 (名古屋医療センター)

Opening Remarks

Manabu Muto (Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University)

冒頭挨拶

武藤 学 (京都大学大学院医学研究科 腫瘍薬物治療学講座)

CP2-1 The dawn of SNS in Japanese Society of Medical Oncology

Yuhei Yamaguchi (Senior Resident, Nagoya Medical Center)

JSMO SNS 元年

山口 祐平 (名古屋医療センター 内科専攻医)

CP2-2 Develop Your Online Presence and Foster Connections: Tips for Using Social Media as a Medical Oncologist

Yuji Uehara (Department of Thoracic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center - Komagome Hospital / Department of Thoracic Oncology, National Cancer Center Hospital East)

SNSをキッカケに広がるアカデミアの世界

上原 悠治 (東京都立駒込病院 呼吸器内科 / 国立がんセンター東病院 呼吸器内科)

CP2-3 Light and dark side of the official SNS of the Japanese Society of Cardiology through 5 years of activities by the official X @JCIRC_IPR and YouTube

Takuya Kishi (Department of Graduate School of Medicine (Cardiology), International University of Health and Welfare)

日本循環器学会公式X @JCIRC_IPRとYouTubeの5年間の活動で見えてきた学会公式SNSの光と闇
 岸 拓弥 (国際医療福祉大学大学院医学研究科 循環器内科)

Day 1 (Thu)
 Day 2 (Fri)
 Day 3 (Sat)
 On-demand
 Room 1
 Room 2
 Room 3
 Room 4
 Room 5
 Room 6
 Room 7
 Room 8
 Room 9
 Room 10
 Room 11
 Room 12
 Room 13
 Meet the Experts
 Poster

Room 7 (1号館 3F 会議室 133+134)

9:00-10:30 Oral Session 2

O2 Hepatobiliary/ Pancreatic Cancer
肝胆胰

E

Chairs : Li-Tzong Chen (Department of Internal Medicine, Kaohsiung Medical University)
Masashi Kanai (Cancer Treatment Center, Kansai Medical University Hospital)
Discussants: Satoshi Kobayashi (Department of Gastroenterology, Kanagawa Cancer Center)
Susumu Hijioka (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital)
司会 : Li-Tzong Chen (Department of Internal Medicine, Kaohsiung Medical University)
金井 雅史 (関西医科大学附属病院 がんセンター)
プレゼンター: 小林 智 (神奈川県立がんセンター消化器内科)
飯岡 範 (国立がん研究センター中央病院肝胆膵内科)

O2-1 Updated results from KEYNOTE-966: pembrolizumab + gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer

Masato Ozaka (The Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR))
尾阪 将人 (The Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR))

O2-2 Pivotal phase 2 trial of tasurgatinib (E7090) for patients (pts) with *FGFR2* fusion-positive cholangiocarcinoma (CCA)

Encore

Takamichi Kuwahara (Aichi Cancer Center, Nagoya, Japan)
桑原 崇通 (Aichi Cancer Center, Nagoya, Japan)

O2-3 A Phase Ia/b study evaluating the safety and efficacy of brigimadlin (BI 907828) in patients with advanced solid tumors

Encore

Noboru Yamamoto (Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan)
山本 昇 (Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan)

O2-4 Chemoradiation Augments Gemcitabine in HRD-Positive Pancreatic Cancer: Results from A Randomized Adjuvant Trial

Yung-Yeh Su (National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan / Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan / Department of Internal Medicine, Kaohsiung Medical University Hospital and Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan)

O2-5 Efficacy and Safety of [177Lu] Lu-DOTA-TATE in Newly Diagnosed Patients with Advanced Grade 2 and Grade 3, Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: Primary Analysis of the Phase 3 Randomized NETTER-2 Study

Encore

Simron Singh (University of Toronto, Toronto, ON, Canada)

10:30-11:30 Mini Oral Session 5

MO5	Hepatobiliary/ Pancreatic Cancer 2 (Pancreatic Cancer 2) 肝胆癌 2 (膵臓 2)	E
Chairs :	Hiroshi Imaoka (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East) Kenji Ikezawa (Osaka International Cancer Institute)	
司会 :	今岡 大 (国立がん研究センター東病院肝胆膵内科) 池澤 賢治 (大阪国際がんセンター肝胆膵内科)	
MO5-1	Efficacy and Safety of Olaparib as a Potential Treatment for Patients with Pancreatic Cancer: A Systematic Review	
	Christian Charlie Chang (Department of Medicine, University of Pelita Harapan)	
MO5-2	Assosiation between HRD and TTF to platinum-based chemotherapy for pancreatic cancer by using the C-CAT database	
	Yurie Tokito (Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo) 時任 佑里恵 (東京大学医学部附属病院 消化器内科)	
MO5-3	Gene Mutations Portraits in Pancreatic Cancer Survival: A Network Meta-Analysis	
	Citra Aryanti (Division of Digestive Surgery, Hasanuddin University)	
MO5-4	Clinical utility of Upfront Comprehensive Genomic Profiling for the treatment of Advanced Pancreatic Cancer	
	Eiichiro So (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine) 宗 英一郎 (慶應義塾大学医学部 内科学教室 (消化器))	
MO5-5	FAT1 regulates expression of tumor suppressor gene PDCD4 in Pancreatic cancer	
	Archismita Kundu (Department of Biochemistry, All India Institute of Medical Sciences, New Delhi)	

13:40-14:30 Mini Oral Session 6

MO6	Rare Cancer 2 (Melanoma) 希少がん 2 (メラノーマ)	E
Chairs :	Keigo Komine (Department of Medical Oncology, Tohoku University Hospital) Yoshihiro Yakushijin (Dept. of Clinical Oncology, Ehime Univ. Grad. School of Med.)	
司会 :	小峰 啓吾 (東北大学病院腫瘍内科) 葉師神 芳洋 (愛媛大学医学部大学院 臨床腫瘍学講座)	
MO6-1	Overall Survival and Safety of Tebentafusp as Potential Treatment for Patients with Uveal Melanoma: A Systematic Review	
	Kho Jesselyne Aurelia Santoso (Faculty of Medicine, Pelita Harapan University)	
MO6-2	The Predictive Potential of Comprehensive SWI/SNF Gene Analysis in Immunotherapy for Malignant Melanoma	
	Rika Moku (Department of Medical Oncology, Hokkaido University Hospital) 柰 里花 (北海道大学病院 腫瘍内科)	
MO6-3	A case of BRAF mutation-positive vaginal malignant melanoma treated with the combination of dabrafenib + trametinib	
	Naoki Okada (Department of Medical Oncology, Kanazawa Medical University) 岡田 直樹 (金沢医科大学 腫瘍内科)	

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

MO6-4 Actionable Oncogenic Gene Alterations in Japanese Malignant Melanoma: Insights from Real-world C-CAT Data
 Takuro Noguchi (Department of Medical Oncology, Hokkaido University Graduate School of Medicine / Department of Medical Oncology, Hokkaido University Hospital)
 野口 卓郎 (北海道大学大学院医学研究院 腫瘍内科学教室 / 北海道大学病院 腫瘍内科)

MO6-5 Combination of Ipilimumab With Nivolumab in Melanoma Grade IV And Asymptomatic Brain Metastasis: Systematic Review
 Natasha K Law (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)

16:10-17:10 Mini Oral Session 7

MO7 Artificial Intelligence (AI) E
 人工知能 (AI)
 Chairs : Ryuji Hamamoto (Division of Medical AI Research and Development, National Cancer Center Research Institute)
 Shigemi Matsumoto (Department of Real World Data R & D, Graduate School of Medicine, Kyoto University)
 司会 : 浜本 隆二 (国立がん研究センター研究所・医療AI研究開発分野)
 松本 繁巳 (京都大学大学院医学研究科 リアルワールドデータ研究開発講座)

MO7-1 AI-Ensemble Model for Precise Identification of Primary Organ in Cancers of Unknown Cause Using DNA Methylation Profiles
 Marco Develasco (Department of Genome Biology, Kindai University Faculty of Medicine)
DNAメチル化プロファイルを用いた原因不明癌における原発臓器の精密同定のためのAIアンサンブルモデル
 Marco Develasco (近畿大学医学部 ゲノム生物学教室)

MO7-2 Enhancing Lung Cancer Prognosis Prediction through Image-based Comprehensive Gene Expression Analysis with Deep Learning
 Yang-Ming Yeh (Institute of Statistical Science, Academia Sinica)

MO7-3 Role of wearable technology for analyzes and monitor of health data in relation to blood Cancer survivors patients
 Vikas Sharma (IDC Research center)

MO7-4 Artificial neural network application in NSCLC overall staging prediction
 Eva Y W Cheung (School of Medical and Health Sciences, Tung Wah College)

MO7-5 Artificial Intelligence-Assisted Colonoscopy Detection Rate on Colorectal Neoplasia Patient: A systematic review of RCTs
 Mohammad Z. Sabran (Faculty of Medicine, Pelita Harapan University, Indonesia)

MO7-6 Exploring the holistic needs assessment in Integrated Cancer Care Program
 Wan-Shuan Lin (Department of Nursing, University of Kang Ning, Taipei, Taiwan)

Room 8 (2号館 3F 会議室 234)

9:00-10:30 Symposium 6 / シンポジウム 6

SY6 Training Program for Improving Cancer Survivorship: Present and Future
がんサバイバーシップの充実に向けた教育研修：現状と将来像

Chairs : Satoshi Ikeda (Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center)

Hisakazu Nishimori (Department of Hematology, Hiroshima City Hiroshima Citizens Hospital)

司会 : 池田 慧 (神奈川県立循環器呼吸器病センター 呼吸器内科)

西森 久和 (広島市立広島市民病院 血液内科)

SY6-1 Cancer survivorship care from the perspective of patients and those involved

Yoko Matsumoto (NPO Ehime Cancer Support Orangenokai)

患者・当事者からみたがんサバイバーシップケア

松本 陽子 (NPO法人愛媛がんサポートおれんじの会)

SY6-2 Development of cancer survivorship educational programs for healthcare providers in Japan

Kenjiro Aogi (Division of Clinical Research Promotion, NHO Shikoku Cancer Center)

日本の医療者に向けたがんサバイバーシップ教育プログラムの開発

青儀 健二郎 (NHO四国がんセンター 臨床研究推進部)

SY6-3 Implementation Strategies of Cancer Survivorship Care Education Program in Japan

Kiyotaka Watanabe (Division of Medical Oncology, Department of Medicine, School of Medicine, Teikyo University)

サバイバーシップ教育プログラムの地域への展開

渡邊 清高 (帝京大学医学部 内科学講座腫瘍内科)

SY6-4 Peer Supporter Training Program

Nobuya Akizuki (Department of Psycho-Oncology/Psychiatry, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital)

ピアサポーター養成事業

秋月 伸哉 (がん・感染症センター都立駒込病院 精神腫瘍科・メンタルクリニック)

10:30-11:30 Mini Oral Session 8

MO8 Palliative Care/Symptom Management 1
緩和ケア・支持療法 1

Chairs : Yu Uneno (Kyoto University Hospital)

Takao Takahashi (Saitama Medical University International Medical Center)

司会 : 采野 優 (京都大学医学部附属病院)

高橋 孝郎 (埼玉医科大学国際医療センター)

MO8-1 A Systematic Review on the Application of Percutaneous Cervical Cordotomy for Cancer Pain Management

Wilky Waluyo (Department of Medicine, Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Banten, Indonesia)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

MO8-2 Which element of advance care planning is associated with the quality of end-of-life care? : A Multicenter Cohort Study
Takaaki Hasegawa (Center for Psycho-oncology and Palliative Care, Nagoya City University Hospital)

質の高い終末期療養を実現するには、アドバンス・ケア・プランニングのどの要素が重要か? : 多施設共同前向き観察研究
長谷川 貴昭 (名古屋市立大学病院緩和ケアセンター)

MO8-3 Efficacy and Safety of Methadone for Pain Induced by Bone Metastasis in Cancer Patients
Yuichiro Nishibori (Division of Thoracic Oncology, Shizuoka Cancer Center / Division of Palliative Medicine, Shizuoka Cancer Center)

骨転移痛に対するメサドンの有効性と安全性の検討
西堀 雄一郎 (静岡県立静岡がんセンター 呼吸器内科 / 静岡県立静岡がんセンター 緩和医療科)

MO8-4 Olanzapine for opioid-induced nausea and vomiting in patients with cancer : multicenter prospective observational study
Takako Ikegami (Department of Palliative Medicine National Cancer Center Hospital)
池上 貴子 (国立がん研究センター中央病院 緩和医療科)

MO8-5 Tranexamic Acid in Bleeding Management of Advanced Cancer in Palliative Care: A Systematic Review and Pooled Analysis
Ian Huang (Department of Internal Medicine, Faculty of Medicine, Universitas Pelita Harapan)

MO8-6 Outcome of cancer treatment in Endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) cases in our hospital
Sena Tsukamoto (Department of Medical Oncology, Kagawa University Hospital)
Endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) 実施症例における当院のがん薬物療法の治療成績
塚本 汐奈 (香川大学医学部附属病院)

13:40-15:10 Symposium 7 / シンポジウム 7

SY7 Isn't that treatment overkill? その治療、やり過ぎじゃないですか?

Chairs : Akira Inoue (Department of Palliative Medicine, Tohoku University School of Medicine)
Yasuhiro Fujisaka (Osaka Medical and Pharmaceutical University, Medical Oncology)
司会 : 井上 彰 (東北大学大学院医学系研究科 緩和医療学分野)
藤原 保仁 (大阪医科大学医学部 内科学講座腫瘍内科学)

SY7-1 Discontinuation of Aggressive Anticancer Treatment at End-of-Life for Cancer Patients: Perspectives from Oncology Palliative and Home-Based Physicians
Shuji Hiramoto (Department of Oncology and Palliative Care, Peace Home Care Clinic)

積極的抗がん治療の適切な終了について
～腫瘍緩和ケア医そして在宅医の視点から～
平本 秀二 (ピースホームケアクリニック 内科・緩和ケア内科・腫瘍内科)

SY7-2 Optimizing Immunotherapy in Cancer: Balancing Efficacy with Quality of Life
Yasushi Goto (National Cancer Center Hospital Department of Thoracic Oncology)

そのICI、やり過ぎでしょ
後藤 悌 (国立がん研究センター中央病院 呼吸器内科)

SY7-3	<p>That infusion is too much, isn't it? ~Consider the optimal infusion volume for patients with advanced cancer~ Tomoo Ikari (Department of Palliative Medicine, Tohoku University School of Medicine / Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University)</p> <p>その輸液、やりすぎでしょ? ~終末期がん患者に最適な輸液量を考察する~ 猪狩 智生 (東北大学大学院医学系研究科 緩和医療学分野 / 北海道大学大学院医学研究院 呼吸器内科学教室)</p>	Day 1 (Thu) Day 2 (Fri) Day 3 (Sat)
SY7-4	<p>Prognostication in patients with advanced cancer in the last months of life Yusuke Hiratsuka (Department of Palliative Medicine, Takeda General Hospital / Department of Palliative Medicine, Tohoku University Graduate School of Medicine)</p> <p>抗がん治療が難しくなってきた時期の予後予測 平塚 裕介 (竹田綜合病院 緩和医療科 / 東北大学大学院医学系研究科 緩和医療学分野)</p>	On-demand Room 1
SY7-5	<p>Communication for appropriate treatment selection Tomohiro Nishi (Department of Medical Oncology, Kawasaki Municipal Ida Hospital)</p> <p>適切な治療選択のためのコミュニケーション 西 智弘 (川崎市立井田病院 腫瘍内科)</p>	Room 2 Room 3
15:30-17:00 Symposium 8 / シンポジウム 8		
SY8	<p>Psychooncology Update ~ Evidence & Practice ~ サイコオンコロジー Update ~エビデンスとプラクティス~</p> <p>Chairs : Koji Sugano (Juntendo Tokyo Koto Geriatric Medical Center) Asao Ogawa (National Cancer Center Hospital East)</p> <p>司会 : 菅野 康二 (順天堂大学医学部附属順天堂東京江東高齢者医療センター) 小川 朝生 (国立がん研究センター東病院)</p>	Room 4 Room 5 Room 6
SY8-1	<p>Smartphone psychotherapy for reducing fear of cancer recurrence: A decentralized randomized clinical trial Tatsuo Akechi (Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences)</p> <p>再発恐怖をスマートフォン精神療法で緩和する -分散型臨床試験基盤を用いた多施設ランダム化比較試験 明智 龍男 (名古屋市立大学大学院医学研究科 精神・認知・行動医学分野)</p>	Room 7 Room 8 Room 9
SY8-2	<p>Communication and decision-making in cancer care Maiko Fujimori (National Cancer Center Institute for Cancer Control)</p> <p>がん医療におけるコミュニケーション/意思決定 藤森 麻衣子 (国立がん研究センター がん対策研究所)</p>	Room 10 Room 11
SY8-3	<p>Delirium in Cancer Patients: Based on the JPOS-JASCC Clinical Practice Guidelines Second Edition Hitoshi Tanimukai (Department of Palliative Medicine, Kyoto University Hospital / Department of Human Health Sciences, Kyoto University)</p> <p>がん患者におけるせん妄 ~がん患者におけるせん妄ガイドライン2022年版を踏まえて~ 谷向 仁 (京都大学医学部附属病院 緩和医療科/京都大学大学院医学研究科 人間健康科学系専攻)</p>	Room 12 Room 13

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

SY8-4 The essence of the Clinical Practice Guidelines for the care of psychologically distressed bereaved families and Future Prospects

Hikomichi Matsuoka (Department of Psycho-Oncology, National Cancer Center Hospital)

遺族ケアガイドラインのエッセンスと今後の展望

松岡 弘道 (国立がん研究センター中央病院 精神腫瘍科)

**SY8-5 The meaning of the third place
Peer Support, Past and Future**

Naomi Sakurai (Cancer Survivors Recruiting Project, General Incorporated Association / Cancer Solutions K.K.)

第三の居場所があることの意味 ～ピアサポートのこれまでとこれから～

桜井 なおみ (一般社団法人CSRプロジェクト / キャンサーソリューションズ株式会社)

Room 9 (2号館 3F 会議室 232+233)

9:00-10:00 Mini Oral Session 9

MO9 Breast Cancer 1 (HER2-negative breast cancer)
乳癌 1 (HER2 陰性乳癌)

E

Chairs : Tsutomu Iwasa (Department of Medical Oncology, Kindai University faculty of medicine)
Fumikata Hara (Cancer Institute Hospital of JFCR)

司会 : 岩朝 勤 (近畿大学病院 腫瘍内科)
原文 堅 (がん研究会有明病院 乳腺内科)

MO9-1 **E7389-LF as 1L chemotherapy for advanced/metastatic HER2-negative breast cancer (HER2- BC): Phase 1 dose-expansion study**

Hiroyuki Yasojima (National Hospital Organization Osaka National Hospital, Osaka, Japan)
八十島 宏行 (National Hospital Organization Osaka National Hospital, Osaka, Japan)

MO9-2 **Toxicity of combination therapy with nivolumab and abemaciclib in HR-positive metastatic breast cancer: WJOG11418B**

Encore

Hitomi Sakai (Advanced Cancer Translational Research Institute, Showa University / Department of Medical Oncology, Kindai University Faculty of Medicine)
酒井 瞳 (昭和大学 先端がん治療研究所 / 近畿大学医学部 内科学腫瘍内科)

MO9-3 **Ribociclib plus letrozole vs letrozole alone in HR+/HER2- advanced breast cancer: a systematic review and meta-analysis**

Mohammad Z. Sabran (Faculty of Medicine, Pelita Harapan University, Indonesia)

MO9-4 **Palbociclib plus letrozole vs letrozole alone in ER+/HER2- advanced breast cancer: a systematic review and meta-analysis**

Mohammad Z. Sabran (Faculty of Medicine, Pelita Harapan University, Indonesia)

10:00-11:30 Oral Session 3

O3 Gastrointestinal Cancer 1 (Gastric Cancer)
消化器 1 (胃がん)

E

Chairs : Tomohiro Nishina (Department of Cancer Genomic Medicine, NHO Shikoku Cancer Center)
Nozomu Machida (Kanagawa Cancer Center, Department of Gastroenterology)

Discussants : Hisato Kawakami (Department of Medical Oncology, Kindai University Faculty of Medicine)
Izuma Nakayama (Department of Gastrointestinal Oncology, National Cancer Center Hospital East)

司会 : 仁科 智裕 (国立病院機構四国がんセンター がんゲノム医療センター)

町田 望 (神奈川県立がんセンター 消化器内科)

プレゼンター: 川上 尚人 (近畿大学医学部内科学腫瘍内科部門)

中山 巖馬 (国立がん研究センター東病院 消化管内科)

O3-1 **A prospective observational study of MSI screening in chemotherapy-naive advanced gastric cancer: WJOG13320GSP**

Encore

Kyoko Kato (Department of Medical Oncology, National Hospital Organization Nagoya Medical Center)

加藤 恭子 (国立病院機構名古屋医療センター 腫瘍内科)

O3-2 **Zolbetuximab + CAPOX in 1L advanced gastric/gastroesophageal junction cancer: Japanese subgroup analysis from GLOW study**

Hirokazu Shoji (Department of Gastrointestinal Oncology, National Cancer Center Hospital)
庄司 広和 (Department of Gastrointestinal Oncology, National Cancer Center Hospital)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

03-3
Encore **Final analysis of FIGHT, A randomized phase 2 trial of Bemarituzumab in 1L advanced gastric/gastroesophageal cancer (GC)**
 Kensei Yamaguchi (Gastroenterological Chemotherapy Department, The Cancer Institute Hospital of JFCR)
 山口 研成 (Gastroenterological Chemotherapy Department, The Cancer Institute Hospital of JFCR)

03-4
First-Line Tislelizumab Plus Chemotherapy in Gastric/Gastroesophageal Junction Cancer: RATIONALE-305 Asian Subgroup
 Ken Kato (National Cancer Center Hospital)
 加藤 健 (National Cancer Center Hospital)

03-5
Encore The intergroup phase III RINDBeRG trial; ramucirumab plus irinotecan beyond PD after ramucirumab for gastric cancer
 Hironaga Satake (Department of Medical Oncology, Kochi Medical School / Department of Medical Oncology, Kobe City Medical Center General Hospital)
 佐竹 悠良 (高知大学医学部 腫瘍内科 / 神戸市立医療センター中央市民病院 腫瘍内科)

13:40-15:10 Oral Session 4

04 Genitourinary Cancer
 泌尿器 E

Chairs : Eric Jonasch (UT MD Anderson Cancer Center)
 Norio Nonomura (Department of Urology, Osaka University)

Discussants : Taigo Kato (Department of Urology, Osaka University Graduate School of Medicine)
 Aiko Maejima (National Cancer Center Hospital, department of Medical Oncology, Urology)
 Kohji Takemura (Toranomon hospital, Department of Medical Oncology)

司会 : Eric Jonasch (UT MD Anderson Cancer Center)
 野々村 祝夫 (大阪大学 泌尿器科学)

マイクアップ : 加藤 大悟 (大阪大学大学院医学系研究科器官制御外科学泌尿器科)
 前嶋 愛子 (国立がん研究センター中央病院 腫瘍内科、泌尿器・後腹膜腫瘍科)
 竹村 弘司 (虎の門病院 臨床腫瘍科)

04-1
Encore Long-Term Outcomes of Active Surveillance for Early-Stage Prostate Cancer -From The MHLW group research 11-10-
 Takuma Kato (Department of Urology, Faculty of medicine, Kagawa University)
早期前立腺癌に対する監視療法の長期成績 -厚生労働省班研究 11-10 より-
 加藤 琢磨 (香川大学医学部附属病院 泌尿器科)

04-2
Real-World Analysis of Sequential Treatment Challenges in Advanced Urothelial Carcinoma Patients in Japan
 Yuki Kita (Department of Urology, Kyoto University)
 北 悠希 (京都大学 泌尿器科)

04-3
Catalog of preoperative blood-based biomarkers in patients treated with radical cystectomy for bladder carcinoma
 Keiichiro Mori (Department of Urology, The Jikei University School of Medicine)
 森 啓一郎 (東京慈恵会医科大学 泌尿器科)

04-4
Encore EV-302/KEYNOTE-A39: Phase 3 Study of Enfortumab Vedotin Plus Pembrolizumab Vs Chemo in 1L Advanced Urothelial Carcinoma
 Thomas Powles (Saint Barts Cancer Centre, Queen Mary University of London)

04-5 **UPDATED EFFICACY AND SAFETY OF ERDAFITINIB IN BCG-UNRESPONSIVE, HIGH-RISK NMIBC WITH FGFR3/2 ALT IN THOR-2 COHORT2**

Encore

Yuji Miura (Department of Medical Oncology, Toranomon Hospital)
三浦 裕司 (虎の門病院 臨床腫瘍科)

15:10-16:10 Mini Oral Session 10

MO10 Lung Cancer/ Thoracic Cancer 2 (Non-Small Cell Lung Cancer-Immunotherapy 2)
呼吸器 2 (非小細胞肺癌-免疫療法 2)

E

Chairs : Masahiro Morise (Department of Respiratory Medicine, Nagoya University Graduate School of Medicine)

Yuka Kato (NHO Shikoku Cancer Center)

司会 : 森瀬 昌宏 (名古屋大学大学院医学系研究科呼吸器内科学)
加藤 有加 (国立病院機構四国がんセンター)

MO10-1 **Pre- and Post-treatment Biomarkers for Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitor**

Daiki Murata (Kurume University School of Medicine, Division of Respiriology, Neurology, and Rheumatology)

非小細胞肺癌に対する免疫チェックポイント阻害剤の治療開始前後の予後予測マーカーに関する検討
村田 大樹 (久留米大学病院第一内科 呼吸器・神経・膠原病内科部門)

MO10-2 **Biomarker research for early response evaluation of immune checkpoint inhibitors in NSCLC using liquid biopsy**

Takahiro Mitsumura (Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital / Department of Respiratory Medicine, Tokyo Medical and Dental University)

リキッドバイオプシーを用いた免疫チェックポイント阻害剤の早期効果判定バイオマーカー研究
三ツ村 隆弘 (虎の門病院 呼吸器センター内科 / 東京医科歯科大学病院 呼吸器内科)

MO10-3 **Early tumor shrinkage as Survival predict factor in patients with non-small cell lung cancer treated with pembrolizumab**

Kentaro Nakanishi (Department of Thoracic Oncology, Kansai Medical University)

進行・再発非小細胞肺癌患者におけるペムブロリズマブ単剤療法の生存予測因子としてのEarly tumor shrinkageの有効性に関する検討
中西 健太郎 (関西医科大学 呼吸器腫瘍内科学講座)

MO10-4 **Pretreatment eosinophil counts as a predictive biomarker in NSCLC patients treated with immune checkpoint inhibitors**

Eiji Takeuchi (Department of Clinical Investigation, NHO Kochi Hospital)

竹内 栄治 (国立病院機構 高知病院 臨床研究部)

MO10-5 **Evaluation of Lymph Node Germinal Centers as Prognostic Indicators in Immune Checkpoint Inhibitor**

Yohei Kawaguchi (Department of Thoracic Surgery, Tokyo Medical University Hachioji Medical Center)

河口 洋平 (東京医科大学八王子医療センター 呼吸器外科)

MO10-6 **Risk factors for immune checkpoint inhibitor-induced pneumonitis in NSCLC with comorbid interstitial pneumonia**

Yuriko Ishida (Department of Respiratory Medicine, Faculty of Medicine Hokkaido University)

石田 有莉子 (北海道大学大学院医学研究院 呼吸器内科学教室)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

On-demand

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Experts

Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

16:10-17:10 Mini Oral Session 11

MO11 Lung Cancer/ Thoracic Cancer 3 (Non-Small Cell Lung Cancer-TKI)
呼吸器 3 (非小細胞肺癌-TKI) E

Chairs : Terufumi Kato (Department of Thoracic Oncology, Kanagawa Cancer Center)
Eisaku Miyauchi (Department of Respiratory Medicine, Tohoku University Hospital)
司会 : 加藤 晃史 (神奈川県立がんセンター 呼吸器内科)
宮内 栄作 (東北大学病院 呼吸器内科)

MO11-1 **KontRAst-01 update: Safety and efficacy of JDQ443 in *KRAS G12C*-mutated non-small cell lung cancer (NSCLC)**
Encore
Noboru Yamamoto (Department of Experimental Therapeutics, National Cancer Center Hospital)
山本 昇 (国立がん研究センター中央病院 先端医療科)

MO11-2 **Beamion LUNG-1, a Phase Ia/b trial of zongertinib (BI 1810631) in pts with solid tumors: focus on pts with *HER2m+* NSCLC**
Encore
Kiyotaka Yoh (Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan)

MO11-3 **Phase 2 study of osimertinib for untreated patients with NSCLC harboring uncommon *EGFR* mutations: UNICORN study**
Encore
Kana Hashimoto (Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Komagome Hospital)
橋本 佳奈 (東京都立駒込病院)

MO11-4 **Impact of Clinical Outcomes of Osimertinib on the C797S Mutation Status after Osimertinib Failure**
Naho Matsubara (Department of Thoracic Oncology, National Cancer Center Hospital)
松原 奈穂 (国立がん研究センター中央病院 呼吸器内科)

MO11-5 **Tepotinib post-marketing surveillance in patients with advanced NSCLC (aNSCLC) with *MET* exon 14 skipping**
Terufumi Kato (Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan)

MO11-6 **Repotrectinib in patients (pts) with *ROS1* fusion-positive (*ROS1+*) NSCLC: Update from the phase 1/2 TRIDENT-1 trial**
Encore
Koichi Goto (Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan)
後藤 功一 (国立がん研究センター東病院 呼吸器科)

Room 10 (2号館 2F 会議室 224)

9:00-10:30 Symposium 9 / シンポジウム 9

SY9 Future aspects of cell therapy
細胞療法のさらなる展開

Chairs : Miki Ando (Department of Hematology, Juntendo University School of Medicine)
Tatsu Shimoyama (Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital)

司会 : 安藤 美樹 (順天堂大学大学院医学研究科 血液学講座)
下山 達 (都立駒込病院 腫瘍内科)

SY9-1 CAR-NK

May Daher (MD Anderson Cancer Center)

SY9-2 Development of CAR-T therapy for solid tumors

Yoshihiro Miyahara (Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine)
宮原 慶裕 (三重大学大学院医学系研究科 個別化がん免疫治療学)

SY9-3 iPSC-derived next-generation T cell therapy for refractory tumors

Miki Ando (Department of Hematology, Juntendo University School of Medicine)
難治性腫瘍に対する iPSC 由来次世代 T 細胞療法
安藤 美樹 (順天堂大学大学院医学研究科 血液内科学)

10:30-11:30 Mini Oral Session 12

MO12 Hematologic Malignancies 1 (Leukemia)
血液 1 (白血病 1)

Chairs : Naoko Hosono (University of Fukui Hospital, Department of Blood Transfusion)
Satoshi Nishiwaki (Department of Advanced Medicine, Nagoya University Hospital)

司会 : 細野 奈穂子 (福井大学医学部附属病院 輸血部)
西脇 聡史 (名古屋大学医学部附属病院先端医療開発部)

MO12-1 NGS profile and the mathematical prediction model for venetoclax combination therapy in HM-SCREEN-Japan 02 study

Tomoaki Ueda (Department of Hematology and Oncology, Osaka University Graduate School of Medicine)
上田 智朗 (大阪大学大学院医学系研究科 血液・腫瘍内科学)

MO12-2 Genomic Prolife and Clinical Features of Clonal Hematopoiesis in AML patients

Sunggi Chi (Department of Hematology, National Cancer Center East / Exploratory Oncology Research & Clinical Trial Center, National Cancer Center)
池 成基 (国立がん研究センター東病院 血液腫瘍科 / 国立がん研究センター・先端医療開発センター)

MO12-3 Flexible genomic profiling study for AML regardless of test point: HM-SCREEN-JAPAN02

Naoko Hosono (Department of Hematology and Oncology, University of Fukui Hospital)
細野 奈穂子 (福井大学医学部附属病院 血液・腫瘍内科)

MO12-4 Effect of cytoskeleton inhibitors on mitochondrial metabolism and function in B-ALL

Bhanu Priya Awasthi (Department of Biochemistry, AIIMS, Ansari Nagar)
Bhanu Priya Awasthi (Department of Biochemistry)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

MO12-5 Examination of tumor-agnostic variants in the combined cohorts of HM-SCREEN-JAPAN 01 and 02 studies

Hironori Arai (Department of Hematology and Oncology, Japanese Red Cross Narita Hospital / Department of Hematology, National Cancer Center Hospital East)
新井 宏典 (成田赤十字病院 血液腫瘍科 / 国立がん研究センター東病院 血液腫瘍科)

MO12-6 Efficacy and safety of venetoclax and azacytidine for acute myeloid leukemia: a retrospective, single-center study

Yuhei Yamaguchi (Department of Hematology, NHO Nagoya Medical Center, Aichi, Japan)
山口 祐平 (名古屋医療センター 血液内科)

13:40-15:40 Joint Symposium 4 (JOA/JSMO) / 合同シンポジウム 4 (日本整形外科学会 / 日本臨床腫瘍学会)

JS4

For well-being of the cancer patients suffering from bone metastases:

To develop a new horizon (onco-orthopaedics)

20 万骨転移患者のウェル・ビーイングを目指して：新しい地平 (オンコ-オルソペディクス) を開拓する



Chairs : Yoshihiro Nishida (Department of Rehabilitation Medicine, Nagoya University Hospital)
Hiroyuki Shibata (Akita University)

司会 : 西田 佳弘 (名古屋大学医学部附属病院 リハビリテーション科)
柴田 浩行 (秋田大学)

JS4-1 The Role of Designated Cancer Care Hospitals in Basic Plan to Promote Cancer Control Programs

Takuji Ueno (Cancer and Disease Control Division, Public Health Bureau, Ministry of Health, Labour and Welfare)

新整備指針および第4期計画で拠点病院に求められる役割ーがん患者・家族のQOL向上を目指してー
上野 琢史 (厚生労働省 健康・生活衛生局 がん・疾病対策課)

JS4-2 Importance of Cancer Board for Bone Metastases

Hideo Morioka (Department of Orthopaedic Surgery, National Hospital Organization Tokyo Medical Center)

骨転移がん患者ボードの重要性

森岡 秀夫 (国立病院機構東京医療センター 整形外科)

JS4-3 How to Host a Remote Bone Metastasis Cancer Board-You don't have to have an all-star cast !!

Teruhisa Azuma (Division of General Internal Medicine, Nara Prefecture General Medical Center)

リモートで骨転移がん患者ボードを開催するには-オールスターキャストでなくても-

東 光久 (奈良県総合医療センター 総合診療科)

JS4-4 Orthopaedic intervention may change QOL and QOD of cancer patients drastically -Proposal of a novel field, onco-orthopaedics-

Hiroataka Kawano (Department of Orthopaedic Surgery, School of Medicine, Teikyo University)

整形外科の介入が変えるがん患者のQOLとQOD -Onco-orthopaedicsという新領域-

河野 博隆 (帝京大学医学部 整形外科学講座)

JS4-5 Impairments, Disabilities, and Handicaps in Cancer Patients with Bone Metastases

Akira Kido (Department of Rehabilitation Medicine, Nara Medical University)

骨転移患者のリハビリテーション処方：障害構造の診断と共有のために

城戸 顕 (奈良県立医科大学 リハビリテーション医学講座)

JS4-6	Comprehensive management of skeletal metastasis - Onco-Orthopaedics/Palliative Surgery/Rehabilitation - Tatsuya Takagi (Department of Palliative Medicine, Orthopedics, Rehabilitation Medicine, Juntendo University) 包括的な骨転移診療 - Onco-Orthopaedics・緩和的外科治療とリハビリテーション - 高木 辰哉 (順天堂大学 緩和医療研究室・整形外科・リハビリテーション科)	                  
JS4-7	What oncologists would like to request from orthopedic surgeons -Collaboration 2- Hisakazu Nishimori (Department of Hematology, Hiroshima City Hiroshima Citizens Hospital) 腫瘍内科 (進行癌の慢性期の主治医) から整形外科にお願いしたいこと -コラボ 2- 西森 久和 (広島市立広島市民病院 血液内科)	
JS4-8	The education project of human resources for locomotive syndrome in cancer patients Nariaki Matsuura (Osaka International Cancer Institute) 「がんロコモ」に配慮できるがんプロフェッショナルの養成 松浦 成昭 (大阪国際がんセンター)	
15:40-17:10 Symposium 10 / シンポジウム 10		
SY10	Clinical pharmacological approaches to appropriate drug therapy for unmet needs アンメットニーズに対する適正な薬物療法に向けた臨床薬理学的アプローチ	
Chairs :	Hidenori Mizugaki (Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center) Akinobu Hamada (National Cancer Center, Division of Molecular Pharmacology)	
司会 :	水柿 秀紀 (国立病院機構北海道がんセンター 呼吸器内科) 濱田 哲暢 (国立がん研究センター研究所 分子薬理研究分野)	
SY10-1	PK/PD of anticancer drugs: careful dosage adjustment Akinobu Hamada (National Cancer Center, Division of Molecular Pharmacology) 抗がん薬のPK/PD総論：慎重投与の概要 濱田 哲暢 (国立がん研究センター研究所 分子薬理研究分野)	
SY10-2	Clinical pharmacology of anticancer drugs for elderly patients Shigehiro Yagishita (Division of Molecular Pharmacology, National Cancer Center Research Institute) 高齢者に対する抗がん薬の臨床薬理 柳下 薫寛 (国立がん研究センター研究所 分子薬理研究分野)	
SY10-3	Appropriate drug therapy for patients with poor Performance Status Haruyasu Murakami (Division of Thoracic Oncology, Shizuoka Cancer Center) PS不良な患者に対する適正な薬物療法 村上 晴泰 (静岡県立静岡がんセンター)	
SY10-4	Pharmacokinetic and dose-finding study in cancer patients with impaired renal function Yutaka Fujiwara (Department of Thoracic Oncology, Aichi Cancer Center) 腎機能障害を有するがん患者に対する臨床薬理学的アプローチ 藤原 豊 (愛知県がんセンター 呼吸器内科)	

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

On-demand

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Experts

Poster

SY10-5

Practice of cancer drug therapy focusing on liver function

Yoshitaka Saito (Department of Pharmacy, Hokkaido University of Science)

肝機能に着目したがん薬物療法の実践

齋藤 佳敬 (北海道科学大学 薬学部)

Room 11 (2号館 2F 会議室 221)

9:00-10:00 Mini Oral Session 13

MO13 Gastrointestinal Cancer 1 (Gastric Cancer, HER2, MSI, GEJC)
消化器 1 (胃がん・HER2, MSI, GEJC)**E**Chairs : Yukiya Narita (Department of clinical oncology, Aichi Cancer Center Hospital)
Masaru Fukahori (Kyoto University Department of Early Clinical Development, Graduate School of Medicine)司会 : 成田 有季哉 (愛知県がんセンター 薬物療法部)
深堀 理 (京都大学医学部附属病院 早期医療開発科)**MO13-1 Potential value of NLR for Nivo + Ipi in MSI-H Gastric Cancer:
Sub-analysis of the NO LIMIT study (WJOG13320G/CA209-7W7)**Naotoshi Sugimoto (Department of Genetic Oncology, Osaka International Cancer Institute)
杉本 直俊 (大阪国際がんセンター 遺伝子診療部)**MO13-2 Clinical impact of *ERBB2* copy number and TMB-H in Nivolumab plus Trastuzumab and chemotherapy in HER2+ gastric cancer****Encore**Hiroki Hara (Department of Gastroenterology, Saitama Cancer Center)
原 浩樹 (埼玉県立がんセンター 消化器内科)**MO13-3 Trastuzumab Deruxtecan and Nivolumab as Third- or Later-line Treatment for HER2-positive Advanced Gastric Cancer****Encore**Keitaro Shimozaki (Department of Gastroenterology, Kawasaki Municipal Hospital / Department of Gastrointestinal Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research / Department of Gastroenterology and Hepatology, Division of Internal Medicine, Keio University School of Medicine)
下嵯 啓太郎 (川崎市立川崎病院 消化器内科 / がん研有明病院 消化器化学療法科 / 慶應義塾大学医学部 内科学教室 (消化器))**MO13-4 Comparing Treatment Outcomes in Advanced Esophagogastric Junction Adenocarcinoma and Gastric Adenocarcinoma****Encore**Toru Kadono (Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University / Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)
角埜 徹 (大阪医科薬科大学病院 化学療法センター / 国立がん研究センター中央病院 消化管内科)**MO13-5 Safety and short-term efficacy of neoadjuvant FLOT therapy for locally advanced esophagogastric junction adenocarcinoma**Kazuhiro Shiraishi (Department of Head and Neck, Esophageal Medical Oncology National Cancer Center Hospital)
白石 和寛 (国立がん研究センター中央病院 頭頸部・食道内科)Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

10:00-11:00 Mini Oral Session 14

MO14 Multidisciplinary Team Program 1 (International session)
多職種連携プログラム 1 (International session)

Chairs : Chikako Shimizu (Department of Breast and Medical Oncology, National Center for Global Health and Medicine)
Tetsuhiro Yoshinami (Center for Cancer Genomics and Personalized Medicine, Osaka University Hospital)

司会 : 清水 千佳子 (国立国際医療研究センター病院 がん総合診療センター 乳腺・腫瘍内科)
吉波 哲大 (大阪大学医学部附属病院 がんゲノム医療センター)

MO14-1 **Clinical course of skin rashes caused by neoadjuvant gemcitabine plus S-1 for resectable pancreatic cancer**

Ayako Yokomizo (Department of Pharmacy, St. Marianna University Hospital)
横溝 綾子 (聖マリアンナ医科大学病院 薬剤部)

MO14-2 **Systematic Screening for Mental Distress in Cancer Patients using a Web Application: Oncopsychometer**

Amina Aquil (Laboratory of Health Sciences and Technologies, Higher Institute of Health Sciences, Hassan First University of Settat)

MO14-3 **Quality of Life Among the Caregivers of Cancer Patients undergoing Out-patient Chemotherapy in ManilaMed**

Alfred Patrick Dionisio Mina (Augusto P. Sarmiento Cancer Institute - The Medical City)

MO14-4 **Improving survival outcomes with ambulatory chemotherapy in metastatic colorectal cancer in Ramathibodi Hospital**

Pichai Chansriwong (Department of Internal Medicine, Ramathibodi Hospital)

MO14-5 **Umbrella reviews of systematic reviews evaluating the effects of immunonutrients on cancer patients undergoing surgery**

Wan-Shiuan Lin (Department of Nursing, University of Kang Ning, Taipei, Taiwan)

13:40-14:40 Mini Oral Session 15

MO15 Gastrointestinal Cancer 2 (Gastric Cancer, Others)
消化器 2 (胃がん・その他)



Chairs : Akira Ooki (Cancer Institute Hospital of Japanese Foundation for Cancer Research)
Hiroshi Ariyama (Department of Medical Oncology, Kitakyushu Municipal Medical Center)

司会 : 大木 暁 (がん研究会有明病院 消化器化学療法科)
有山 寛 (北九州市立医療センター 腫瘍内科)

MO15-1 **A phase I study of pevonedistat plus CapeOX in patients with advanced gastric cancer refractory to platinum (NCCH-1811)**

Encore

Hirokazu Shoji (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)
庄司 広和 (国立がん研究センター中央病院 消化管内科)

MO15-2 **Establishing real-world data on actual advanced gastric cancer therapy using CyberOncology®: A feasibility study**

Nozomu Machida (Department of Gastroenterology, Kanagawa Cancer Center)
町田 望 (神奈川県立がんセンター 消化器内科)

MO15-3 Early-onset gastric cancer has displayed distinct genetic profiles compared to late-onset gastric cancer

Kunihito Matsuguma (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)

松隈 国仁 (国立がん研究センター中央病院 消化管内科)

MO15-4 The negative impact of the COVID-19 pandemic on gastric cancer care in Japan: Tokushukai REAI-world Data project 08

Rai Shimoyama (Department of General Surgery, Shonan Kamakura General Hospital)

下山 ライ (湘南鎌倉総合病院 外科)

MO15-5 A comparison of the efficacy and safety of CapeOX and DS as adjuvant chemotherapy for pStage III gastric cancer

Toru Imai (Department of Medical Oncology, National Cancer Center Hospital / Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)

今井 亨 (国立がん研究センター中央病院 腫瘍内科 / 国立がん研究センター中央病院 消化管内科)

14:55-15:55 Mini Oral Session 16

MO16 Gastrointestinal Cancer 3 (Gastric Cancer, ICI+Chemotherapy)
消化器 3 (胃がん・ICI+化学療法)



Chairs : Yoshihiro Shibata (Fukuoka Wajiro Hospital Department of Medical Oncology)

Hiroyuki Arai (Department of Clinical Oncology, St. Marianna University School of Medicine)

司会 : 柴田 義宏 (福岡和白病院 腫瘍内科)

新井 裕之 (聖マリアンナ医科大学 臨床腫瘍学講座)

MO16-1 KEYNOTE-859 Asia Subgroup Analysis: Pembrolizumab ± Chemotherapy for Advanced HER2-Negative Gastric (G) Adenocarcinoma

Encore

Hisateru Yasui (Kobe City Medical Center General Hospital)

安井 久晃 (Kobe City Medical Center General Hospital)

MO16-2 Treatment outcomes of chemotherapy plus nivolumab for HER2-negative advanced gastric cancer (AGC) with CPS status

Takeshi Kawakami (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)

川上 武志 (静岡県立静岡がんセンター 消化器内科)

MO16-3 Impact of Adding Nivolumab to First-Line Chemotherapy in Patients with Advanced Gastric Cancer

Mai Utsumi (Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University Hospital)

内海 麻衣 (大阪医科薬科大学病院 第二内科)

MO16-4 Outcomes of patients with unresectable gastric cancer treated with nivolumab and chemotherapy as first-line therapy

Atsushi Naganuma (Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center)

First line で Nivolumab と化学療法の併用療法を導入した治癒切除不能進行・再発胃癌の当院治療成績

長沼 篤 (国立病院機構高崎総合医療センター 消化器内科)

MO16-5 Nivolumab plus mFOLFOX6 for AGC with massive ascites or inadequate oral intake due to severe peritoneal metastasis

Yurika Nakayama (Third Department of Internal Medicine, University of Toyama)

中山 優吏佳 (富山大学附属病院 第三内科)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

On-demand

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Experts

Poster

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

MO16-6 **A retrospective study of early clinical outcomes of first-line nivolumab plus chemotherapy for advanced gastric cancer**
 Kaori Hino (Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center)
 日野 佳織 (国立病院機構四国がんセンター 消化器内科)

16:10-17:10 Mini Oral Session 17

MO17 **Gastrointestinal Cancer 4 (Gastric Cancer, 2nd/late-line chemotherapy)**
 消化器 4 (胃がん・2次治療以降) E
 Chairs : Taito Esaki (NHO Kyushu Cancer Center)
 Toshifumi Yamaguchi (Osaka Medical and Pharmaceutical University)
 司会 : 江崎 泰斗 (九州がんセンター 消化管・腫瘍内科)
 山口 敏史 (大阪医科薬科大学病院 化学療法センター)

MO17-1 **Pharmacokinetics and exposure-toxicity analyses of paclitaxel in gastric cancer patients receiving sb- or nab-paclitaxel**
 Takahiro Tsushima (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)
 對馬 隆浩 (静岡県立静岡がんセンター 消化器内科)

MO17-2 **A multicenter observational study on the efficacy of Ramucirumab before Nivolumab in gastric cancer patients**
 Yuka Obayashi (Department of Internal Medicine, Hiroshima City Hiroshima Citizens Hospital)
 大林 由佳 (広島市立広島市民病院 内科)

MO17-3 **The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab**
 Chiaki Inagaki (Department of Medical Oncology, Kindai University Faculty of Medicine)
 稲垣 千晶 (近畿大学医学部・大学院医学研究科 腫瘍内科)

MO17-4 **Impact on time-of-day nivolumab monotherapy infusion in patients with metastatic gastric cancer**
Encore
 Yasunobu Ishizuka (Department of Clinical Oncology, Aichi Cancer Center Hospital)
 石塚 保亘 (愛知県がんセンター 薬物療法部)

MO17-5 **Ramucirumab beyond PD in combination with irinotecan after paclitaxel + ramucirumab in gastric cancer: A phase II trial**
 Yasuyoshi Sato (Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo / Department of Chemotherapy, Cancer Center, The University of Tokyo Hospital)
フッ化ピリミジン系薬剤とプラチナ系薬剤の前治療歴がありパクリタキセル+ラムシルマブ療法に不応となった進行・再発胃癌に対するイリノテカン+ラムシルマブ療法の第II相試験
 佐藤 靖祥 (東京大学大学院医学系研究科 消化管外科学 / 東京大学医学部附属病院 臨床腫瘍科)

MO17-6 **The scoring system for selecting Nivolumab or Irinotecan in the later-line chemotherapy for advanced gastric cancer**
Encore
 Takeshi Kawakami (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)
 川上 武志 (静岡県立静岡がんセンター 消化器内科)

Room 12 (2号館 2F 会議室 222+223)

9:00-10:20 Oral Session 5

05 Clinical Trial Facilitation Program 臨床試験推進プログラム

Chairs : Nagio Takigawa (General Internal Medicine 4, Kawasaki Medical School)
Munetaka Takekuma (Shizuoka Cancer Center)
Discussant : Kazuki Nozawa (Department of Center for Cancer Genomics and Advanced Therapeutics, Breast Oncology, Aichi Cancer Center Hospital)
司会 : 瀧川 奈義夫 (川崎医科大学 総合内科学4)
武隈 宗孝 (静岡県立静岡がんセンター 産婦人科)
ディスクサント : 能澤 一樹 (愛知県がんセンター ゲノム医療センターがんゲノム医療室・乳腺科部)

05-1 The current status and challenges of Emerging biopharma (EBP) in new drug development from the standpoint of CRO

Miyu Kato (IQVIA Services Japan K.K.)

CROの立場から見た新興バイオ医薬品企業 (EBP: Emerging biopharma) の新薬開発における現状と課題

加藤 未有 (IQVIAサービシーズ ジャパン株式会社)

05-2 WJOG (West Japan Oncology Group) Breast Cancer Consensus Meeting 2023

Yuri Kimura (Department of Breast Surgery, St. Luke's International Hospital / WJOG (West Japan Oncology Group) BRIGHT)

WJOG (West Japan Oncology Group) 乳癌コンセンサス会議 2023

木村 優里 (聖路加国際病院 乳腺外科 / WJOG (West Japan Oncology Group) BRIGHT)

05-3 Initiatives to improve the treatment opportunity using the patient-proposed healthcare services - the BELIEVE trial -

Kanako Kondo (Clinical Research Support Office, National Cancer Center Hospital)

患者申出療養制度を利用した治療機会提供の取り組み —NCCH1901 試験を通じて—

近藤 奏子 (国立がん研究センター中央病院 臨床研究支援部門)

05-4 Approval delay in drugs from non-global company: analysis of novel drugs for hematologic malignancies

Encore

Kensuke Matsuda (Office of New Drug 5, Pharmaceuticals and Medical Devices Agency / Department of Hematology and Oncology, JR Tokyo General Hospital)

新興企業による薬剤開発と日欧におけるドラッグラグ・ドラッグロス：

血液悪性腫瘍における解析

松田 健佑 (医薬品医療機器総合機構 新薬審査第五部 / JR東京総合病院 血液・腫瘍内科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

10:20-11:40 Oral Session 6

06 Head and Neck Cancer
頭頸部



Chairs : Sadamoto Zenda (National Cancer Center Hospital East)
Yasushi Shimizu (Department of Medical Oncology, Hokkaido University Hospital)
Discussant : Tomoya Yokota (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)
司会 : 全田 貞幹 (国立がん研究センター東病院)
清水 康 (北海道大学病院 腫瘍内科)
ティムカサント : 横田 知哉 (静岡県立静岡がんセンター 消化器内科)

06-1 Post-hoc analysis of TRAEs observed in a phase 2 study of encorafenib + binimetinib in metastatic *BRAF* V600-mutated TC

Shunji Takahashi (Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research)
高橋 俊二 (がん研究会有明病院 総合腫瘍科)

06-2 Real-world treatment patterns of patients with locally advanced squamous cell carcinoma of the head and neck in Japan

Kenichi Nibu (Department of Otolaryngology-Head and Neck Surgery, Kobe University Hospital)
丹生 健一 (神戸大学大学院医学研究科耳鼻咽喉科 頭頸部外科学分野)

06-3 The impact of relative dose of cisplatin to skeletal muscle mass on adverse events in patients with head and neck cancer

Satoshi Suzuki (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)
鈴木 哲史 (静岡県立静岡がんセンター 消化器内科)

06-4 Impact of *PIK3CA* and cell cycle pathway alterations on durvalumab efficacy in head and neck squamous cell carcinoma

Dong Hyun Kim (Department of Internal Medicine, Seoul National University Hospital)

13:40-14:40 Mini Oral Session 18

MO18 Gynecologic Cancer 1
婦人科 1



Chairs : Koji Nishino (Niigata University Graduate School of Medical and Dental Sciences, Department of Familial and Hereditary Oncology)
Kan Yonemori (National Cancer Center Hospital)
司会 : 西野 幸治 (新潟大学医学部 家族性・遺伝性腫瘍学講座)
米盛 勸 (国立がん研究センター中央病院 腫瘍内科)

MO18-1 演題取下

MO18-2 演題取下

MO18-3 The Role of Exercise Intervention in Women With Ovarian Cancer Undergoing Chemotherapy: A Systematic Review

Madeleine C. Rusbiyanto (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)

MO18-4 *BRCA1* methylation is an independent favorable prognostic factor in high-grade serous ovarian cancers

Takahiro Ebata (Department of Epigenomics, Life Science Tokyo Advanced Research Center, Hoshi University / Department of Medical Oncology, National Cancer Center Hospital)
江畑 貴大 (星薬科大学先端生命科学研究所 エピゲノム創薬研究室 / 国立がん研究センター中央病院 腫瘍内科)

MO18-5 Efficacy and Safety of Veliparib with First-Line Chemotherapy as Combination Therapy in OC: A Systematic Review

Clarissa Ardalin Cendera (Faculty of Medicine, Pelita Harapan University)

MO18-6 Prospective changes in Financial Toxicity and Health-Related Quality of Life in Patients with Gynecologic Cancer

Yusuke Kajimoto (Graduate School of Pharmaceutical Sciences, The University of Tokyo / Oncology Science Unit, MSD K.K.)

梶本 裕介 (東京大学大学院薬学系研究科 / MSD株式会社 オンコロジーサイエンスユニット)

15:15-16:15 Mini Oral Session 19

MO19 Breast Cancer 2 (HER2-expressing breast cancer)

乳腺 2 (HER2 発現乳癌)

E

Chairs : Junichiro Watanabe (Department of Breast Oncology, Juntendo University Graduate School of Medicine)

Shigenori Nagai (Breast Oncology, Saitama Cancer Center)

司会 : 渡邊 純一郎 (順天堂大学大学院医学研究科 乳腺腫瘍学講座)

永井 成勲 (埼玉県立がんセンター 乳腺腫瘍内科)

MO19-1 OS results from the PRECIOUS (JBCRG-M05) : Pertuzumab retreatment for HER2-positive advanced breast cancer patients

Encore

Masato Takahashi (Department of Breast Surgery, Hokkaido University Hospital)

高橋 将人 (北海道大学病院 乳腺外科)

MO19-2 Clinical outcome of treatment rechallenge with HER2-directed antibody-drug conjugate in metastatic breast cancer

Mark M. Ando (Perpetual Succour Hospital - Cebu Cancer Institute)

MO19-3 Comparison of HER2 expression status between conventional HER2 test and VENTANA HER2 (4B5) of metastatic breast cancer

Nahomi Tokudome (Division of Breast Oncology, Shizuoka Cancer Center)

徳留 なほみ (静岡県立静岡がんセンター 女性内科)

MO19-4 Trastuzumab Deruxtecan, Its Efficacy in Patients with Metastatic HER2-Positive Breast Cancer: A Systematic Review

Vether Fernhandho (Faculty of Medicine, Pelita Harapan University)

MO19-5 Real-World and Post-marketing Disproportionality Analysis of T-DM1: Data Mining of FDA Adverse Event Reporting System

Endong Chen (Department of Breast Surgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China)

MO19-6 Prognostic impact of HER2-low status in metastatic triple negative breast cancer (mTNBC) treated with ICI

Rui Kitadai (Department of Medical Oncology, National Cancer Center Hospital)

北台 留衣 (国立がん研究センター中央病院 腫瘍内科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

16:15-17:15 Mini Oral Session 20

MO20 Hematologic Malignancies 2 (Lymphoma 1)
血液 2 (リンパ腫 1)

E

Chairs : Koji Izutsu (Department of Hematology, National Cancer Center Hospital)
Shin Lee (Department of Hematology and Oncology, Matsunami General Hospital)
司会 : 伊豆津 宏二 (国立がん研究センター中央病院 血液腫瘍科)
Lee Shin (松波総合病院血液・腫瘍内科)

MO20-1 **Outcomes in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) with
Encore** **Brexucabtagene Autoleucel in ZUMA-2 and ZUMA-18**

Andre Goy (John Theurer Cancer Center)

MO20-2 **Long-Term Follow-up Shows Epcoritamab Drives Deep, Durable Responses in Relapsed/
Refractory Follicular Lymphoma (R/R FL)**

Koji Izutsu (Department of Hematology, National Cancer Center Hospital)
伊豆津 宏二 (Department of Hematology, National Cancer Center Hospital)

MO20-3 **Early relapse of localized diffuse large B-cell lymphoma**

Hiroto Kaneko (Department of Hematology, Aiseikai Yamashina Hospital)
兼子 裕人 (愛生会山科病院 血液内科)

MO20-4 **Extranodal lesions of DLBCL at the 1st relapse might predict CNS lesions in the 2nd
relapse**

Yuka Okabe (Department of Hematology/Oncology, Wakayama Medical University)
岡部 友香 (和歌山県立医科大学 血液内科)

MO20-5 **A prospective study of estimating prognosis in older aggressive lymphoma by geriatric
assessment at single institution**

Tsutomu Takahashi (Department of Hematology, Shimane University Hospital)
高齢者機能評価による高齢アグレッシブリンパ腫の予後予測：単施設前向き観察研究
高橋 勉 (島根大学医学部附属病院 血液内科)

MO20-6 **Real-World Treatment Patterns and Outcomes in Japanese Patients With Large B-cell
Lymphoma After Two Systemic Therapies**

Laura Liao (Genmab, US Inc.)

Room 13 (2号館 1F 展示室 211)

9:00-10:00 Mini Oral Session 21

MO21 Translational Research/ Clinical Pharmacology 1 (Basic Research)
TR・臨床薬理 1 (基礎医学)**E**

Chairs : Kenji Tsuchihashi (Department of Hematology, Oncology and Cardiovascular Medicine)
Masahiro Seike (Department of Pulmonary Medicine and Oncology, Graduate School of Medicine,
Nippon Medical School)

司会 : 土橋 賢司 (九州大学病院 血液・腫瘍・心血管内科)
清家 正博 (日本医科大学付属病院 呼吸器内科)

MO21-1 Characterization of URST7 as a novel prognostic biomarker and therapeutic target for various subtypes of breast cancer

Regina Wachuka Mbugua (Department of Medical Oncology and Cancer Center, Shiga University of Medical Science / Center for Advanced Medicine against Cancer, Shiga University of Medical Science)

MO21-2 Identification of URST7 as a new prognostic biomarker and therapeutic target for oral cancer

Bayarbat Tsevegjav (Department Med. Oncol. & Cancer Center, Shiga University Medical Science / Center Advanced Medicine against Cancer, Shiga University of Medical Science)

MO21-3 *Ent*-kaurane diterpenoids in castration-resistant prostate cancer: crosstalk in ferroptosis, autophagy and apoptosis

Tzu-Ching Weng (School of Pharmacy, National Taiwan University)

MO21-4 Discovery of novel HDAC6 inhibitors in NSCLC: roles of DNA repair impairment

Tse-Yu Chen (School of Pharmacy, National Taiwan University)

MO21-5 CADM1 and SPC25 gene mutations in lung cancer patients with idiopathic pulmonary fibrosis

Aya Fukuizumi (Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School)

福泉 彩 (日本医科大学付属病院 呼吸器・感染・腫瘍部門)

MO21-6 Patient-derived lung cancer organoids illuminate IGF-1 dependency in POU2F3- and YAP1- type small cell lung cancer

Takahiro Fukushima (Division of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine)

福島 貴大 (慶應義塾大学病院 呼吸器内科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

10:00-11:30 Symposium 11 / シンポジウム 11

SY11 To overcome resistance to immune checkpoint inhibitors
免疫チェックポイント阻害薬の耐性克服を目指して **O E**

Chairs : Yosuke Togashi (Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University)
Yuki Kagoya (Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine)
司会 : 富樫 庸介 (岡山大学学術研究院医歯薬学域)
籠谷 勇紀 (慶應義塾大学医学部先端医学研究所 がん免疫研究部門)

SY11-1 Overview of resistance mechanisms to immune checkpoint inhibitors
Yosuke Togashi (Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University)
免疫チェックポイント阻害薬の耐性メカニズム
富樫 庸介 (岡山大学学術研究院医歯薬学域)

SY11-2 The mechanism of gut microbiome-mediated immunity on the clinical efficacy of anti-PD-1 immunotherapy in solid tumors
Yi-Tzu Lin (Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center)
腸内細菌による免疫制御が、固形がんに対する抗PD-1抗体の臨床効果に与えるメカニズムの解明
林 怡孜 (国立研究開発法人国立がん研究センター 先端医療開発センター 免疫TR分野)

SY11-3 Rewiring the transcriptional network to enhance the functions of antitumor T cells
Yuki Kagoya (Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine)
転写ネットワーク改変による抗腫瘍T細胞の機能強化
籠谷 勇紀 (慶應義塾大学医学部先端医学研究所 がん免疫研究部門)

SY11-4 Regulatory Innate Lymphoid cells: Novel barriers to overcome for Immunotherapy
Pamela S. Ohashi (Princess Margaret Cancer Centre, University of Toronto, Department of Immunology, Toronto, ON)

13:40-15:10 Oral Session 7

07 Translational Research/ Clinical Pharmacology
TR・臨床薬理 **E**

Chairs : Shigehisa Kitano (Department of Advanced Medical Development, The Cancer Institute Hospital of JFCR)
Masayuki Takeda (Department of Cancer Genomics and Medical Oncology, Nara Medical University)
Discussant : Yasutoshi Kuboki (Department of Experimental Therapeutics, National Cancer Center Hospital East)
司会 : 北野 滋久 (がん研究会有明病院 先端医療開発科)
武田 真幸 (奈良県立医科大学 がんゲノム・腫瘍内科)
ディスカッサント : 久保木 恭利 (国立がん研究センター東病院 先端医療科)

07-1 Effects of SGLT2 Inhibitors on Clinical Cancer Survival
Wan Ming Chen (Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan)

- 07-2** **ABBV-400 monotherapy in *MET* gene-amplified (*MET*-amp) advanced solid tumors: results from overall and Japanese patients**
Noboru Yamamoto (Department of Experimental Therapeutics)
***MET* 遺伝子増幅 (*Met*-amp) を有する進行固形癌での ABBV-400 単剤療法 : 全体及び日本人患者での結果**
山本 昇 (国立がん研究センター中央病院 先端医療科)
- 07-3** **The efficacy and safety of pimitespib in patients with solid tumors: A phase 1 study to assess cardiac safety**
Akihiko Shimomura (Department of Breast and Medical Oncology, National Center for Global Health and Medicine)
固形がん患者におけるピミテスピブの有効性及び安全性: 心血管系安全性を評価した臨床第1相試験
下村 昭彦 (国立国際医療研究センター病院 乳腺・腫瘍内科)
- 07-4** **A phase 1 study of zanidatamab monotherapy in Japanese patients with metastatic or unresectable HER2-expressing cancers**
Toshihiko Doi (National Cancer Center Hospital East)
土井 俊彦 (National Cancer Center Hospital East)
- 07-5** **Phase I trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenzimab in solid tumors**
Emiliano Calvo (START Madrid-CIOCC, Centro Integral Oncologico Clara Campal, Madrid, Spain)
- Encore**
- 15:30-17:00 Oral Session 8
- 08** **Gastrointestinal Cancer 2 (Esophageal Cancer/Colorectal Cancer)**
消化器 2 (食道がん・大腸がん) **E**
- Chairs :** Hiroki Osumi (Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research)
Ian Chau (Royal Marsden Hospital)
- Discussants :** Yasuyuki Kawamoto (Division of Cancer Center, Hokkaido University Hospital)
Daisuke Kotani (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)
- 司会 :** 大隅 寛木 (がん研有明病院 消化器化学療法科)
Ian Chau (Royal Marsden Hospital)
- ディスカッサント :** 川本 泰之 (北海道大学病院 消化器内科・腫瘍センター)
小谷 大輔 (国立がん研究センター東病院 消化管内科)
- 08-1** **Efficacy of Pembrolizumab in metastatic colorectal cancer with TMB-High/non-MSI-high**
Kyoko Yamaguchi (Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital / Department of Clinical Education Center, Kyushu University Hospital)
山口 享子 (九州大学病院 血液・腫瘍・心血管内科 / 九州大学病院 臨床教育研修センター)
- 08-2** **First-line FOLFOX therapy for advanced esophageal squamous cell carcinoma: Multicenter prospective study in Japan**
Shun Yamamoto (Department of Head and Neck, Esophageal Medical Oncology)
山本 駿 (国立がん研究センター中央病院 頭頸部・食道内科)
- 08-3** **Prospects and challenges of personalized medicine for esophageal cancer based on Cancer Genomic Profiling Test**
Ryuichi Morita (Department of Gastroenterology and Hepatology, Kyoto prefectural University of Medicine / Cancer Genome Medical Center, University Hospital of KPUM)
森田 竜一 (京都市立医科大学大学院 医学研究科 消化器内科学 / 京都府立医科大学附属病院 がんゲノム医療センター)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

On-demand

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Experts

Poster

08-4

A predictive model for R0 resection in unresectable locally advanced esophageal cancer treated with induction DCF

Hiroyuki Kodama (Department of clinical oncology, Aichi Cancer Center Hospital)
児玉 紘幸 (愛知県がんセンター 薬物療法部)

Meet the Experts ① (4号館 3F 会議室 436)

9:00-10:00 Meet the Experts 1

ME1 Advanced Care Planning: What's wrong? What should we do?
懐疑派から見たアドバンスケアプランニング：なにが変なのか？どうすればいいのか？

Chair : Akihito Tsuji (Department of Medical Oncology, Kagawa University Hospital)
司会 : 辻 晃仁 (香川大学医学部附属病院 腫瘍内科)

ME1 **Advanced Care Planning: What's wrong? What should we do?**
Tatsuya Morita (Department of Palliative and Supportive Care, Seirei Mikatahara General Hospital)
懐疑派から見たアドバンスケアプランニング：なにが変なのか？どうすればいいのか？
森田 達也 (聖隷三方原病院 緩和支援治療科)

10:15-11:15 Meet the Experts 2

ME2 Current Insights of Chemotherapy in Colorectal Cancer **E**

Chairs : Hiroki Osumi (Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research)
Shogen Boku (Cancer Treatment Center, Kansai Medical University Hospital)
司会 : 大隅 寛木 (がん研有明病院 消化器化学療法科)
朴 将源 (関西医科大学附属病院 がんセンター)

ME2 **Current Insights of Chemotherapy in Colorectal Cancer**
Josep Tabernero (Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain)

13:40-14:40 Meet the Experts 3

ME3 How I treat elderly patients with multiple myeloma **E**

Chair : Kentaro Fukushima (Department of Hematology and Oncology, Osaka University Graduate School of Medicine)
司会 : 福島 健太郎 (大阪大学大学院医学系研究科 血液・腫瘍内科学)

ME3 **How I treat elderly patients with multiple myeloma**
Thierry Facon (Lille University Hospital)

15:30-16:30 Meet the Experts 4

ME4 Patient Involvement Globally: How patients are becoming integral to healthcare decisions, policies and practices **E**

Chairs : Yoshiyuki Majima (NPO PanCAN Japan)
Shun Tezuka (Pharmaceuticals and Medical Devices Agency)
司会 : 眞島 喜幸 (全国がん患者団体連合会 / PanCAN Japan)
手塚 瞬 (医薬品医療機器総合機構 (PMDA))

ME4 **Patient Involvement Globally: How patients are becoming integral to healthcare decisions, policies and practices**
Neil Bertelsen (HTAi Patient & Citizen Involvement in HTA Group, PFMD)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Meet the Experts ② (4号館 3F 会議室 437)

9:00-10:00 Meet the Experts 5

ME5 Rare Cancer Update 希少がんアップデート

Chairs : Hisateru Yasui (Department of Medical Oncology, Kobe City Medical Center General Hospital)
Kazuki Sudo (National Cancer Center Hospital, Department of Medical Oncology)

司会 : 安井 久晃 (神戸市立医療センター中央市民病院 腫瘍内科)
須藤 一起 (国立がん研究センター中央病院 腫瘍内科)

ME5 Rare Cancer Update

Akira Kawai (Department of Musculoskeletal Oncology, National Cancer Center Hospital / Rare Cancer Center, National Cancer Center)

希少がんアップデート

川井 章 (国立がん研究センター中央病院 骨軟部腫瘍科 / 国立がん研究センター 希少がんセンター)

10:15-11:15 Meet the Experts 6

ME6 Resistance mechanism of targeted therapy for NSCLC with driver mutation. Next step

E

Chairs : Hayato Koba (Department of Respiratory Medicine, Kanazawa University Hospital)
Megumi Furuta (Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University)

司会 : 木場 隼人 (金沢大学附属病院 呼吸器内科)
古田 恵 (北海道大学大学院医学研究院 呼吸器内科学教室)

ME6 Resistance mechanism of targeted therapy for NSCLC with driver mutation. Next step Pasi Janne (Dana-Farber Cancer Institute)

13:40-14:40 Meet the Experts 7

ME7 Immune Surveillance: Perspectives in antigen recognition and response

E

Chair : Yosuke Togashi (Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University)

司会 : 冨樫 庸介 (岡山大学 学術研究院医歯薬学域)

ME7 Immune Surveillance: Perspectives in antigen recognition and response

Pamela S. Ohashi (Princess Margaret Cancer Centre, University of Toronto, Department of Immunology, Toronto, ON)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

On-demand

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Experts

Poster

15:30-16:30 Meet the Experts 8

ME8 Cancer survivorship care: How can we contribute to survivors who live beyond treatment? がんサバイバーシップケア — 医療者はがん治療を超えて生きる人にどう貢献できるか？

Chairs : Kiyotaka Watanabe (Division of Medical Oncology, Department of Medicine, School of Medicine, Teikyo University)
Saiko Kurosawa (Department of Oncology, Ina Central Hospital)
司会 : 渡邊 清高 (帝京大学医学部内科学講座 腫瘍内科)
黒澤 彩子 (伊那中央病院 腫瘍内科)

ME8 Cancer survivorship care: How can we contribute to survivors who live beyond treatment?

Miyako Takahashi (Japan Cancer Survivorship Network)

がんサバイバーシップケア — 医療者はがん治療を超えて生きる人にどう貢献できるか？

高橋 都 (NPO法人日本がんサバイバーシップネットワーク)

ポスター① (3号館 B1F カスケード)

11:40-12:25 Poster Session 1

P1 Gastrointestinal Cancer 1 (Esophageal Cancer 1)
消化器 1 (食道 1)

- P1-1 **The efficacy of ICI combination therapy on dysphagia in advanced esophageal cancer patients**
Yurika Nakayama (Third Department of Internal Medicine, University of Toyama)
中山 優吏佳 (富山大学附属病院 第三内科)
- P1-2 **The role of N6-methyltransferase FTO on PD-L1 in esophageal squamous cell carcinoma cells**
Takashi Imajima (Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University)
今嶋 克志 (九州大学医学部 第一内科 (病態修復内科))
- P1-3 **Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy for First-line Treatment of Esophageal Cancer**
Shoichiro Hirata (Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine)
平田 翔一郎 (岡山大学病院 消化器内科)
- P1-4 **Evaluation of Endobronchial Ultrasonography to Predict Fistula in Advanced Esophageal Cancer Prior to Chemoradiotherapy**
Aya Takigawa (Miyazaki Prefectural Miyazaki Hospital, Department of Oncology)
瀧川 彩 (県立宮崎病院 腫瘍内科)
- P1-5 **Efficacy and safety of modified-DCF for neoadjuvant chemotherapy in resectable esophageal cancer**
Toshiki Oba (Department of Medical Oncology, Kameda Medical Center)
大場 俊輝 (亀田総合病院 腫瘍内科)
- P1-6 演題取下
- P1-7 **Efficacy of Nivolumab for Esophageal Cancer Patients with PD-L1 CPS $\geq 1\%$ and $\geq 5\%$: A Systematic Review and Meta-Analysis**
Azzahra M. Noersamsjah (Faculty of Medicine, Pelita Harapan University)
- P1-8 **Definitive chemoradiation with Folfox regimen in locally advanced middle-lower third esophageal cancer in Vietnam**
Giap Ngoc Hoang (Department of Medical Oncology No. 3, K Hospital)
- P1-9 演題取下

11:40-12:25 Poster Session 2

P2 Gastrointestinal Cancer 2 (Esophageal Cancer 2)
消化器 2 (食道 2)

- P2-1 **Real-World Clinical Outcomes of Nivolumab as a Second- or Later-Line Therapy for Esophageal Squamous Cell Carcinoma**
Manato Ohsawa (Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine Hiroshima University)
大澤 真那人 (広島大学原爆放射線医科学研究所 腫瘍外科)

P2-2	Improvement of dysphagia in metastatic esophageal squamous carcinoma patients during chemotherapy plus PD-1 inhibitor Takanori Hama (Department of Gastroenterology, Kanagawa Cancer Center) 濱 崇哲 (神奈川県立がんセンター 消化器内科)	Day 1 (Thu)
P2-3	A retrospective study of ipilimumab and nivolumab for unresectable advanced or recurrent esophageal cancer Hiroki Oka (Department of Medical Oncology, Mie University Hospital) 当院における切除不能進行・再発食道癌に対するイピリムマブとニボルマブ療法の後方視的研究 岡 弘毅 (三重大学医学部附属病院 腫瘍内科)	Day 2 (Fri)
P2-4	Neoadjuvant chemotherapy with docetaxel, nedaplatin, 5-FU for esophageal cancer: a long-term follow-up analysis Hiroyuki Ohnuma (Department of Medical Oncology, Sapporo Medical University School of Medicine) 大沼 啓之 (札幌医科大学附属病院 腫瘍内科)	Day 3 (Sat)
P2-5	Scrutinizing Possible Risk Factors and their Association with Oesophageal Cancer: A Case-Control Study in Assam, India Biraj Kumar Kalita (Manipur University)	On-demand
P2-6	5-fold cross-validation approach to assess the robustness of Machine learning models in prediction of oesophageal cancer Biraj Kumar Kalita (Manipur University)	Room 1
P2-7	Postoperative Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Preliminary Results from a phase II trial H Zhu (Fudan University, Shanghai Cancer Center)	Room 2
P2-8	Spatially and phenotypically distinct CD39+ CD8+ T cell response following PD-1 blockade in esophageal cancer Kenro Tanoue (Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University) 田ノ上 絢郎 (九州大学 血液・腫瘍・心血管内科)	Room 3
P2-9	演題取下	Room 4
11:40-12:25 Poster Session 3		
P3	Gastrointestinal Cancer 3 (Esophageal Cancer 3) 消化器 3 (食道 3)	Room 5
P3-1	Chemotherapy with biweekly modified DCF in metastasis esophageal cancer: A retrospective study in Vietnamese patients Hung Van Nguyen (Department of Oncology and Palliative Care, Hanoi Medical University Hospital / Department of Oncology, Hanoi Medical University)	Room 6
P3-2	Safety and efficacy of Toripalimab on Esophageal cancer: a Systematic Review and Meta-analysis Dion Ravinder T. Subroto (Faculty of Medicine, Pelita Harapan University)	Room 7
P3-3	Progression Free Survival and Overall Survival of Pembrolizumab for Patients with Esophageal Cancer: A Meta-Analysis Kho Jesselyne Aurelia Santoso (Faculty of Medicine, Pelita Harapan University)	Room 8
		Room 9
		Room 10
		Room 11
		Room 12
		Room 13
		Meet the Experts
		Poster

P3-4 Encore	Mixed Neuroendocrine-Non-neuroendocrine Neoplasm (MiNEN) of the Esophagus: A Case Report Cristina G Domingo (Cancer Institute St Lukes Medical Center Quezon City)
P3-5	Challenges in Diagnosing Advanced Submucosal Esophageal Squamous Cell Carcinoma (ESCC) - A Case Report Andrew Chandra (Medical Doctor of International SOS, Jakarta and Internal Medicine Department of Pondok Indah Hospital, Jakarta)
P3-6	THE EFFICACY AND SAFETY OF DOCETAXEL, CISPLATIN AND FLUOROURACIL CHEMOTHERAPY FOR ESOPHAGEAL CANCER: A SYSTEMATIC REVIEW Irene D. Evangelista (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)
P3-7	A case of esophageal cancer successfully treated with conversion surgery under immune-related adverse event management Satoshi Kamiya (Department of Surgery, Tokyo Dental College Ichikawa General Hospital) 神谷 諭 (東京歯科大学市川総合病院 外科)
P3-8	The Role of PD-L1 Inhibitor Combined with Chemotherapy as the Main Treatment of Advanced Submucosal Esophageal SCC Andrew Chandra (Medical Doctor of International SOS, Jakarta and Internal Medicine Department of Pondok Indah Hospital, Jakarta)
P3-9	Antihistamines H1 Use on Survival Outcomes in ESCC Patients Undergoing Concurrent Chemoradiotherapy Szu-Yuan Wu (Asia University, Taiwan / Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan)
11:40-12:25 Poster Session 4	
P4	Hematologic Malignancies 1 (Lymphoma 1) 血液 1 (リンパ腫 1)
P4-1	Efficacy and Safety of Brentuximab Vedotin on Pediatric Patients with Hodgkin Disease: A Systematic Review Frederika Tan (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)
P4-2	Efficacy and safety of chimeric antigen receptor-T cells in B cell lymphoma malignancy: A Systematic Review meta-analysis Andree Kurniawan (Faculty of Medicine, Pelita Harapan University / Trainee, Hematology and Medical Oncology, Internal Medicine, Faculty of Medicine, Universitas Indonesia)
P4-3	An experience of pola-R-CHP regimen for DLBCL patients at our hospital Takenori Takahata (Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine) 高畑 武功 (弘前大学大学院医学研究科 消化器血液内科学講座)
P4-4	Four cases of follicular lymphoma with tumor-associated bronchiolitis obliterans Takashi Nakamura (Department of Oncology and Hematology, The Jikei University) 中村 嵩 (東京慈恵会医科大学附属病院 腫瘍・血液内科)
P4-5	Patient characteristics and treatment patterns in patients with Mantle Cell Lymphoma in Japan: a real-world study Shinya Rai (Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osakasayama, Japan) 頼 晋也 (近畿大学病院 血液・膠原病内科)

- P4-6** **Obinutuzumab-CVP for frail patients with follicularlymphoma**
Toshiki Yamada (Department of Hematology, Gifu Prefectural General Medical Center)
Frail患者における濾胞性リンパ腫に対するObinutuzumab併用CVP療法の使用経験
山田 俊樹 (岐阜県総合医療センター 血液内科)

11:40-12:25 Poster Session 5

- P5** Hematologic Malignancies 2 (Lymphoma 2)
血液 2 (リンパ腫 2)
- P5-1** **Efficacy of Zanubrutinib Against Patients With relapsed/Refractory Non-Hodgkin Lymphoma: A Systematic Review**
Gavin M Sukendro (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)
- P5-2** **Efficacy and Safety of Extracorporeal Photopheresis as Immunotherapy for Cutaneous T-cell Lymphoma: A Systematic Review**
Alycia J. Cheryl (Faculty of Medicine, Pelita Harapan University)
- P5-3** **KI-67 AS A PREDICTOR OF SURVIVAL FACTOR IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS AT DHARMAIS NCC: A RETROSPECTIVE STUDY**
Anisa H Syafiyah (Dharmais Cancer Center, Jakarta-Indonesia)
- P5-4** **Characteristics and Treatment Outcomes of T-cell Lymphoma in Tertiary Referral Cancer Center in Jakarta-Indonesia**
Devi A. R. Amelia (Internal Medicine, Faculty of Medicine, Universitas Indonesia, RSUPN dr. Ciptomangunkusumo)
- P5-5** **HCV reactivation with hepatitis flare after immunochemotherapy in a patient with follicular lymphoma**
Yotaro Motomura (Department of Hematology, Tokyo Medical and Dental University (TMDU))
化学療法後にC型肝炎ウイルス感染の再活性化を来した濾胞性リンパ腫
本村 鷹多朗 (東京医科歯科大学 血液内科)
- P5-6** **Experiences of using Pola-R-CHP therapy for untreated Diffuse large B-cell lymphoma (DLBCL) in our hospital**
Takayoshi Miyazono (Department of Hematology, Imamura General Hospital)
当院における未治療びまん大細胞B細胞性リンパ腫 (DLBCL) に対するPola-R-CHP療法の使用経験
宮園 卓宜 (慈愛会 今村総合病院 血液内科)

11:40-12:25 Poster Session 6

- P6** Hematologic Malignancies 3 (Leukemia 1)
血液 3 (白血病 1)
- P6-1** **演題取下**
- P6-2** **Blinatumomab Compared to Standard Chemo in Acute Lymphoid Leukemia: A Systematic Review of Randomized Controlled Trials**
Prudence Wirajaya (Faculty of Medicine, Pelita Harapan University)
- P6-3** **Is Azacitidine Combined with Venetoclax More Superior than Decitabine Combined with Venetoclax? A Meta-Analysis Study**
Devina R. T Subroto (Faculty of Medicine, Sebelas Maret University)

Day 1 (Thu)	P6-4	演題取下
Day 2 (Fri)	P6-5	CHALLENGES OF ADHERENCE TO TYROSINE KINASE INHIBITOR TREATMENT AMONG CHRONIC MYELOID LEUKEMIA PATIENTS IN MALAYSIA Chee Chean Dang (Department of Pharmacy, Hospital Melaka, Ministry of Health Malaysia)
Day 3 (Sat)	P6-6	Overall Outcomes of Imatinib As the First Line Treatment in Patients with Chronic Myeloid Leukemia : A systematic review Yudi A.P. Ontowirjo (Faculty Of Medicine, Pelita Harapan University)
On-demand	P6-7	Sorafenib Maintenance Post-Allogeneic HCT in Reducing Relapse of Patients with FLT3-ITD AML: A Systematic Review Giuseppe L. Triaswhoro (Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia / Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia)
Room 1	P6-8	Efficacy of Venetoclax Plus LDAC for Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Systematic Review Cindytia R. P. Djojomartono (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)
Room 2	P6-9	COVID-19 patients with myeloid malignancy in our hospital Yoshihiro Kin (Department of Hematology, Daini Osaka Police Hospital) 金 義浩 (第二大阪警察病院 血液内科)
Room 3	P6-10	Leukemia in Sub-Saharan countries - A Comprehensive Case Study of Ghana Atiku Adam (Oncology Department, Korle Bu Teaching Hospital)
Room 4		
Room 5		
Room 6		11:40-12:25 Poster Session 7
Room 7	P7	Hematologic Malignancies 4 (Leukemia 2) 血液 4 (白血病 2)
Room 8	P7-1	Safety and Efficacy of Nivolumab as the Initial Treatment for Patients with Leukemia: A Systematic Review Dion Ravinder T. Subroto (Faculty of Medicine, Pelita Harapan University)
Room 9	P7-2	Comparative Effectiveness of Bosutinib versus Imatinib in Patients with CML: a Systematic review Ayu I.U. Amalia (Faculty of Medicine, Pelita Harapan University)
Room 10	P7-3	Efficacy of Azacitidine and Venetoclax in treating Acute Myeloid Leukemia: A Systematic Review Yosef Raynard Gunawan (Faculty of Medicine, Pelita Harapan University, Indonesia)
Room 11	P7-4	Venetoclax and Azacitidine for Acute Myeloid Leukemia Patients: A Systematic Review and Meta-analysis Azzahra M. Noersamsjah (Faculty of Medicine, Pelita Harapan University)
Room 12	P7-5	Anti-Carcinogenic Activity Of Ethanolic Extract Of White Tea (Camellia Sinensis) In A Leukemic Rat Model Dinesh Dayma (Department of Zoology, J K College,)
Room 13	P7-6	Cognitive impairment in paediatric and adolescent ALL patients: an Institutional based study Nishant, (Department of Psychiatry, DIMHANS, S.P. Medical College & AG of Hospitals, Bikaner, Rajasthan, India)
Meet the Experts		
Poster		

P7-7	Efficacy of Zanubrutinib in Patients with Lymphocytic Leukemia: A Systematic Review Vether Fernhandho (Faculty of Medicine, Pelita Harapan University)	Day 1 (Thu)
P7-8	Achievement of deep molecular response and treatment free remission by asciminib-treatment in CML Ryo Yoshimaru (Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan) 慢性骨髄性白血病のアシミニブ治療におけるDMR/TFRの到達 吉丸 峻 (国立がん研究センター東病院 血液腫瘍科)	Day 2 (Fri)
P7-9	MDS overt AML patients treated with Azacitidine with Venetoclax may be caused highly positivity for the FLT3 mutation Masahide Yamazaki (Department of Internal Medicine, Keiju Medical Center) 山崎 雅英 (恵寿総合病院 内科)	Day 3 (Sat)
P7-10	Philadelphia chromosome-positive secondary extramedullary leukemia with a myeloid/T-cell phenotype Miho Watanabe (Department of hematology, Kumamoto University) 渡辺 美穂 (熊本大学病院血液・膠原病・感染症内科学)	On-demand

11:40-12:25 Poster Session 8

P8	Hematologic Malignancies 5 (Other (Myeloma etc.)) 血液 5 (その他 (骨髄腫等))	Room 1
P8-1	演題取下	Room 2
P8-2	Combination of Daratumumab With Lenalidomide and Dexamethasone For Multiple Myeloma Sufferers : A Systematic Review Ferry Darmawan (Faculty of Medicine, Pelita Harapan University)	Room 3
P8-3	A case of multiple solitary plasmacytoma with nasal involvement in a young woman Miki Joyce (Department of oncology and hematology, Kobe university) ジョイス 美紀 (神戸大学医学部附属病院 腫瘍・血液内科)	Room 4
P8-4	Is isatuximab, pomalidomide and dexamethasone effective for relapsed multiple myeloma with 1q+ and del(17p) ? Chiaki Kato (Iwate Medical University School of Medicine) 1q増幅と17p欠失を有するダブルヒット再発難治性多発性骨髄腫にIsaPd療法は有効か？ 加藤 千晶 (岩手医科大学医学部)	Room 5

17:25-18:10 Poster Session 9

P9	Gastrointestinal Cancer 4 (Gastric Cancer 1) 消化器 4 (胃 1)	Room 6
P9-1	Deep Learning in Detection of Epstein-Barr Virus Associated Gastric Cancer in Histology Slides: Systematic review Riona Sutanto (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)	Room 7
P9-2	Efficacy and safety of Nivolumab+chemotherapy for advanced or recurrent gastric cancer in our hospital Hidekazu Takahashi (Funabashi Municipal Medical Center, Department of Clinical Oncology) 高橋 秀和 (船橋市立医療センター 腫瘍内科)	Room 8

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Day 1 (Thu)	P9-3	The efficacy and safety of Chemotherapy with nivolumab for the unresectable gastric cancer patients Naoto Takase (Department of Medical Oncology) 高瀬 直人 (宝塚市立病院 腫瘍内科)
Day 2 (Fri)	P9-4	Experiences with Trastuzumab Deruxtecan in 11 Cases of Advanced Gastric Cancer Hiroaki Yamane (Department of Surgery, JA Hiroshima General Hospital / Yamane Clinic) 山根 宏昭 (広島総合病院 外科 / 山根クリニック)
Day 3 (Sat)	P9-5	Predictive biomarker study for gastric cancer treated with first-line nivolumab plus chemotherapy Koki Uehara (Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University) 上原 康輝 (九州大学大学院医学研究院病態修復内科学)
On-demand	P9-6	演題取下
Room 1	P9-7	演題取下
Room 2	P9-8	The possible mechanism of hyperthermia combined 5-Fluorouracil to treat gastric cancer Guan-Yu Chen (School of Medical Laboratory Science and Biotechnology, College of Medical Science and Biotechnology, Taipei Medical University, Taipei, Taiwan)
Room 3		
Room 4		
Room 5		17:25-18:10 Poster Session 10
Room 6	P10	Gastrointestinal Cancer 5 (Gastric Cancer 2) 消化器 5 (胃 2)
Room 7	P10-1	The most favorable reconstruction anastomosis in laparoscopic distal gastrectomy: A result from network meta-analysis Citra Aryanti (Division of Digestive Surgery, Hasanuddin University)
Room 8	P10-2	Perioperative & Postoperative Oxaliplatin and S-1 (SOX) Adjuvant Chemotherapy on Gastric Cancer Patients' D2 Gastrectomy Jasmine A. K Subrata (Pelita Harapan University)
Room 9	P10-3	The Impact and Safety of TAS-102 vs Placebo on Gastric Cancer Patients: A Systematic Review and Meta-Analysis of RCTs Angely M. Susanto (Faculty of Medicine, Pelita Harapan University)
Room 10	P10-4	Efficacy of Pembrolizumab versus paclitaxel for gastric cancer: meta-analysis Nikolaus Albert (Faculty of Medicine, Pelita Harapan University, Indonesia)
Room 11	P10-5	Benefit of Nivolumab Combination Chemotherapy for Elderly Patients with Unresectable Gastric Cancer Takehiko Tsumura (Department of Medical Oncology, Osaka Red Cross Hospital) 津村 剛彦 (大阪赤十字病院 腫瘍内科)
Room 12	P10-6	Immunotherapy for Advanced Gastric Cancer with Disseminated Intravascular Coagulation: A Single-Institution Case Series Masanori Nasu (Department of Medical Oncology, Kindai university hospital) 那須 雅典 (近畿大学病院 腫瘍内科)
Room 13	P10-7	Nivolumab + Chemotherapy for advanced Gastric Cancer by PD-L1 status Saori Miyajima (Department of Gastroenterology, Ishikawa Prefectural Central Hospital) 宮島 沙織 (石川県立中央病院 消化器内科)
Meet the Experts	Poster	

P10-8	Effect of early blood cell changes on the efficacy of immune checkpoint inhibitors in gastric cancer Hiroto Inoue (Division of Digestive Endoscopy, Shiga University of Medical Science) 井上 博登 (滋賀医科大学医学部附属病院 光学医療診療部)
P10-9	Prospective observational study to evaluate of trastuzumab deruxtecan in HER2-positive Gastric Cancer Fumiyasu Hanamura (Department of Internal Medicine, Kyushu University Beppu Hospital) 花村 文康 (九州大学病院別府病院 内科)
17:25-18:10 Poster Session 11	
P11	Gastrointestinal Cancer 6 (Gastric Cancer 3) 消化器 6 (胃 3)
P11-1	Management of severe Immunotherapy-Related Adverse Event for patients with advanced or recurrent gastric cancer Tomono Kawase (Department of Surgery, Toyonaka Municipal Hospital) 川瀬 朋乃 (市立豊中病院 外科)
P11-2	Predictors of response to Nivolumab combination chemotherapy for unresectable advanced HER2-Negative Gastric Cancer Sachiko Nagasu (Multidisciplinary Treatment Cancer Center, Kurume University Hospital / Department of Surgery, Kurume University) 長主 祥子 (久留米大学病院 がん集学治療センター / 久留米大学病院 外科)
P11-3	Efficacy and safety of chemotherapy plus nivolumab for advanced gastric cancer with ascites Toshihiko Matsumoto (Department of Clinical oncology, Ichinomiyanishi Hospital / Department of Medical Oncology, Kobe City Medical Center General Hospital) 松本 俊彦 (一宮西病院 腫瘍内科 / 神戸市立医療センター中央市民病院 腫瘍内科)
P11-4	Cytotoxicity and underlying mechanism of marine antimicrobial peptide X in human gastric cancer cells Chun-Ming Yang (School of Medical Laboratory Science and Biotechnology, College of Medical Science and Biotechnology, Taipei Medical University, Taipei, Taiwan)
P11-5	Evaluation of hyperthermic intraperitoneal chemotherapy with marine antimicrobial peptide X in gastric cancer cell lines Wei-Ting Chuang (School of Medical Laboratory Science and Biotechnology, College of Medical Science and Biotechnology, Taipei Medical University, Taipei, Taiwan)
P11-6	Effects of Trastuzumab Therapy on Overall Survival in HER2-Positive Gastric Cancer: A Systematic Review Michelle Vania (Faculty of Medicine, Pelita Harapan University)
P11-7	Are The Lifestyle, Mental Health and SocioEconomic Factors Influence Gastric Cancer? Rahmat Fauzan (Padang State University)
P11-8	Recent Advances Using Circulating Tumor DNA (ctDNA) in the Management of Gastric Cancer Roland Helmizar (Faculty of Medicine Baiturrahmah University, Padang, Indonesia)

P11-9 Association of Charlson Comorbidity Index and Safety of Endoscopic Resection Gastric Cancer Patients: Systematic Review
 Riona Sutanto (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)

17:25-18:10 Poster Session 12

P12 Gastrointestinal Cancer 7 (Gastric Cancer 4)
 消化器 7 (胃 4)

P12-1 Apatinib as Neoadjuvant Treatment in Patient with Advanced Gastric Cancer : A systematic review
 Melanie D. Sembiring (Faculty of Medicine, Pelita Harapan University)

P12-2 Efficacy and safety of Trastuzumab deruxtecan for unresectable advanced or recurrent HER2-positive gastric cancer
 Rin Inamoto (Saitama Cancer Center)
HER2陽性切除不能進行・再発胃癌におけるトラスツズマブ デルクステカンの使用経験
 稲本 林 (埼玉県立がんセンター)

P12-3 A real world retrospective study of advanced gastric cancer patients treated with nivolumab plus chemotherapy
 Masato Komoda (Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center)
 薦田 正人 (九州がんセンター 消化管・腫瘍内科)

P12-4 A case of carcinomatous meningitis from gastric cancer in which intrathecal chemotherapy resulted in symptom relief
 Kanami Furukawa (Department of Hematology and Oncology, Japan Community Healthcare Organization (JCHO) Kyushu Hospital)
 古川 佳那美 (九州病院 血液・腫瘍内科)

P12-5 Clinical assessment of nivolumab in combination with S-1 plus oxaliplatin for the patients with advanced gastric cancer
 Shigefumi Yoshino (Department of Surgery, National Hospital Organization Kanmon Medical Center)
当院における切除不能・再発胃癌に対する SOX+ニボルマブ療法の臨床的検討
 吉野 茂文 (独立行政法人国立病院機構 関門医療センター 外科)

P12-6 演題取下

P12-7 A MSI-H mutational advanced gastric cancer case with Bulky N treated by pembrolizumab as a first-line therapy
 Kazuma Kobayashi (Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences)
 小林 和真 (長崎大学大学院 移植・消化器外科)

P12-8 The efficacy and tolerability of postoperative docetaxel plus S-1 therapy at our hospital
 Reo Omori (Department of Medical Oncology, Osaka City General Hospital)
 大森 怜於 (大阪市立総合医療センター 腫瘍内科)

P12-9 Trifluridine/tipiracil for advanced gastric patients with previous history of drug-induced interstitial lung diseases
 Yusuke Kawanaka (Department of Medical Oncology, Kindai University)
 川中 雄介 (近畿大学病院 腫瘍内科)

P12-10 **Quality of Life Gastric Cancer Patients in Indonesia using Indonesia Family Life Survey**
Derizal Derizal (IT Trisakti)

17:25-18:10 Poster Session 13

P13 Gastrointestinal Cancer 8 (Small Bowel Cancer)
消化器 8 (小腸)

P13-1 演題取下

17:25-18:10 Poster Session 14

P14 Medical Case Report 1 (Gastrointestinal Tract 1)
ケースレポート 1 (消化器 1)

P14-1 **Two cases of immune thrombocytopenic purpura associated with nivolumab-containing regimen for advanced gastric cancer**

Yoshihisa Takeuchi (Chiba Cancer Center)
竹内 良久 (千葉県がんセンター 消化器内科)

P14-2 **A case of durable disease control achieved with Trametinib monotherapy in pancreatic cancer harboring *MKR1-BRAF* fusion**

Shogo Yamamura (Department of clinical oncology, Kyoto university hospital)

***MKR1-BRAF* fusionを有する膵癌に対しTrametinib単剤を投与し、長期間病勢制御を得られた一例**
山村 彰吾 (京都大学医学部附属病院 腫瘍内科)

P14-3 **Clinical characteristics of long-term survivors with nivolumab in pretreated advanced gastric cancer: a case series**

Taro Mizuno (Department of Gastroenterology, Nagoya City University West Medical Center)

ニボルマブ投与後に長期生存を得られた既治療進行胃癌5例の臨床的特徴
水野 太朗 (名古屋市立大学医学部附属西部医療センター 消化器内科)

P14-4 **Two cases of microsatellite instability-high gastrointestinal cancers with pathological complete response**

Kunishige Koga (Department of Gastroenterology, Chiba Cancer Centre)

病理学的完全奏効を示した高頻度マイクロサテライト不安定性を有する消化管癌の2例
古賀 邦林 (千葉県がんセンター 消化器内科)

P14-5 **A case of combined hepatocellular-cholangiocarcinoma treated with sequential therapy including durvalumab/tremelimumab**

Shinji Unome (Department of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University)

混合型肝癌に対してDurvalumab/Tremelimumab併用療法を含むSequential治療を施行した一例
宇野女 慎二 (岐阜大学医学部医学系研究科 消化器内科学)

P14-6 **Myocardial metastasis from spindle cell carcinoma of the esophagus : A case report**

Yoshihiro Shibata (Department of Medical Oncology, Fukuoka Wajiro Hospital)

心筋転移をきたした食道紡錘細胞癌の一例
柴田 義宏 (福岡和白病院 腫瘍内科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Poster Experts

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

P14-7 **Hyperammonemia-induced impairment of consciousness after chemotherapy against a patient with recurrent rectal cancer**
Kosuke Sagara (Department of Medical Oncology, Fukuoka Wajiro Hospital)
再発大腸癌に対して sLV5FU2+Bevacizumab 療法を施行中に高アンモニア血症に起因する意識障害を発症した一例
相良 浩輔 (福岡和白病院 腫瘍内科)

P14-8 **A case of carcinomatosis of the bone marrow from rectum surviving by remarkable response with Cetuximab**
Yusuke Sanechika (Department of Surgery, Tane General Hospital)
Cetuximabが著明に奏効し、予後改善を示した直腸癌術後骨髄癌腫症の1例
實近 侑亮 (多根総合病院 外科)

17:25-18:10 Poster Session 15

P15 Medical Case Report 2 (Hematologic Malignancies 1)
ケースレポート 2 (血液 1)

P15-1 **AUTOLOGOUS HSCT IN RELAPSED HODGKIN'S LYMPHOMA IN THE PHILIPPINES: A RETROSPECTIVE SINGLE-CENTER CASE SERIES**
Sofia Dominique D. Unson (St. Luke's Medical Center)

P15-2 **Cerebrovascular malformation mimicking recurrent lymphoma on dual time-point ¹⁸F-FDOPA PET**
Woosuck Suh (Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea)

P15-3 **Efficacy of venetoclax and azacitidine therapy for therapy-related acute myeloid leukemia**
Yasuhiro Tanaka (Department of Hematology, Shinko hospital)
治療関連急性骨髄性白血病に対する VenAza 療法の有効性の検討
田中 康博 (神鋼記念病院 血液内科)

P15-4 **A rare e14a3BCR::ABL1 fusion transcript in myeloid leukemia**
Naoko Takemoto (Department of Medical Oncology and Hematology, Kobe University Hospital)
武本 奈緒子 (神戸大学医学部附属病院 腫瘍血液内科)

P15-5 **Cytomegalovirus-induced stomatitis in a patient with refractory diffuse large B-cell lymphoma: a case report**
Masahiro Manabe (Department of Hematology, Osaka General Hospital of West Japan Railway Company)
難治性びまん性大細胞型B細胞リンパ腫症例に合併したサイトメガロウイルスによる口内炎
間部 賢寛 (西日本旅客鉄道株式会社 大阪鉄道病院 血液内科)

P15-6 **Complete Response of EZH2 Inhibitor Tazemetostat against Multiply Relapsed Follicular Lymphoma in Leukemic Phase**
Shohei Kikuchi (Department of Hematology, Toyama University Hospital)
多再発濾胞性リンパ腫白血化症例に対して、タゼメスタットにより完全寛解を得た一例
菊地 尚平 (富山大学附属病院 血液内科)

P15-7 **AML with BCR/ABL1, masked Ph chromosome**
Tatsuya Imai (Hyogo Prefectural Harima-Himeji General Medical Center)
AML with BCR/ABL1, masked Ph chromosome の症例
今井 達也 (兵庫県立はりま姫路総合医療センター 腫瘍・血液内科)

P15-8 Polatuzumab vedotin plus bendamustine and rituximab for elderly DLBCL patients with severe complications

Hideko Goto (Department of hematology, Chuno Kosei Hospital)

重篤な合併症を伴う高齢者DLBCLに対するPola-BRの経験

後藤 英子 (中濃厚生病院 血液内科)

P15-9 Three cases of Primary central nervous system lymphoma treated with ASCT

Shinya Kobayashi (Department of Hematology and Oncology, Nara prefecture general medical center)

自家末梢血幹細胞移植 (ASCT) を施行した中枢神経原発リンパ腫の3例

小林 真也 (奈良県総合医療センター 血液・腫瘍内科)

17:25-18:10 Poster Session 16

P16

Medical Case Report 3 (Hematologic Malignancies 2)
ケースレポート 3 (血液 2)

P16-1 Experience in maintenance therapy with BTK inhibitor in Primary testicular DLBCL with isolated CNS metastasis

Santhosh Meedimale (Department of Medical Oncology, IMS, SUM Hospital)

P16-2 Switch ciclosporin to tacrolimus: overcoming neurotoxicity and GHVD in Thalassemia allogenic transplantation

Le Trang Nguyen (Pharmacy Department, Vinmec Times City General Hospital; Affiliated faculty VinUniversity / Affiliated faculty VinUniversity, Hanoi, Vietnam / Pharmacy Department, Vinmec Times City General Hospital)

P16-3 Total skin electron beam therapy (TSEBT) for mycosis fungoides: the first CARE-compliant reports from Indonesia

Andre Prawira Putra (Department of Radiation Oncology, Faculty of Medicine Universitas Indonesia-Dr. Cipto Mangunkusumo Hospital, Indonesia)

P16-4 PRIMARY BREAST LYMPHOMA, A RARE CAUSE OF BREAST MASS IN TWO MIDDLE-AGED FILIPINO WOMEN

Gale Rizzae M. Alcala (Section of Medical Oncology, St. Luke's Medical Center, Philippines)

P16-5 演題取下

P16-6 Challenges in Managing Refractory Classical Hodgkin Lymphoma in a Developing Country

Dimas Priantono (Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital, Jakarta, Indonesia)

P16-7 Case Report: A Diffuse Large B-Cell Non-Hodgkin Lymphoma Mixed Follicular Lymphoma in Elderly with Complete Response

Galuh CK Sugianto (Division of Hematology-Medical Oncology, Department of Internal Medicine, Medical Faculty University of Indonesia-Cipto Mangunkusumo General Hospital)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Poster Experts

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

P16-8

Dermatopathic lymphadenitis mimicking relapse of Hodgkin lymphoma complicated by atopic dermatitis

Masaki Maruta (Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University)

化学療法終了直後にアトピー性皮膚炎の増悪に伴う皮膚病性リンパ節症を合併し、再発との鑑別を要したホジキンリンパ腫

丸田 雅樹 (愛媛大学医学部附属病院 第一内科)

ポスター② (4号館 1F 白鳥ホール (展示内))

11:40-12:25 Poster Session 17

- | P17 | Translational Research/ Clinical Pharmacology 1 (Basic Research 1)
TR・臨床薬理 1 (基礎医学 1) |
|-----------------|---|
| P17-1 | Anti-Mitochondria Stress and Anti-Apoptotic Effects of Nicotinamide Mononucleotide in UV filter-induced Hematotoxicity
She-Hung Chan (Department of Cosmetic Science, Providence University) |
| P17-2 | Potent Carbon Neutralization in Cancer Cells Induces Drug Resistance to Nanomedicine
Yingqiu Xie (Department of Biology, School of Sciences and Humanities, Nazarbayev University) |
| P17-3 | Discovery of novel HDAC6 inhibitors and potential combination strategy against ovarian cancer cells
An-Jui Chi (School of Pharmacy, National Taiwan University) |
| P17-4 | Phenol stimulates tumor proliferation and metastasis through regulating β-3 adrenergic receptor
Chung Yu Lin (Department of Biological Sciences, National Sun Yat-sen University) |
| P17-5 | Characterization of URST8 as a novel biomarker and therapeutic target for lung cancer
Atsushi Takano (Department of Medical Oncology and Cancer Center, Shiga University of Medical Science / Center for Advanced Medicine against Cancer, Shiga University of Medical Science / Center for Antibody and Vaccine Therapy, Institute of Medical Science, The University of Tokyo)
高野 淳 (滋賀医科大学 臨床腫瘍学講座 / 滋賀医科大学 先端がん研究センター / 東京大学医科学研究所 抗体ワクチンセンター) |
| P17-6 | Inhibition of non-homologous end joining overcomes paclitaxel resistance in non-small cell lung cancer
Kosuke Tsuji (Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University)
非小細胞肺癌における非相同末端結合阻害によるパクリタキセル耐性克服に関する研究
辻 康介 (北海道大学大学院 医学研究院 呼吸器内科学教室) |
| P17-7 | An Agent-Based Modeling Aided Cellular Model for Simulating Dynamic Cancer Growth
Shawn Z Zhang (John D. O'Bryant School of Math and Science) |
| P17-8
Encore | Targeting Stem Cells and Dysplastic Features With Dual MEK/ERK and STAT3 Suppression in Gastric Carcinogenesis
Hyesung Kim (Jeju National University College of Medicine, Jeju, Republic of Korea) |

11:40-12:25 Poster Session 18

- | P18 | Translational Research/ Clinical Pharmacology 2 (Basic Research 2)
TR・臨床薬理 2 (基礎医学 2) |
|-------|---|
| P18-1 | miRNA-224 as Novel Prognostic Marker in Cancer: A Systematic Review and Meta-Analysis
Indra Kusuma (Faculty of Medicine, Pelita Harapan University) |

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Poster Experts

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

- P18-2** **Repositioning VU-0365114 as a novel microtubule-destabilizing agent for treating cancer and overcoming drug resistance**
Pei-Ming Yang (Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University / Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University / Taipei Cancer Center, Taipei Medical University / TMU Research Center of Cancer Translational Medicine / Cancer Center, Wan Fang Hospital, Taipei Medical University / TMU and Affiliated Hospitals Pancreatic Cancer Groups, Taipei Medical University)
- P18-3** **Worthy or not? The Affected Factors on the Success in Blood Donor Selection Process**
Fikri Gemilang (Alumnus Universitas Pembangunan Nasional Veteran Yogyakarta, Indonesia)
- P18-4** **Chinese Herbal Medicines in Lung Cancer - a double-edged sword**
Chun-Kwok Cheng (School of Medical and Health Sciences, Tung Wah College, Hong Kong SAR)
- P18-5** **Microplastics induce inflammation and immune response for carcinogenesis on peripheral blood mononuclear cells**
Ka Tik Cheung (Department of Applied Science, School of Science and Technology, Hong Kong Metropolitan University, Hong Kong SAR, China)
- P18-6** **Characterization of plasma metabolomics and proteomics profiling in patients with CRP-positive squamous cell carcinoma**
Tomoyuki Iwasaki (Department of Medical Oncology, Tohoku University Hospital)
CRP陽性扁平上皮癌患者血漿検体を用いたメタボローム・プロテオームプロファイリング
岩崎 智行 (東北大学病院 腫瘍内科)
- P18-7** **Cellular uptake pathway and effect of CPX-351 in myelodysplastic syndrome patient-derived cell line**
Hiroaki Araie (Department of Hematology & Oncology, University of Fukui Hospital)
骨髓異形成症候群患者由来の細胞株における新規リポソーム製剤 CPX-351の細胞内取り込み経路と効果の検討
新家 裕朗 (福井大学医学部附属病院 血液・腫瘍内科)

11:40-12:25 Poster Session 19

P19 Translational Research/ Clinical Pharmacology 3 (Clinical Pharmacology)
TR・臨床薬理 3 (臨床薬理)

- P19-1** **Effect of VEGFA and CCL4L2 variants on hand-foot skin reaction and survival of regorafenib in Japanese patients with CRC**
Kotaro Ono (Division of Cancer Genome and Pharmacotherapy, Showa University School of Pharmacy)
日本人大腸がん患者におけるレゴラフェニブのHFSR及びPFSに対するVEGFA及びCCL4L2遺伝子多型の影響
小野 航太郎 (昭和大学 薬学部 がんゲノム医療薬学部門)
- P19-2** **Pharmacokinetics of xevinapant and its metabolite, D-1143-MET1, in healthy East Asian participants**
Motonobu Osada (Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA)
長田 元伸 (メルクバイオフーマ株式会社 研究開発本部 臨床開発センター)

P19-3 A pilot study to explore the impact of leptin and ghrelin on the efficacy of anamorelin for cachexia in NSCLC patients

Ryoko Higashiyama (Department of Thoracic Oncology, National Cancer Center Hospital)
東山 量子 (国立がん研究センター中央病院 呼吸器内科)

11:40-12:25 Poster Session 20

P20

Translational Research/ Clinical Pharmacology 4 (Innovative Drug Research & Development)
TR・臨床薬理 4 (創薬研究開発)

P20-1 Photodynamic-controllable smart delivery of combined PARP inhibitor with natural nanoparticles for anticancer treatment

Aruzhan Onggarbek (Department of Biology, School of Sciences and Humanities, Nazarbayev University)

P20-2 Cysteine Induces DNA Damage Repair Signaling and Monosulfidptosis Stress

Jialu Li (School of Sciences and Humanities, Nazarbayev University)

11:40-12:25 Poster Session 21

P21

Translational Research/ Clinical Pharmacology 5 (Molecular Diagnostics/Genomic Medicine)
TR・臨床薬理 5 (分子・遺伝子診断)

P21-1 CLINICAL UTILITY OF NGS IN IMPROVING SURVIVAL OUTCOMES OF PATIENTS WITH ADVANCED SOLID TUMORS IN THE PHILIPPINES

Chito C Cabiling (Cancer Institute, St. Luke's Medical Center, Quezon City, Philippines)

P21-2 Detection of HPV from the residual of liquid-based cytology samples using multiplex digital PCR: a pilot study

Ellie S.M. Chu (School of Medical and Health Sciences, Tung Wah College, Hong Kong SAR)

P21-3 A pilot study on miRNA detection in residual of liquid-based high-risk genotype HPV samples for ovarian cancer diagnosis

Ellie S.M. Chu (School of Medical and Health Sciences, Tung Wah College, Hong Kong SAR)

P21-4 The role that hospitals for cancer genomic medicine should play for hereditary tumor patients and their relatives

Dai Inoue (Department of Clinical Genomics)

遺伝性腫瘍患者と血縁者に対してがんゲノム医療機関が果たすべき役割

井上 大 (東京都立多摩総合医療センター ゲノム診療科)

P21-5 A novel bioinformatics tool contributes to revealing alternative splicing dysregulation in cancer by exploring microexon

Haruko Nakagawa (Department of Professional Development, Tokyo Medical and Dental University Hospital / Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU) / Department of Functional Genome Informatics, Medical Research Institute, Tokyo Medical and Dental University (TMDU))

中川 晴子 (東京医科歯科大学病院 総合教育研修センター / 東京医科歯科大学大学院 医歯学総合研究科 / 東京医科歯科大学 難治疾患研究所 ゲノム機能情報分野)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Poster Experts

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

P21-6 Cancer Pathway Index, an automated scoring system of cancer-related actionable pathways for CGP test

Chiho Nakashima (Saga University Hospital Cancer Center)

Cancer Pathway Index – 包括的がんゲノムプロファイリング検査のための自動スコアリングシステム

中島 千穂 (佐賀大学医学部附属病院 がんセンター)

P21-7 Retrospective Analysis of GenMineTOP sample temperature management and DNA, RNA quality

Yosuke Saito (Department of Cancer Genomic Testing, Yamagata University School of Medicine / Department of Medical Oncology, Yamagata Uncertainty School of Medicine)

齋藤 陽介 (山形大学医学部 ゲノム医療管理室 / 山形大学医学部 腫瘍内科)

P21-8 Ultra-sensitive tumor-informed ctDNA assay predicts survival in advanced melanoma patients treated with ICI treatment

Encore

Howard Pan (Personalis Inc, United States)

11:40-12:25 Poster Session 22

P22 Translational Research/ Clinical Pharmacology 6 (Companion Diagnostics)

TR・臨床薬理 6 (コンパニオン診断薬)

P22-1 Survey on the implementation of companion diagnostics and Comprehensive Genome Profile tests using NDB sampling dataset

Yukiko Mori (Division of Medical Information Technology and Administration Planning, Kyoto university Hospital / Department of Clinical Oncology, Kyoto University Hospital)

森 由希子 (京都大学医学部附属病院 医療情報企画部 / 京都大学医学部附属病院 腫瘍内科)

11:40-12:25 Poster Session 23

P23 Translational Research/ Clinical Pharmacology 7 (Developmental Therapeutics)

TR・臨床薬理 7 (新規抗がん薬・分子標的薬)

P23-1 A Phase I Study of ATR Inhibitor Tuvusertib (DDRiver Solid Tumors 301): Dose Confirmation in Japanese Patients

Noboru Yamamoto (National Cancer Center Hospital, Tokyo, Japan)

P23-2 演題取下

P23-3 Adaptive resistance to selpercatinib via HER3 signaling in RET altered cancer cells

Yuki Katayama (Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine)

RET 変異がんにおける HER3 活性化を介したセルベルカチニブの適応耐性の克服

片山 勇輝 (京都府立医科大学大学院医学研究科 呼吸器内科学)

P23-4 Targeting S1P signaling pathway in triple negative breast cancer with TP53 mutations

Masayuki Nagahashi (Department of Surgery, Division of Breast and Endocrine Surgery, Hyogo Medical University)

永橋 昌幸 (兵庫医科大学 乳腺・内分泌外科)

11:40-12:25 Poster Session 24

P24 Translational Research/ Clinical Pharmacology 8 (Other)
TR・臨床薬理 8 (その他)

- P24-1** **Characterization of URST4 as a new biomarker and therapeutic target for various subtypes of breast cancer**
Hoa Thi Nguyen (Department of Medical Oncology and Cancer Center, Shiga University of Medical Science / Center for Advanced Medicine against Cancer, Shiga University of Medical Science)
- P24-2** **EFFECTIVENESS OF MULTIMODAL INTERVENTION AND GAMIFICATION TO IMPROVE BLOOD CULTURE CONTAMINATION IN ONCOLOGY PATIENTS**
Haritha Madigubba (Department of Clinical Microbiology and Hospital Infection Control, Medicovert Hospitals, India)
- P24-3** **Patient derived cell line with *KIF5B-RET* fusion, which grows both subcutaneously and in central nervous system in mice**
Akihiro Nishiyama (Division of Medical Oncology Cancer Research Institute, Kanazawa University)
臨床検体から樹立した、皮下腫瘍ならびに中枢神経変モデルの作製が可能な*KIF5B-RET*融合遺伝子陽性肺がん細胞株の有用性について
西山 明宏 (金沢大学附属病院 がんセンター 金沢大学がん進展制御研究所/腫瘍内科)

17:25-18:10 Poster Session 25

P25 Translational Research/ Clinical Pharmacology 9 (Translational Research 1)
TR・臨床薬理 9 (橋渡し研究 1)

- P25-1** **The expand indication of the HER2 targeted therapies by monitoring of circulating tumor cells**
Encore
Yasuaki Kimura (Department of surgery, Jichi Medical University Saitama Medical Center)
循環腫瘍細胞のモニタリングによるHER2標的治療の適応拡大
木村 恭彰 (自治医科大学附属さいたま医療センター 一般・消化器外科)
- P25-2** **Activated IL6/JAK/STAT3 signaling causes resistant to EGFR inhibitor in EGFR mutated non-small cell lung cancer (NSCLC)**
Kimio Yonesaka (Department of Medical Oncology, Kindai University Faculty of Medicine)
EGFR変異肺癌におけるIL6/JAK/STAT3シグナル依存的なEGFR阻害剤への耐性について
米阪 仁雄 (近畿大学医学部 腫瘍内科)
- P25-3** **MAGE-A4 expression is associated with unfavorable prognosis in breast cancer**
Kanao Saito (Department of Medical Oncology, Mie University Hospital)
MAGE-A4陽性乳癌は予後不良である
斎藤 佳菜子 (三重大学医学部附属病院 腫瘍内科)
- P25-4** **Response to mRNA SARS-CoV-2 vaccination evaluated by B-cell receptor repertoire after tixagevimab/cilgavimab**
Yohei Funakoshi (Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine)
B細胞受容体レパトア解析を用いた、チキサゲビマブ/シルガビマブ投与後におけるmRNA SARS-CoV-2ワクチンの免疫反応評価
船越 洋平 (神戸大学医学部附属病院 腫瘍・血液内科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

P25-5 Association between Serum HER2 Extracellular Domain and Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer

Kazuki Nozawa (Department of Breast Oncology, Aichi Cancer Center Hospital, Aichi, Japan)

HER2低発現およびHER2陽性転移再発乳癌における血清HER2蛋白とトラスツズマブ・デルクステカン (T-DXd) の関連性

能澤 一樹 (愛知県がんセンター 乳腺科部)

P25-6 Meta-analysis of single-cell gene expression data of NSCLC integrated by variational inference and a neural network

Hiroaki Ikushima (Department of Respiratory Medicine, The University of Tokyo / Department of Respiratory Medicine, NTT Medical Center Tokyo)

変分推論とニューラルネットワークによる非小細胞肺癌単一細胞遺伝子発現データのメタ解析

生島 弘彬 (東京大学医学部附属病院 呼吸器内科 / NTT東日本関東病院 呼吸器内科)

17:25-18:10 Poster Session 26

P26 Translational Research/ Clinical Pharmacology 10 (Translational Research 2)
TR・臨床薬理 10 (橋渡し研究 2)

P26-1 Optimal combination immunotherapy with anti-PD1 antibody and other immune checkpoint inhibitors in ovarian cancer

Encore

Dong Hoon Suh (Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital)

P26-2 A>I(G) RNA Editing as a Potential Biomarker for Predicting Drug Responses in Breast Cancer: from cell lines to women

Yanara A Bernal (Programa de doctorado en ciencias Innovacion en Medicina Instituto de ciencias e Innovacion en Medicina, Facultad de Medicina Clinica Alemana, Universidad del Desarrollo)

P26-3 Optimizing Immunologic Synergy: Stereotactic Ablative Radiotherapy and Low-Dose Cyclophosphamide

Seok-Joo Chun (Department of Radiation Oncology, Seoul National University Hospital)

P26-4 Role of myokine in non-small cell lung cancer patients receiving immune checkpoint inhibitors as first-line therapy

Shinkichi Takamori (Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. / Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan.)

一次治療として免疫チェックポイント阻害薬を投与された進行非小細胞肺癌患者におけるマイオカインの臨床的意義

高森 信吉 (独立行政法人国立病院機構九州がんセンター / 大分大学医学部附属病院 呼吸器外科)

P26-5 Bevacizumab-mediated increase of VEGF-A121 plasma concentrations: A novel insight into VEGF-A121 kinetics

Masashi Okawa (Department of Cardiovascular and Gastroenterological Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University)

大川 政士 (鹿児島大学大学院医歯学総合研究科 心臓血管消化器外科学)

P26-6 Midkine promotes tumor growth and Cisplatin resistance through AKT pathway activation in small cell lung cancer

Shotaro Ito (Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University)

Midkineは小細胞肺癌においてAKT pathwayを介して腫瘍増殖、Cisplatin抵抗性に関する
伊藤 祥太郎 (北海道大学大学院医学研究院 呼吸器内科学教室)

17:25-18:10 Poster Session 27

P27

Patient Advocacy 1 (Patient Advocacy)
患者支援 1 (患者支援)

P27-1 Psychological readiness for salvage chemotherapy: Adult patients with hematological malignancies who have first relapsed

Kazuko Akashi (Health Sciences, Graduate School, The University of Tokushima)

初回再発した成人期の造血器腫瘍患者が捉える化学療法への構え
明石 和子 (徳島大学大学院 保健科学研究科)

P27-2 Questionnaire survey to identify needs for appearance care

Makiko Ono (Department of Medical Oncology / Department of Advanced Medical Development / Survivorship Support Office, Total Care Center)

アピアランスケアのニーズ把握のためのアンケート調査

小野 麻紀子 (がん研究会有明病院 総合腫瘍科 / 先端医療開発科 / トータルケアセンター サバイバーシップ支援室)

P27-3 Report of the Cancer Salon at Jichi Medical University Hospital - the 9th report

Rie Yamamoto (Mental Health Care Center, Jichi Medical University Hospital)

自治医科大学附属病院がんサロンの活動統報 ー第9報ー
山本 理栄 (自治医科大学附属病院 こころのケアセンター)

P27-4 A大学病院のがん相談支援センターにおける高齢がん患者の相談ニーズ

Yumi Nakamura (Nara Medical University Hospital)

中村 由美 (奈良県立医科大学附属病院 がん相談支援センター)

P27-5 Support needs for patients with neuroendocrine tumors

～From the perspective of a cancer medical network navigator～

Yoko Iwamura (Center for Neuroendocrine Neoplasms, Hokkaido University Hospital)

神経内分泌腫瘍患者の療養の現状と患者支援ニーズの検証

～がん医療ネットワークナビゲーターの立場から～
岩村 陽子 (北海道大学病院 神経内分泌腫瘍センター)

P27-6 Patient and Public Involvement (PPI) for clinical trials in Japan Clinical Oncology Group (JCOG) – lay summary

Aya Kimura (Clinical Research Support Office, National Cancer Center Hospital)

JCOGにおける患者・市民参画の取り組みーLay summaryの作成

木村 綾 (国立がん研究センター中央病院 臨床研究支援部門 多施設研究支援室)

P27-7 Surgical experience for pancreatic cancer patients

Mineka Takabayashi (Japanese Red Cross Suwa Hospital)

膵臓癌患者の手術体験

高林 峰香 (諏訪赤十字病院)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Poster Experts

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

P27-8 Questionnaire survey on the experience and awareness of personalized medicine in patients with lung cancer

Encore
Kazuo Hasegawa (NPO Lung Cancer Patients Group One Step)
肺癌患者の個別化医療の経験・認識に関するアンケート調査
長谷川 一男 (肺がん患者の会ワンステップ)

17:25-18:10 Poster Session 28

P28 Patient Advocacy 2 (Survivorship)
患者支援 2 (がんサバイバーシップ)

P28-1 Incidence and Characteristics of Secondary Neoplasms in Childhood Cancer Survivors
Yuri Hirakawa (Department of Oncology/Hematology, Kobe University Hospital)

小児がん経験者における二次がんの発症割合およびその特徴
平川 結梨 (神戸大学医学部附属病院 腫瘍・血液内科)

P28-2 Current status and challenges of talksusing ACP questionnaires for pancreatic cancer patient in outpatient chemo room

Rumi Tamura (The Cancer Institute Hospital of JFCR)
外来治療室における、膵臓がん患者を対象としたACP(アドバンスケアプランニング) 質問紙を用いた面談の実践状況と今後の課題
田村 瑞美 (公益財団法人がん研究会有明病院)

P28-3 Clinical application of portable fNIRS to measure cognitive impairment after chemotherapy in a colorectal cancer patient

Kazuya Saita (Department of Psychosocial Rehabilitation, Graduate School of Biomedical and Health Sciences, Hiroshima University)
大腸癌患者における補助化学療法後の認知機能障害を測定するためのポータブル型脳機能測定機器を用いた臨床応用
齊田 和哉 (広島大学大学院医系科学研究科 精神機能制御科学)

17:25-18:10 Poster Session 29

P29 Patient Advocacy 3 (Community Cancer Care)
患者支援 3 (地域連携)

P29-1 Current Situation and Problems of Cancer Genome Profiling in an Uncertified Hospital of Genomic Medicine

Tetsuhito Muranaka (Department of Internal Medicine, Wakkanai City Hospital)
非ゲノム医療拠点病院におけるがんゲノムプロファイリング検査の現状と問題点
村中 徹人 (市立稚内病院 内科)

17:25-18:10 Poster Session 30

P30 Patient Advocacy 4 (Adolescents and Young Adults with Cancer)
患者支援 4 (AYA)

P30-1 Empowering *Your* Future - Inaugural Adolescents and Young Adults Oncology (AYAO) Asian Symposium

Nurul Shazwani (Department of Medical Oncology, National Cancer Centre Singapore)

P30-2	A Scoping Review on Prevalence of Anxiety and Depression (AnD) in Adolescent and Young Adult Cancer (AYA) Patients Tessa Teo (National Cancer Centre, Singapore)	Day 1 (Thu)
P30-3	Examination of fertility preservation in AYA generation breast cancer patients Tomoko Itagaki (JA Hiroshima General Hospital) AYA世代乳癌患者の妊孕性温存に関する検討 板垣 友子 (JA広島総合病院 乳腺外科)	Day 2 (Fri) Day 3 (Sat)
17:25-18:10 Poster Session 31		
P31	Patient Advocacy 5 (Geriatric Oncology) 患者支援 5 (高齢者)	Room 1
P31-1	Association between FI-CGA-10 and prediction tools for toxicity and mortality in older adults with advanced GI cancer Kohei Arimizu (Geriatric Oncology Service, National Hospital Organization Kyushu Cancer Center / Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center) 高齢の進行消化器癌患者におけるFI-CGA-10と化学療法の毒性 / 予後予測ツールとの相関 有水 耕平 (国立病院機構九州がんセンター 老年腫瘍科 / 国立病院機構九州がんセンター 消化管・腫瘍内科)	Room 2 Room 3 Room 4
P31-2	Association between geriatric assessment and survival in elderly patients with HER2 negative gastric cancer Kunihiro Tsuji (Departments of Medical Oncology, Ishikawa Prefectural Central Hospital) 高齢者HER2陰性胃癌における高齢者機能評価の意義 辻 国広 (石川県立中央病院 腫瘍内科)	Room 5 Room 6
P31-3	Hearing and Communication with Elderly Cancer Outpatients Undergoing Chemotherapy Kanakano Ikeda (Osaka University Hospital) 外来がん薬物療法を受ける高齢がん患者のきこえに伴うコミュニケーションの実態 池田 香菜子 (大阪大学医学部附属病院 看護部)	Room 7 Room 8
P31-4	Support for the elderly cancer patients with ambulatory chemotherapy ; interprofessional cooperation using Geriatric-8 Miyuki Ogaki (Department of Nursing, Kyoto City Hospital) 外来化学療法を受ける高齢がん患者への支援 Geriatric-8 (G8) を用いた多職種連携の取組 大柿 深雪 (京都市立病院 看護部)	Room 9 Room 10
P31-5	Support for elderly cancer patients in outpatient settings Mayumi Suda (National Cancer Center Hospital East) 外来における高齢がん患者への支援の取り組み 須田 真弓 (国立がん研究センター東病院)	Room 11 Room 12
P31-6	A qualitative study of the factors that shape benefits and motivate older patients to participate in cancer care Toshihiko Kirishima (Department of medical oncology, Kyoto city hospital / Graduate school of business administration, Kobe university) 高齢者のがん医療における便益形成と治療への参加意欲を高める要因に関する質的研究 -サービスの便益遅延性に着目して- 桐島 寿彦 (京都市立病院 腫瘍内科 / 神戸大学大学院 経営学研究科)	Room 13 Meet the Experts Poster

ポスター③ (4号館 3F 438)

11:40-12:25 Poster Session 32

P32 Palliative Care/Symptom Management 1 (Symptom Management 1)
緩和ケア・支持療法 1 (支持療法 1)

- P32-1 Appearance of injection site reactions due to fosnetupitant**
Katsunori Fujii (Saiseikai Utsunomiya Hospital, Pharmacy Department)
ホスネツピタントによる注射部位反応の出現状況
藤井 克知 (済生会宇都宮病院 薬剤部)
- P32-2 A retrospective study of cardiopulmonary exercise testing (CPX) in cancer survivors at cardiovascular risk**
Asaki Saijo (Department of Cardiology, Toranomon Hospital / Department of Medical Oncology, Toranomon Hospital)
心血管リスクを有するがん患者における心肺運動負荷試験 (CPX) の後方視的研究
西條 朝貴 (虎の門病院 循環器センター内科 / 虎の門病院 臨床腫瘍科)
- P32-3 Using Fosnetupitant for gastrointestinal cancer regimens with moderate risk of Chemotherapy-induced nausea and vomiting**
Takashi Iwata (Oncology Center, Aichi Medical University / Outpatient Chemotherapy, Aichi Medical University Hospital)
消化器癌の中等度催吐性リスクレジメンに対するホスネツピタントの使用経験について
岩田 崇 (愛知医科大学 臨床腫瘍センター / 愛知医科大学病院 外来化学療法室)
- P32-4 Evaluation of steroid sparing in patients using GEM+nab-PTX at our hospital**
Takayuki Koizumi (Department of Pharmacy, Isesaki Municipal Hospital)
当院のGEM+nab-PTX施行患者におけるステロイドスペアリングの評価
小泉 崇行 (伊勢崎市民病院 薬剤部)
- P32-5 Questionnaire Survey on Taxane-Induced Nail Change**
Kazumasa Yamamoto (Department of Medical Oncology, Toranomon Hospital)
タキサン系抗がん剤による爪障害に関するアンケート調査
山本 一将 (虎の門病院 臨床腫瘍科)
- P32-6 Retrospective analysis of opioid pain management during chemoradiotherapy for esophageal cancer in our institute**
Kei Takenaka (Kobe minimally invasive Cancer Center)
当院における食道がん化学放射線治療中のオピオイドによる疼痛管理状況についての後方視的検討
竹中 圭 (神戸低侵襲がん医療センター 腫瘍内科)
- P32-7 膵臓癌の術前補助療法におけるゲムシタピン+S-1療法による皮疹の実態調査**
Fumina Katori (Department of Pharmacy, Saiseikai Yokohamashi Tobu Hospital)
香取 史菜 (済生会横浜市東部病院 薬剤部)
- P32-8 An unresectable pancreatic cancer patient who showed marked efficacy of anamorelin in maintaining quality of life**
Motoyasu Kan (Department of Gastroenterology, Chiba University Hospital / Department of Medical Oncology, Chiba University Hospital)
アナモレリンにより著明な食欲増進と体重増加を認めQOLの維持に有効であった切除不能膵癌の一例
菅 元泰 (千葉大学医学部附属病院 消化器内科 / 千葉大学医学部附属病院 腫瘍内科)

P32-9	<p>Prospective study to assess taste related to eating disorders during chemotherapy using a dietary app: OISHY study Toshiharu Hirose (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)</p> <p>食事アプリを用いた化学療法中の摂食障害に関する味覚の前向き検討: OISHY 試験 廣瀬 俊晴 (国立がん研究センター中央病院 消化管内科)</p>	Day 1 (Thu)
P32-10	<p>Prescribing status of chemotherapy-induced peripheral neuropathy drugs in DPC hospitals (2016-2022) Hiroyuki Hirakawa (Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital)</p> <p>DPC 病院における化学療法誘発性末梢神経障害治療薬の処方状況調査 (2016-2022年) 平川 寛之 (東北医科薬科大学病院 薬剤部)</p>	Day 2 (Fri)
P32-11	<p>Antiemetic therapy using fosnetupitant is useful for improving the efficiency of outpatient chemotherapy Yuka Kobayashi (Department of medical oncology, Nagaoka Chuo General Hospital)</p> <p>ホスネツピタントを使用した制吐療法は外来化学療法の効率化に有用である 小林 由夏 (長岡中央総合病院 腫瘍内科)</p>	Day 3 (Sat)
11:40-12:25 Poster Session 33		On-demand
P33	<p>Palliative Care/Symptom Management 2 (Symptom Management 2) 緩和ケア・支持療法 2 (支持療法 2)</p>	Room 1
P33-1	<p>Comparison between Y-site co-infusion versus standard dexamethasone for preventing HSRs from oxaliplatin administration Jarearnjit Phavirunsiri (Department of Medical Oncology, Phramongkutklao Hospital)</p>	Room 2
P33-2	<p>A retrospective analysis of patient-specific factors on regorafenib-induced proteinuria in colorectal cancer Yumiko Furuta (Department of Pharmacy, Kyoto-Katsura Hospital)</p> <p>大腸がん患者におけるレゴラフェニブ誘発性蛋白尿の発現リスクに関する後方視的研究 古田 祐美子 (京都桂病院)</p>	Room 3
P33-3	<p>The efficacy of NK-1 receptor antagonist for the colorectal cancer patients treated with oxaliplatin based regimen Naoto Takase (Department of Medical Oncology, Takarazuka City Hospital)</p> <p>大腸がん患者におけるオキサリプラチンベースレジメン投与時のNK1 受容体拮抗薬の有無が悪心・嘔吐に与える影響に関する検討 高瀬 直人 (宝塚市立病院 腫瘍内科)</p>	Room 4
P33-4	<p>Usefulness of anamorelin in real-world clinical practice Saya Kitashiro (Department of Medical Oncology, Tane General Hospital)</p> <p>北代 紗也 (多根総合病院 腫瘍内科)</p>	Room 5
P33-5	<p>Retrospective multicenter clinical study of risk factors for cetuximab-related infusion reaction in Japanese patients Chiharu Onoda (Pharmaceutical Department, Yaizu City Hospital)</p> <p>セツキシマブ関連 Infusion Reaction リスク因子に関する多機関共同後方視的研究 小野田 千晴 (焼津市立総合病院 薬剤部)</p>	Room 6
		Room 7
		Room 8
		Room 9
		Room 10
		Room 11
		Room 12
		Room 13
		Meet the Experts
		Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

- P33-6** **Survey on the use of fosnetupitant in breast cancer patients**
Megumi Yatabe (Department of Pharmacy National Hospital Organization Saitama Hospital)
乳がん患者におけるホスネツピタントの使用実態調査
矢田部 恵 (国立病院機構埼玉病院 薬剤部)
-
- P33-7** **Factors Related to Gemcitabine-induced Phlebitis in Our Hospital**
Kota Oyadomari (Pharmaceutical Department, Fukuoka Wajiro Hospital)
当院におけるGEMによる血管痛関連要因の探索
親泊 広大 (福岡和白病院医療技術部 薬局)
-
- P33-8** **Patient-supported approach to appearance care at our hospital
~Appearance care from notification to end-of-life care~**
Mayumi Seto (Miyagi Cancer Center)
当院における患者支援アピアランスケアの取り組み～告知からお看取りまでのアピアランスケア～
瀬戸 真由美 (宮城県立がんセンター)
-
- P33-9** **肝細胞癌に対するシスプラチン動注療法におけるオランザピンおよびアプレピタントの制吐効
果と安全性：非ランダム化前向き研究**
Shunsuke Okuyama (Department of Gastroenterology and Hepatology, Kurashiki Central Hospital)
奥山 駿佑 (倉敷中央病院 消化器内科)
-
- P33-10** **Experience switching from non-PEG-G-CSF to PEG-G-CSF body pots**
Ayumi Ozeki (Department of Pharmacy, Shonantobu General Hospital / Faculty of Pharmacy,
Shonan University of Medical Sciences)
非PEG化G-CSF製剤からPEG化G-CSF ボディポットへの切り替え経験
尾関 あゆみ (湘南東部総合病院 薬剤科 / 湘南医療大学 薬学部)
-
- P33-11** **Survey on the response to extravascular leakage associated with cancer drug therapy**
Kenji Miyazawa (Department of Pharmacy, Kanazawa Medical Center / Ishikawa Cancer
Treatment Committee)
がん薬物療法に伴う血管外漏出時の対応に関する実態調査
宮澤 憲治 (金沢医療センター 薬剤部 / 石川県がん治療委員会)

17:25-18:10 Poster Session 34

P34 Palliative Care/Symptom Management 3 (Palliative Medicine)
緩和ケア・支持療法 3 (緩和医療)

- P34-1** **Role of Exercise in Enhancing Quality of Life and Physical Health in Breast Cancer
Survivors: A Systematic Review**
Yoselin Yen (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)
-
- P34-2** **Advanced Care Planning involving children to enrich the rest of patients' lives, which
ends with home medical care**
Hideko Akagi (Department of Medical Oncology, Nippon Medical School Musashi-kosugi Hospital)
**残りの人生を豊かにするために子供達を巻き込んだAdvanced Care Planning;
在宅医療を取り入れ家族に囲まれて最後を迎える当院のACPの軌跡**
赤木 秀子 (日本医科大学武蔵小杉病院 腫瘍内科)

- P34-3 Prognostic Evaluation of Anamorelin Hydrochloride Administration in Cancer Cachexia Patients with Weight Loss**
Takaharu Kiribayashi (Department of Surgery, Toho University Ohashi Medical Center)
体重減少伴うがん悪液質患者へのアナモレリン塩酸塩投与による予後の検討
桐林 孝治 (東邦大学医療センター大橋病院 外科)
- P34-4 Examination about Actual state and Significance of the Medical treatment of Cancer in the Integrated Community Care Ward**
Kan Kato (Department of Internal Medicine, Tokyo Kensei Hospital / Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital)
地域包括ケア病棟におけるがん診療の実態とその意義についての検討
加藤 冠 (東京健生病院 内科 / がん・感染症センター都立駒込病院 呼吸器内科)
- P34-5 Pathophysiological Investigation of Cancer Pain by Explicability of Machine Learning**
Kazuki Shimada (Department of Palliative Medicine, Kyoto University Hospital)
機械学習の説明性によるがん疼痛の病態検討
嶋田 和貴 (京都大学医学部附属病院 緩和医療科・緩和ケアセンター)
- P34-6 A best supportive care for the patient with vulvar cancer**
Yoshitomo Ashitate (Urakawa Red Cross Hospital)
芦立 嘉智 (浦河赤十字病院 外科)
- 17:25-18:10 Poster Session 35
- P35 Palliative Care/Symptom Management 4 (Psycho-Oncology)**
緩和ケア・支持療法 4 (サイコオンコロジー)
- P35-1 THE IMPACT OF COVID-19 PANDEMIC ON PSYCHOLOGICAL WELL-BEING OF ONCOLOGY HEALTHCARE PROVIDERS IN MALAYSIA**
Nadiyah Zainal (Clinical Oncology Unit, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia)
- P35-2 INTERNET-BASED COGNITIVE BEHAVIORAL THERAPY FOR DEPRESSION AND ANXIETY SYMPTOMS IN CANCER: A META-ANALYSIS**
Encore
Cristina G Domingo (Cancer Institute St Lukes Medical Center Quezon City)
- P35-3 Internet-delivered Cognitive Behavioural Therapy Effect in Breast Cancer Survivors: a Systematic Review**
Kimberley Colfoort (Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia)
- P35-4 Impacts of psycho-education among advanced cancer patients in Indonesia**
Nurul Huda (Nursing Faculty, Universitas Riau, Indonesia)
- P35-5 Unspoken challenges managing breast cancer in a schizophrenic patient: a case report**
Jasmin Munchar Elias (Jalan University)

P36 Palliative Care/Symptom Management 5 (Other)
緩和ケア・支持療法 5 (その他)

- P36-1 Bilateral Anterior Stereotactic Cingulotomy for Cancer Pain: A Systematic Review**
Charlotte A Jonatan (Department of Medicine, Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Banten, Indonesia)
- P36-2 Amitriptyline on the Treatment of Peripheral Neuropathic Pain in Cancer Patients: A Meta-analysis**
Jirah Martha V. Malbas (Section of Medical Oncology, St. Luke's Medical Center)
- P36-3 PATTERNS OF CANCER PATIENT PRESENTATION TO THE EMERGENCY DEPARTMENT: A SINGLE INSTITUTION STUDY**
Vickee Rajeswaran (Department of Clinical Oncology, Sultan Ismail Hospital)
- P36-4 Clinical Profile of Palliative Care in North-Eastern region of India**
Manoj K Behera (Clinical Oncology, Health City Hospital)
- P36-5 Safety and efficacy of Trifluridine/tipiracil plus Bevacizumab for elderly patients with metastatic colorectal cancer**
Takanori Miyoshi (Department of Pharmacy, National Hospital Organization Kyushu Medical Center)
高齢者大腸癌患者における Trifluridine/tipiracil + Bevacizumab 療法の安全性および有効性の検討
三好 孝法 (国立病院機構九州医療センター 薬剤部)
- P36-6 救急病院における緊急緩和ケア受入れの実態**
Masae Shibata (Department of Medical Oncology, Fukuoka Wajiro)
柴田 昌枝 (福岡和白病院)
- P36-7 Report of Clinical Characteristics in Cases of Thrombosis in Our Department**
Shoko Aoki (Department of Medical Oncology, Kameda Medical Center)
当科での血栓症発症例における臨床的特徴の報告
青木 聖子 (亀田総合病院 腫瘍内科)
- P36-8 Sudden death in a patient with metastatic tumors in the liver: a role of metabolic acidosis and tumor lysis syndrome**
Satoshi Hirakawa (Department of Supportive Care in Cancer, Seirei Hamamatsu General Hospital)
倦怠感を訴え突然死した転移性肝腫瘍：代謝性アシドーシスと腫瘍崩壊症候群を併発した子宮原発悪性腫瘍
平川 聡史 (聖隷浜松病院 支持療法科)
- P36-9 How to reduce the number of cases that lose the opportunity for treatment**
Hisashi Ishikura (Department of Surgery, Japanese Red Cross Tokushima Hospital)
治療の機会を失う症例をいかに少なくするか～当院の事例を参考に～
石倉 久嗣 (徳島赤十字病院 外科)

P37 Lung Cancer/ Thoracic Cancer 1 (Early Stage Non-Small Cell Lung Cancer/Perioperative Treatment
呼吸器 1 (非小細胞肺癌 / 周術期))

- P37-1** **A Diagnostic Nomogram for Pathological Invasiveness in Early LUAD: Integration of Autoantibody and Radiomics Features**
Zhen Gao (Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China / Centre of Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, UK)
- P37-2** **Progression-Free Survival Stratification of Taiwanese Lung Adenocarcinoma Patients based on Mutant Transcriptomics**
Rodrigo Espinoza Silva (Institute of Statistical Science, Academia Sinica / Institute of Bioinformatics and Structural Biology, National Tsing Hua University / Taiwan International Graduate Program (TIGP) - Bioinformatics, Academia Sinica)
- P37-3** **Safety and Efficacy of Nivolumab Plus Ipilimumab for Patients with Non-Small-Cell Lung: A Meta-analysis**
Sherina Kosayuz (Department of medicine, Pelita Harapan University)
- P37-4** **Efficacy and Toxicity of Pemetrexed and Cisplatin in Early Stage Non-small Cell Lung Cancer: A Systematic Review of RCTs**
Michelle Gracia Kumala (Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia)
- P37-5** **Efficacy and Safety of Cemiplimab in Non-Small-Cell Lung Cancer : Systematic Review and Meta-Analysis**
Devina R. T Subroto (Faculty of Medicine, Sebelas Maret University)

P38 Lung Cancer/ Thoracic Cancer 2 (Metastatic Non-Small Cell Lung Cancer/Tyrosine Kinase Inhibitor 1)
呼吸器 2 (非小細胞肺癌 / 転移性-TKI 1))

- P38-1** **Systematic Review: Efficacy of Brigitinib Versus Crizotinib in Metastatic Non-small Cell Lung Carcinoma**
Michelle G Setiawan (Faculty of Medicine, Pelita Harapan University)
- P38-2** **Efficacy and Safety of Lazertinib in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review**
Jennifer Evangeline Gunawan (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)
- P38-3** **Relation of PDL1 and Variant Allele Frequency, Their Impact On Prognosis In EGFR Mutation Non-Small Cell Lung Cancer**
Santhosh Meedimale (Department of Medical Oncology, IMS , SUM Hospital)
- P38-4** **Efficacy and Survival Impact of Ramucirumab+Erlotinib in Metastatic NSCLC Patients: A Systematic Review & Meta-Analysis**
Louis Julian (Faculty of Medicine, University of Pelita Harapan)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

P38-5 Encore	Impact of triple therapy targeted for EGFR, AXL, and MCL-1 in lung cancer cells expressing mutant EGFR Yohei Matsui (Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine) 松井 遥平 (京都府立医科大学附属病院 呼吸器内科)
P38-7	Final Report on the Specified Drug Use-Results Survey of Dabrafenib/Trametinib in Patients with <i>BRAF</i>-Mutant NSCLC Tomoaki Kaizuka (Global Drug Development Division, Novartis Pharma K.K.) 貝塚 友明 (ノバルティス ファーマ株式会社, グローバル医薬品開発本部)
P38-8 Encore	Mechanism of osimertinib resistance using ct-DNA analyses for EGFR mutated NSCLC, results from ELUCIDATOR Akihiro Tamiya (Department of Internal Medicine, NHO Kinki-Chuo Chest Medical Center) 田宮 朗裕 (国立病院機構近畿中央呼吸器センター 内科)
P38-9	A Retrospective Study to Determine the Characteristics of Early Resistance to Alectinib in ALK-Positive NSCLC Go Makimoto (Department of Allergy and Respiratory Medicine, Okayama University Hospital) 横本 剛 (岡山大学病院 呼吸器・アレルギー内科)
P38-10	Risk Factors for ILD with Osimertinib in Patients with EGFR-Positive Lung Cancer and Safety of Rechallenge with EGFR-TKI Ayaka Mukai (Osaka City General Hospital, Respiratory Medicine) 向井 文香 (大阪市立総合医療センター 呼吸器内科)
11:40-12:25 Poster Session 39	
P39	Lung Cancer/ Thoracic Cancer 3 (Metastatic Non-Small Cell Lung Cancer/Tyrosine Kinase Inhibitor 2) 呼吸器 3 (非小細胞肺がん / 転移性-TKI 2)
P39-1	Efficiency of metformin to overcome EGFR-TKI resistance in NSCLC patients: A Systematic Review Stefanie Valentina (Faculty of Medicine, Pelita Harapan University / Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University)
P39-2	Outcomes of 1G and 2G generation EGFR-TKI in NSCLC patients with common EGFR mutation, a real-world study in Taiwan Yen Ting Chen (Department of chest medicine, Mackay memorial hospital, Taiwan)
P39-3	EFFICACY OF SELPERCATINIB IN RET FUSION-POSITIVE NON-SMALL-CELL LUNG CANCER PATIENTS: A SYSTEMATIC REVIEW Evelyn Yunita (Faculty of Medicine, Pelita Harapan University, Indonesia)
P39-4	Evaluating the Efficacy of Lorlatinib versus Crizotinib in ALK-Positive Lung Cancer Patients : A Systematic Review William W. Sito (Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia)
P39-5	Safety and Efficacy of Lorlatinib as a Treatment for Patients with Non-Small Cell Lung Cancer Tirza A. Nugroho (Faculty of Medicine, Pelita Harapan University)
P39-6	Is alectinib combination the answer for osimertinib resistance in Non-Small Cell Lung Cancer? A systematic review Sanjeev Kharel (Maharajgunj Medical Campus, Tribhuvan University Teaching Hospital)

P39-7	Retrospective analysis of gefitinib combined with carboplatin plus pemetrexed for NSCLC with activating EGFR mutations Kyoji Tsurumi (Department of Respiratory Medicine, Miyagi Cancer Center) 鶴見 恭士 (宮城県立がんセンター)
P39-8	The efficacy of reduced dose osimertinib for EGFR mutation-positive non-small cell lung cancer patients Hirokazu Iso (Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital) 磯 博和 (東京都立病院機構 がん・感染症センター都立駒込病院 呼吸器内科)
11:40-12:25 Poster Session 40	
P40	Lung Cancer/ Thoracic Cancer 4 (Metastatic Non-Small Cell Lung Cancer/Tyrosine Kinase Inhibitor 3) 呼吸器 4 (非小細胞肺がん / 転移性-TKI 3)
P40-1	Efficacy Of Dabrafenib & Trametinib Combination Therapy In NSCLC With BRAF V600E Mutation : A Systematic Review Reylinge Relia Margouw (Faculty of Medicine, Pelita Harapan University)
P40-2	Evaluating The Efficacy of Osimertinib's Role in EGFR-Mutated Non-Small Cell Lung Cancer : A Systematic Review Sharanya sharanya (Faculty of Medicine, Pelita Harapan University)
P40-3	Efficacy between Osimertinib and Standard EGFR Tyrosine Kinase Inhibitor Treatments on Non-Small Cell Lung Cancer Sasmita Pradnyandari (Faculty of Medicine, Pelita Harapan University)
P40-4	Efficacy of Gefitinib in Comparison to Docetaxel as Therapy for the Treatment NSCLC: A Systematic Review Kenjiro G Santoso (Faculty of Medicine, University of Pelita Harapan)
P40-5	Safety evaluation for first-line therapy of EGFR-TKI for patients with EGFR mutation Encore Yuki Akazawa (Department of Thoracic Oncology, NHO Osaka Toneyama Medical Center) 赤澤 結貴 (大阪刀根山医療センター 呼吸器腫瘍内科)
P40-6	The detection rate of EGFR gene mutations in the Cobas EGFR mutation test and the Oncomine Dx in our hospital Masahide Ota (Department of Cancer Genomics and Medical Oncology, Nara Medical University / Department of Respiratory Medicine, Nara Medical University) 当院におけるコバスとオンコマインでのEGFR遺伝子変異検出率の検討 大田 正秀 (奈良県立医科大学 がんゲノム・腫瘍内科学講座 / 奈良県立医科大学 呼吸器内科学講座)
P40-7	Impact of dose reduction on efficacy in EGFR mutant NSCLC patients treated with osimertinib as a initial treatment Motohiro Tamiya (Thoracic Oncology, Osaka International Cancer Institute) 田宮 基裕 (大阪国際がんセンター 呼吸器内科)
P40-8	Efficacy of ramucirumab plus erlotinib in patients with advanced non-small cell lung cancer harboring EGFR mutations Yuki Takeyasu (Department of Thoracic Oncology, Kansai Medical University Hospital) 竹安 優貴 (関西医科大学)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

17:25-18:10 Poster Session 41

- P41** Lung Cancer/ Thoracic Cancer 5 (Locally Advanced Non-Small Cell Lung Cancer)
呼吸器 5 (非小細胞肺がん / 局所進行)
- P41-1** **Survival and Pulmonary Toxicity in Non-Small Cell Lung Cancer: The Role of GTV Volume and Dosimetric Parameters**
Wissal hassani (Oncology Hospital, Hassan II University Hospital, Fez, Morocco)
- P41-2** **Statin Therapy in Unresectable Stage III Lung Squamous Cell Carcinoma: Improved Survival in CCRT**
Szu-Yuan Wu (Asia University, Taiwan / Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan)
- P41-3** **Efficacy of Durvalumab After Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer:A Systematic Review**
Bianca A. Willardi (Faculty of Medicine, Pelita Harapan University, Indonesia)
- P41-4** 演題取下
- P41-5** **Pre-CCRT PET-CT and Other Prognostic Factors of Survival for Unresectable Stage III EGFR Mutation Lung Cancer**
Szu-Yuan Wu (Asia University, Taiwan / Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan)
- P41-6** **The toxicity profile of durvalumab leading to interruption for stage III non-small cell lung cancer in clinical practice**
Takahiro Teshirogi (Department of Pharmacy, National Cancer Center Hospital East)
手代木 貴宏 (国立がん研究センター東病院 薬剤部)
- P41-7** **The Effect of Muscle Mass Changes During Chemoradiotherapy on Durvalumab Maintenance Therapy for Locally Advanced NSCLC**
Shun Futamura (Fukuchiyama city hospital)
局所進行非小細胞肺癌における化学放射線治療中の筋肉量変化がDurvalumab維持療法に与える影響
二村 俊 (市立福知山市民病院)
- P41-8** **Second-line Treatment after Chemoradiotherapy in Non-Small Cell Lung Cancer**
Kosuke Takahashi (Department of Respiratory Medicine, Anjo Kosei Hospital)
高橋 孝輔 (安城更生病院 呼吸器内科)

17:25-18:10 Poster Session 42

- P42** Lung Cancer/ Thoracic Cancer 6 (Metastatic Non-Small Cell Lung Cancer/Immunotherapy 1)
呼吸器 6 (非小細胞肺がん / 転移性・免疫療法 1)
- P42-1** **Outcomes post Immunotherapy and Platinum-Doublet Chemotherapy (PDC) for Metastatic Non-Small Cell Lung Cancer in Japan**
Stephen V Liu (Georgetown University)
Encore
- P42-2** **Systematic Review of Pembrolizumab vs. Chemotherapy in PD-L1-positive advanced NSCLC as first line of treatment**
William Atmadji (Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia)
- P42-3** **Efficacy and Safety of Nivolumab and Ipilimumab Compared to Chemotherapy in Metastatic NSCLC : A Systematic Review**
Patriana Yossa (Faculty of Medicine, Pelita Harapan University, Indonesia)

P42-4	Efficacy of Nivolumab and Ipilimumab in Metastatic Non-Small Cell Lung Cancer: Systematic Review Alia S. Zahra (Faculty of Medicine, Pelita Harapan University)	Day 1 (Thu)
P42-5	Efficacy and Safety of Camrelizumab and Carboplatin and Pemetrexed in Advanced Nonsquamous NSCLC: A Systematic Review Jennica I.X Hasan (Faculty of Medicine, Pelita Harapan University)	Day 2 (Fri)
P42-6	GRIIm-Score and RMH score can be prognostic factors of immunotherapy in patients ≥ 70 with advanced NSCLC Ippei Miyamoto (Nihon University School of Medicine, Department of Internal Medicine, Division of Respiratory Medicine) Gustave Roussy免疫スコアとRMHスコアは免疫療法を行う70歳以上の高齢者肺癌の予後予測因子となりうる 宮本 一平 (日本大学医学部内科学系 呼吸器内科学分野)	Day 3 (Sat) On-demand Room 1
P42-7	Clinical impact of concomitant BIO-three in advanced non-small cell lung cancer treated with immune checkpoint inhibitor Hitomi Nakatsukasa (Department of Pharmacy, Osaka Metropolitan University Hospital) 中務 ひとみ (大阪公立大学医学部附属病院 薬剤部)	Room 2 Room 3
P42-8	Outcomes by potential clinical trial eligibility in a prospective observational study of ABCP in advanced EGFR+ NSCLC Yuta Yamanaka (Department of Thoracic Oncology, Kansai Medical University Hospital) 山中 雄太 (関西医科大学附属病院)	Room 4 Room 5
P42-9	Fluoropyrimidine has a potential to be an immunologically optimal partner of immunotherapy for thoracic malignancies Hirokazu Ogino (Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University) 荻野 広和 (徳島大学大学院医歯薬学研究所 呼吸器・膠原病内科学分野)	Room 6 Room 7
P42-10	ABCP Combination Therapy for EGFR-TKI-Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer Hironori Kobayashi (Department of Medical Oncology, Kameda Medical Center) 小林 弘典 (亀田総合病院 腫瘍内科)	Room 8 Room 9
17:25-18:10 Poster Session 43		
P43	Lung Cancer/ Thoracic Cancer 7 (Metastatic Non-Small Cell Lung Cancer/Immunotherapy 2) 呼吸器 7 (非小細胞肺癌 / 転移性・免疫療法 2)	Room 10
P43-1 Encore	Real-world outcomes of 1L anti-PD(L)1-based combinations in mNSCLC: Japan Cohort Ticiana A. Leal (Winship Cancer Institute, Emory University)	Room 11
P43-2	Association of PDL1 expression and EGFR point mutation in metastatic lung adenocarcinoma: Real-world experience Santhosh Meedimale (Department of Medical Oncology, IMS, SUM Hospital)	Room 12
P43-3	Efficacy of Tremelimumab and Durvalumab Combination in Metastatic Non-Small Cell Lung Cancer : Systematic Review Aurelia Clarabelle (Faculty of Medicine, Pelita Harapan University)	Room 13 Meet the Poster Experts

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

P43-4 Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression in elderly patients
 Shuhei Nozawa (Department of Respiratory Medicine, Nagano Municipal Hospital)
 野沢 修平 (長野市民病院 呼吸器内科)

P43-5 Efficacy of immune checkpoint inhibitor with or without chemotherapy for advanced NSCLC: A single institution experience
 Kazuhiko Shibata (Division of Medical Oncology, Dept. of Medicine, Kouseiren Takaoka Hospital)
 柴田 和彦 (厚生連高岡病院 腫瘍内科)

P43-6 Impact of Gastrointestinal Medication Use on the Efficacy of I-O+Chemotherapy for Non-Small Cell Lung Cancer
 Akira Nakao (Department of Respiratory Medicine, Faculty of Medicine, Fukuoka University)
非小細胞肺癌に対する複合免疫療法の効果に及ぼす常用薬としての消化器系薬剤使用の影響
 中尾 明 (福岡大学病院 呼吸器内科)

P43-7 Pembrolizumab or nivolumab plus ipilimumab combined with chemotherapy for advanced NSCLC: a retrospective analysis
 Takayo Ota (Department of Breast Medical Oncology, Izumi City General Hospital)
 大田 隆代 (和泉市立総合医療センター 乳腺内科)

P43-8 The utilization of carboplatin, nanoparticle albumin-bound paclitaxel, and atezolizumab at a single center
 Hironori Ashinuma (Division of Respiratory Medicine, Chiba Cancer Center)
 芦沼 宏典 (千葉県がんセンター 呼吸器内科)

17:25-18:10 Poster Session 44

P44 Lung Cancer/ Thoracic Cancer 8 (Metastatic Non-Small Cell Lung Cancer/Immunotherapy 3)
 呼吸器 8 (非小細胞肺癌 / 転移性・免疫療法 3)

P44-1 Clinical factors associated with outcome in NSCLC patients treated with immune checkpoint inhibitors
 WenJuii Wu (Department of Pulmonology, Mackay Memorial Hospital)

P44-2 The Role of Immune Checkpoint Inhibitors in Advanced Lung Cancer
 Jasneet Gill (Department of Medical Oncology, Hamidia Hospital)

P44-3 TTF-1 may be a useful marker for advanced NSCLC treated with anti-PD-1 antibody and anti-CTLA-4 antibody
 Taro Yoneda (Respiratory Medicine, Komatsu Municipal Hospital)
 米田 太郎 (国民健康保険小松市民病院 呼吸器内科)

P44-4 Pembrolizumab Monotherapy or Combination with Chemotherapy for PD-L1 Positive NSCLC: a retrospective analysis
 Takafumi Okabe (Department of Oncology, Izumi City General Hospital)
 岡部 嵩記 (和泉市立総合医療センター 腫瘍内科)

P44-5 Infusion timing of ICI monotherapy in patients with advanced NSCLC: A Single institution-retrospective study
 Shinnosuke Takemoto (Department of Respiratory Medicine, Nagasaki University Hospital)
 竹本 真之輔 (長崎大学病院 呼吸器内科)

- P44-6** **Real-world analysis of pembrolizumab for non-small cell lung cancer at our hospital**
 Minoru Fukuda (Cancer Center, Nagasaki Prefecture Shimabara Hospital)
当院における非小細胞肺癌に対するペムブロリズマブ療法リアルワールド解析
 福田 実 (長崎県島原病院 がん診療センター)
-
- P44-7** **Investigation of combined immunotherapy for non-squamous cell carcinoma over 75 years old in our hospital**
 Susumu Noguchi (Department of Respiratory Medicine, Shiga General Hospital)
 野口 進 (滋賀県立総合病院 呼吸器内科)
-
- P44-8** **Thrombocytopenic purpura associated with durvalumab consolidation therapy after chemoradiotherapy: A case report**
 Tetsuo Tsuji (Department of Respiratory Medicine, National Hospital Organization Kanazawa Medical Center)
 辻 徹朗 (国立病院機構金沢医療センター 呼吸器内科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

ポスター⑤ (2号館 3F 3F ホワイト)

11:40-12:25 Poster Session 45

P45 Lung Cancer/ Thoracic Cancer 9 (Metastatic Non-Small Cell Lung Cancer/Chemotherapy 1)
呼吸器 9 (非小細胞肺癌 / 転移性 - 化学療法 1)

P45-1 **Utility of neutrophil-to-lymphocyte ratio in the management of non-small cell lung cancer with brain metastases**
Pratik Lamichhane (Department of Internal Medicine, Tribhuvan University Teaching Hospital, Institute of Medicine)

P45-2 **NCI677397 targeting USP24-mediated induction of lipid peroxidation induces ferroptosis in drug-resistant cancer cells**
Shao-an Wang (School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan)

P45-3 **Efficacy and safety of TS-ONE in Advanced Non-Small Cell Lung Cancer in Thailand: a multicenter retrospective study**
Kunlatida Maneenil (Oncology Unit, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand)

P45-4 **Efficacy of Gefitinib in Comparison with Combination Chemotherapy for Non-Small-Cell Lung Cancer: A Systematic Review**
Derbie Liani (Faculty of Medicine, Pelita Harapan University)

P45-5 **EGFR expression Influences on the response to ALK inhibitor therapy in ALK-rearranged non-small cell lung cancer**
Ryo Sawada (Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine)
澤田 凌 (京都府立医科大学大学院医学研究科呼吸器内科学)

P45-6 **Efficacy and safety of ABCP for non-squamous NSCLC: the analysis in single instituter**
Keisuke Shiraha (Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center)
白羽 慶祐 (国立病院機構岡山医療センター 呼吸器内科)

11:40-12:25 Poster Session 46

P46 Medical Case Report 4 (Lung 1)
ケースレポート 4 (肺 1)

P46-1 **BRAF and PD-L1 positive lung adenocarcinoma with musculoskeletal metastasis treated with Vemurafenib and Pembrolizumab**
Encore
Florge Francis A Sy (Division of Medical Oncology, Philippine General Hospital)

P46-2 **Clinical challenge of two competing targetable mutations in non-small cell lung cancer: a case report**
Sonya Park (Department of Radiology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea)

P46-3 **Case series on Stereotactic Body Radiation Therapy in Primary Lung Cancer & Metastases: Early Experiences from Indonesia**
Angela Giselvania (Department of Radiation Oncology, Dr Cipto Mangunkusumo National General Hospital)

- P46-4** **First report of small cell transformation in a patient with BRAF V600E-mutated advanced non-small cell lung cancer**
Thanakorn Charoenthanadhol (Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Khon Kaen University)
- P46-5** **Lambert-Eaton myasthenic syndrome recurrence induced by pembrolizumab in a patient with squamous cell lung cancer**
Suzuka Matsuoka (Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center)
Pembrolizumabにより Lambert-Eaton 筋無力症候群を再発した肺扁平上皮癌の1例
松岡 涼果 (岡山医療センター 呼吸器内科)
- P46-6** **The experience of multidisciplinary therapy for SCLC with myelocarcinomatosis and refractory gastro intestinal bleeding**
Shun Takahashi (Kushiro Rosai Hospital, Internal Medicine)
骨髄癌腫症と難治性の消化管出血を伴う肺小細胞癌に対して集学的治療を行った1例
高橋 惇 (釧路労災病院 内科)
- P46-7** **A case of RET T754K mutation combined with KIF5B-RET fusion and suspected resistance to selpercatinib**
Masahiro Iwasaku (Cancer Genome Medical Center Kyoto Prefectural University of Medicine / Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine)
RET K754K 変異によるセルベルカチニブ耐性が示唆された KIF5B-RET 融合遺伝子の一例
岩破 将博 (京都府立医科大学大学院医学研究科 がんゲノム医療センター / 京都府立医科大学大学院医学研究科 呼吸器内科)
- P46-8** **A case of combined large cell neuroendocrine carcinoma with EGFR exon19 deletion and responding to Osimertinib**
Takahiro Shimizu (Department of Internal Medicine, Fukui-ken Saiseikai Hospital)
EGFR exon19 欠失変異陽性の混合型大細胞神経内分泌癌に対しオシメルチニブを投与した一例
清水 崇弘 (福井県済生会病院)
- P46-9** **A case of Micronodular Thymic Carcinoma with Lymphoid Hyperplasia**
Takashi Yoshimatsu (Department of General Thoracic Surgery, Fukuoka Wajiro Hospital)
リンパ性間質を伴う小結節性胸腺癌の1例
吉松 隆 (福岡和白病院 呼吸器外科)
- P46-10** **オシメルチニブにより急性心不全発症した EGFR 変異陽性非小細胞肺癌の一例**
Niina Mimura (Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University Faculty of Medicine)
三村 仁一奈 (和歌山県立医科大学 呼吸器内科・腫瘍内科)

17:25-18:10 Poster Session 47

P47 Lung Cancer/ Thoracic Cancer 10 (Small Cell Lung Cancer)
呼吸器 10 (小細胞肺癌)

- P47-1** **The Safety And Efficacy of Atezolizumab In Small Cell Lung Cancer : A Systematic Review**
Ansell W. P. Perdana (Faculty of Medicine, Pelita Harapan University)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Poster Experts

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

P47-2	Comparison of clinical outcomes of LD-SCLC between elderly and younger patients: A single center retrospective analysis Shin Saito (Department of Pulmonary Medicine, Sendai Kousei Hospital) 齋藤 伸 (仙台厚生病院 呼吸器内科)
P47-3	Real world evidence of systemic chemotherapy for patients with extensive-disease small-cell lung cancer (TREAD 06) Tomoya Fukui (Department of Respiratory Medicine, Shonan Kamakura General Hospital) 実臨床における進展型小細胞肺癌患者に対するがん薬物療法の徳洲会メディカルデータベースを用いた後ろ向きコホート研究 (TREAD 06) 福井 朋也 (湘南鎌倉総合病院 呼吸器内科)
P47-4	Patterns of progression in patients with extensive-stage small cell lung cancer treated with chemoimmunotherapy Yuichiro Nishibori (Division of Thoracic Oncology, Shizuoka Cancer Center) 西堀 雄一郎 (静岡県立静岡がんセンター 呼吸器内科)
P47-5	Long-term survival in six patients with small cell lung cancer treated with immune checkpoint inhibitors Tsukasa Ueda (Department of Respiratory Medicine, Kanazawa University Hospital) 上田 宰 (金沢大学附属病院 呼吸器内科)
P47-6	A study of prognostic factors including NLR, Plt/Lym, and CRP/Alb in patients with small cell lung cancer Naruo Yoshimura (Department of Respiratory Medicine, Faculty of Medicine, Tohoku Medical and Pharmaceutical University) 小細胞肺癌患者におけるNLR、PLR、CRPアルブミン比を含めた予後予測因子の検討 吉村 成央 (東北医科薬科大学医学部 内科学第一 (呼吸器内科))
P47-7	Real-world analysis of advanced SCLC patients unfit for immunochemotherapy Takahisa Kawamura (Osaka international cancer institute) 川村 卓久 (大阪国際がんセンター 呼吸器内科)
17:25-18:10 Poster Session 48	
P48	Lung Cancer/ Thoracic Cancer 11 (Other (Mesothelioma, Thymic Malignancies, etc.)) 呼吸器 11 (その他 (中皮腫、胸腺がん等))
P48-1	Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in Esophageal Squamous Cell Carcinoma Yizhang Chen (Thoracic Surgery of Guangdong Provincial People's Hospital/Guangdong Academy of Medical Sciences)
P48-2	Deep Learning-Based Artificial Intelligence for Multiple Pulmonary Nodules Identification: A Systematic Review Felicia Sidharta (Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia)
P48-3	Tuberculous pleural effusion derived exosomal miRNAs promotes proliferation of lung cancer cells via cyclin D1 Ji Young Hong (Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Chuncheon Sacred Heart Hospital, Hallym University Medical Center)

- P48-4** **Evaluation of Cases Undergoing Surgery for Metastatic Spinal Tumors at Our Hospital**
 Aoi Kuroda (Department of Respiratory Medicine, Tokyo Dental College Ichikawa General Hospital)
転移性脊椎腫瘍に対して当院で手術を施行した症例の検討
 黒田 葵 (東京歯科大学市川総合病院 呼吸器内科)
- P48-5** **Retrospective analysis of chemotherapy in super-elderly patients with malignant pleural mesothelioma**
 Ryo Takahashi (Dept. of Respiratory Medicine and Hematology / Dept. of Thoracic Oncology)
超高齢悪性胸膜中皮腫患者における化学療法の意義
 高橋 良 (兵庫医科大学 呼吸器・血液内科学 / 兵庫医科大学 胸部腫瘍学)
- P48-6** **Real-world evidence of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma**
 Takanori Kondo (Department of Respiratory Medicine, Hyogo College of Medicine)
当院における悪性胸膜中皮腫に対するイピリムマブ+ニボルマブ併用療法の有効性と安全性の検討
 近藤 孝憲 (兵庫医科大学 呼吸器内科)
- P48-7** **Distinct immune related adverse events of nivolumab plus ipilimumab between NSCLC and MPM**
 Akiko Tamura (National Cancer Center Hospital)
 田村 旺子 (がん研究センター中央病院 呼吸器内科)
- P48-8** **Ipilimumab and nivolumab combination therapy for malignant pleural mesothelioma in our hospital**
 Hiroyuki Sakashita (Yokosuka Kyosai Hospital, Department of Chemotherapy / Yokosuka Kyosai Hospital, Department of Respiratory Internal Medicine)
 坂下 博之 (横須賀共済病院 化学療法科 / 横須賀共済病院 呼吸器内科)